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Abstract 
Although several lipids have been shown to participate in intracellular signal transduction 
events and to influence central cellular processes, the bioactive actions of most lipids remain 
unexplored. This lack of knowledge is mainly due to a shortage of tools to manipulate lipid levels 
within living cells in a non-invasive way and to identify new protein interactors of single lipid 
species. This work presents the development of two methods to overcome these drawbacks 
applied to sphingosine (Sph). The origin of calcium signaling properties of Sph and its 
involvement in the pathophysiological development of the lysosomal storage disease Niemann-
Pick type C (NPC) are reported.   
First, ‘caged’ variants of sphingosine were synthesized which enable the precise elevation of Sph 
levels in single living cells within seconds using light. This acute increase in Sph concentration 
led to an immediate release of lysosomal calcium through the actions of the two-pore channel 1 
(TPC1). In cells derived from NPC patients, an accumulation of Sph in the endolysosomal 
compartments was visualized for the first time. Additionally, NPC cells exhibited reduced 
calcium signals upon Sph uncaging, indicating that Sph accumulation is upstream of a calcium 
defect in this disease. Sph-induced calcium release also initiated the nuclear translocation of 
transcription factor EB, which positively regulates the expression of autophagic and lysosomal 
biogenesis genes, further underlining the importance of lysosomal calcium release in direct 
lysosome-to-nucleus signaling pathways.  
In order to capture Sph-interacting proteins, a trifunctional Sph (TFS) was developed. TFS 
facilitates the release and immediate crosslinking of Sph to its interacting partners within the 
living cell. Mass-spectrometric analyses identified known Sph-binding proteins such as the 
ceramide synthase, as well as novel putative Sph-interactors. The general applicability of this 
method was proven by using trifunctional diacylglycerol as well as a trifunctional fatty acid. TFS 
was further employed in investigations of the subcellular localization and transport of Sph 
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through the cell. NPC patient fibroblasts showed a striking accumulation of Sph in late 
endosomes and lysosomes. Sph transport out of these vesicles was severely hindered in the NPC 
condition. The kinetics of Sph efflux correlated with the severity of symptoms in different NPC 
patients, so this assay could potentially be used for monitoring and prognosis of NPC disease 
severity.  
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Zusammenfassung 
Nur einige von tausenden Lipidspezies in eukaryotischen Zellen sind bereits bekannte bioaktive 
Lipide, welche in komplexe intrazelluläre Signalübertragungsnetzwerke eingebunden sind. Viele 
andere Lipide haben noch unerforschte Auswirkungen auf zelluläre Prozesse. Mögliche Gründe 
dafür sind die Schwierigkeiten, die Konzentration dieser Lipide in lebenden Zellen durch nicht-
invasive Methoden zu manipulieren oder deren Wechselwirkungen mit Lipid-bindenden 
Proteinen zu erforschen.  
In dieser Arbeit werden Methoden zur spezifischen Freisetzung von Lipiden mit hoher zeitlicher 
und räumlicher Auflösung sowie zur Proteom-weiten Identifizierung von Lipid-bindenden 
Proteinen in lebenden Zellen vorgestellt. Als Modelllipid diente Sphingosin (Sph), ein einkettiges 
Lipid aus der Gruppe der Sphingolipide, welches eine bedeutende, allerdings noch nicht näher 
definierte Rolle in der Pathologie der lysosomalen Erbkrankheit Niemann-Pick Typ C (NPC) 
spielt.  
Die Modifizierung von Sph mit verschiedenen photospaltbaren Schutzgruppen lieferte inerte 
Sph-Vorläufer, welche nach Zugabe zu verschiedenen Zelllinien kein Signal auslösten. Erst durch 
Photospaltung direkt am Mikroskop erhöhte sich die Konzentration von Sph in einzelnen 
lebenden Zellen innerhalb von Sekunden. Dieser Anstieg löste die Freisetzung von Kalzium aus 
den lysosomalen Kalzium-Speichern aus, welche durch den Kalzium-Kanal TPC1 gesteuert 
wurde. Untersuchungen von NPC-Patientenzellen zeigten sowohl ein reduziertes lysosomales 
Kalzium-Signal als auch erhöhte Sph Konzentrationen in Endosomen und Lysosomen, welches 
den Schluss nahelegt, dass die Akkumulation von Sph in diesen Zellen zur Senkung des 
lysosomalen Kalziumspiegels beiträgt und somit die Fusion von Endosomen und Lysosomen 
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erschwert. Die Bedeutung des Sph-induzierten Kalzium-Signals wurde durch die nachfolgende 
nukleare Translokation des Transkriptionsfaktors EB unterstrichen.  
Die Entwicklung eines trifunktionalen Sph (TFS) ermöglichte die Freisetzung und sofortige 
Quervernetzung von Sph mit wechselwirkenden Proteinen in lebenden Zellen. Nachfolgende 
massenspektrometrische Analysen identifizierten bereits bekannte als auch potenziell neue Sph-
bindende Proteine und zeigten die Anwendbarkeit dieses Konzepts auf andere Signallipide. TFS wurde 
auch benutzt, um die Lokalisation von Sph in NPC-Patientenzellen zu untersuchen. Eine deutliche 
Ansammlung von Sph in Endosomen und Lysosomen sowie ein erschwerter Transport von Sph aus 
diesen Organellen wurde sichtbar. Die Kinetik des Sph-Transports korrelierte direkt mit der Schwere der 
Smyptome dieser NPC-Patienten. Dieser Assay könnte somit in Zukunft zur Beobachtung und Prognose 
von NPC-Patienten verwendet werden.  
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“But then science is nothing but a series of questions that lead to more questions.”  
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Chapter 1 - Introduction 
1.1. Sphingolipids form a network of highly bioactive lipids and are involved in 
many cellular processes 
Lipids are crucial for the functioning of all organisms. At the physiological level, lipids serve for 
the storage of energy in adipose tissues, mostly in the form of triglycerides1. On a cellular level, 
lipids are needed as structural components of membranes and are therefore essential for 
constituting the plasma membrane as well as for forming intracellular organelles2. However, 
more than 37 000 structurally distinct lipids have been identified so far3, with more likely to 
come as technologies advance. Each eukaryotic cell is estimated to contain over 1000 different 
lipid species2. This diversity is too great to result from mere structural roles, and leads to the 
hypothesis that structurally different lipids have distinct functions. Indeed, some lipids have 
been shown to act as signaling molecules and their deregulation results in severe diseases such 
as cancer, inflammation and metabolic syndrome4.  
 
Figure 1.1 Major groups of membrane lipids in mammalian cells. The common backbone of each group is highlighted in red, 
fatty acids are shown in blue and R signifies variable headgroup modifications such as phosphate, ethanolamine, choline or 
sugars.  
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In mammalian cells, lipids are classified into three main categories: glycerolipids, sphinoglipids 
and sterol lipids (see Figure 1.1). Glycerolipids share glycerol as a common backbone and are 
the most abundant cellular lipids. The major glycerolipid by mass, phosphatidylcholine (PC), is 
the primary component of cellular membranes and already accounts for over 30 % of total 
cellular lipid content5. Sterols share the fused four-ring core structure of steroids (highlighted in 
red in Figure 1.1) and are modified by an alcohol functionality at position 3 of ring A. The main 
sterol lipid cholesterol and its derivates are essential for regulating membrane fluidity6, while 
other sterol lipids such as bile acids aid in the solubilization and absorption of dietary fat from 
the intestine through formation of micelles7. Other steroid-derived molecules (e.g. androgens, 
estrogens or corticosteroids) have different biological roles as hormones and signaling 
molecules8,9.  
Sphingolipids are a closely related group of bioactive lipids which have a sphingoid (sometimes 
called long chain base) backbone. In mammalian cells, this backbone is sphingosine (see Figure 
1.2 – sphingosine is highlighted in bold). Sphingolipids are synthesized via a de novo pathway 
starting with the condensation of L-serine with palmitoyl-CoA by the serine palmitoyltransferase 
(SPT) at the endoplasmic reticulum (ER). This is not only the start but also the key regulatory 
step for sphingolipid biosynthesis. Mutations in SPT can lead to a severe disease of the 
peripheral nervous system called hereditary sensory and autonomic neuropathy type I 
(HSAN1)10. The next step is mediated by 3-ketodihydrosphingosine reductase (KDSR) and yields 
dihydrosphingosine (dhSph), which can be recognized by several ceramide synthases (CerS) to 
form a variety of different dihydroceramides (dhCer), differing in fatty acyl chain length and 
saturation11. 
The dhCers are converted to ceramides (Cer) by the actions of a sphingolipid desaturase (DES). 
Ceramides are the central point of sphingolipid metabolism and have been implicated in the 
regulation of many biological processes, ranging from apoptosis12 to inflammation13 or 
autophagy14. Cers are further modified in four different ways:  
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Figure 1.2 Overview of the sphingolipid metabolic pathway. 
1.) Cer is phosphorylated by ceramide kinase (CerK) to give another biologically active 
lipid, ceramide-1-phosphate (C1P), which, interestingly, promotes cell survival15 and migration16, 
contrary outcomes to its parent molecule Cer.  
2.) A family of sphingomyelin synthases (SMS) adds a choline headgroup to Cer, thus 
producing sphingomyelin (SM), the most abundant sphingolipid in mammalian cells. SM is found 
in high concentration (14-18 mol%17) at plasma membrane and is enriched in erythrocytes, 
nerve tissue and the brain18.  
3.) Cers are also modified by galactosyl- or glucosylceramide synthases (CDS) which 
attach galactose or glucose moieties to the headgroup of Cer to form galactosylceramide 
(GalCer) or glucosylceramide (GluCer) as illustrated in Figure 1.2. These serve as starting points 
for the formation of all complex glycosphinoglipids, which reach a great variety in glycan 
composition and are important receptors for carbohydrate binding proteins19. Mutations in 
Chapter 1 - Introduction 
 
4 
 
enzymes of the glycosphingolipid metabolism lead to severe lipid storage disorders, such as 
Gaucher disease20, Fabry disease21, Tay-Sachse and Sandhoff disease22 among others.  
4.)  The breakdown of Cer by ceramidases (CDase) leads to the formation of sphingosine 
(Sph), an important signaling molecule, which has been shown to be implicated in the regulation 
of growth arrest, apoptosis23,24 and the pathophysiology of another lipid storage disease, 
Niemann-Pick type C25 (see chapter 1.2).  
Through the actions of two sphingosine kinases (SK1 and SK2), Sph can be rapidly converted to 
another powerful signaling lipid, sphingosine-1-phosphate (S1P), which is involved in 
proliferation and inflammation26 and is therefore closely linked to carcinogenesis27. Like Cer and 
C1P, Sph and S1P also exhibit completely contrary signaling properties, even though they are 
closely linked structurally and metabolically. Given this high degree of convertibility between 
lipids with such opposing effects, it was proposed that the relative ratio between pro- and anti-
apoptotic lipid levels, rather than the absolute concentrations determines cell fate in a 
‘rheostat’ fashion28.  Finally, the exit point of the sphingolipid metabolic pathway is the cleavage 
of the sphingosine backbone of S1P by sphingosine-1-phosphate lyase (S1PL) yielding 
hexadecanal and ethanolaminophosphate. S1PL is the only known enzyme to enable the 
irreversible exit of the sphingoid substrate from the sphingolipid metabolic pathway29 and its 
knock-down leads to an accumulation of cholesterol esters and sphingolipids alongside severe 
neurodegenerative symptoms in mice30–32.  
The difficulties in studying sphingolipid signaling lie mainly in the high interconnectivity of the 
metabolic pathway, where many paths, often operating at the same time, can lead to the same 
lipid. Additionally, many sphingolipid metabolizing enzymes exist in families of different 
paralogs, all of which catalyze the same reaction (e.g. synthesis of Cer from Sph) but are 
regulated differently or even make products of different molecular identity (e.g. Cer with 
different fatty acid chain lengths and unsaturations)33. Yet another layer of complexity is added 
when considering the different subcellular localizations of the sphingolipid metabolic enzymes. 
Figure 1.3 summarizes what is known about sphingolipid localization, transport and metabolism 
in the cellular context.  
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Figure 1.3 Subcellular compartmentalization of the sphingolipid metabolism. Figure is reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Molecular Cell Biology, Hannun & Obeid
34
 copyright 2008 under license number 3655250849060.  
Many enzymes involved in the catabolism of higher sphingolipids (such as GBA, SMase or CDase) 
are localized to the endolysosomal system35 (see Figure 1.3), whereas most enzymes involved in 
the de novo pathway are localized to the ER34. SM-synthases and glycosphingolipid synthases 
are localized to the Golgi apparatus36. Taking into account the poor solubility of lipids in cells 
(Cer in this example), it is necessary to facilitate transport from ER to Golgi, and subsequently to 
the plasma membrane. This may happen via vesicular transport or even dedicated transfer 
proteins such as the ceramide transfer protein (CERT)37. The regulation of this transport is 
another way to influence the levels of certain lipids in the cell and therefore transport proteins 
such as CERT could develop into important targets for therapy, specifically anticancer therapy in 
the future38. 
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1.2. Sphingosine accumulates in the lipid storage disorder Niemann-Pick type C 
Niemann-Pick disease type C (NPC) is a lysosomal storage disorder with a wide variability in 
clinical expression and age of onset. Typically, NPC patients develop neurological symptoms 
such as ataxia and progressive dementia and often die within the first decade25. As with most 
other lysosomal diseases, the genetic cause for NPC is well identified. Mutations in the genes 
encoding for two lysosomal proteins NPC1 (95 % of cases) or NPC2 (5 % of cases) lead to the 
development of this fatal neurodegenerative disorder39. However, the cellular functions of 
these proteins remain unclear. NPC2 is a small, soluble, lysosomal glycoprotein of 132 amino 
acids, which has been shown to extract and transport cholesterol between membranes40. NPC1 
on the other hand is a multipass transmembrane protein with 13 transmembrane domains 
localized to the limiting membrane of late endosomes/lysosomes41 (Figure 1.4). Its exact 
function remains unclear, but one luminal loop has been found necessary and sufficient for 
filovirus entry and infection42 (see also chapter 1.5). Homology studies have furthermore 
identified a putative sterol sensing domain39.   
 
Figure 1.4 Topology of the NPC1 protein. Figure adapted from 
41
. 
Mutational analysis of 30 unrelated NPC patients showed some clustering of the mutations in 
the luminal cysteine-rich loop as well as the sterol-sensing domain (SSD)43, indicating the likely 
importance of these domains for the proper functioning of the NPC1 protein. In addition to the 
SSD, the N-terminal domain of NPC1 has also been shown to bind cholesterol44,45. It seems that 
the NPC1 protein could be cholesterol-regulated, if not acting as a cholesterol transporter. And 
indeed, NPC patient cells show a striking accumulation of unesterified cholesterol in the 
endosomal/lysosomal system. This has been used for clinical diagnosis of NPC using filipin46, a 
mixture of fluorescent compounds that form specific complexes with unesterified cholesterol. 
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An exemplary staining of control and NPC patient fibroblasts used in our laboratory is shown in 
Figure 1.5.  
 
Figure 1.5 Cholesterol accumulates in NPC disease. Filipin staining of control and NPC patient fibroblasts. 
On the other hand, mutagenesis studies have demonstrated a primary role of the SSD domain in 
sphingolipid distribution47, indicating cholesterol accumulation is a secondary event in the NPC 
disease. Indeed, other diseases such as cystic fibrosis, most sphinoglipidoses and Huntington’s 
disease show a lysosomal cholesterol accumulation even though the NPC1 protein remains 
functional48–50. Additionally, cholesterol lowering therapies are not of clinical benefit to NPC 
patients51 and cholesterol has been shown to be transported out of Npc1-/- late endosomes / 
lysosomes through other mechanisms52,53. All these facts point toward a secondary role of 
cholesterol in NPC disease. In the search for other potential causative substances, it becomes 
clear that the materials stored in NPC are highly complex and belong to different classes of 
lipids. Apart from cholesterol, sphingomyelin, higher glycosphingolipids as well as sphingosine 
accumulate54. The reason for this collective accumulation is thought to be a trafficking block at 
the lysosomal stage so that lipids and proteins cannot leave the endolysosomal system to reach 
the Golgi aparatus55. It remains unclear which of these substances is the offending metabolite. 
Several hints point toward glycosphingolipids, particularily the observation that inhibition of 
glycosphingolipid synthesis through the amino sugar miglustat reverses the NPC trafficking 
defect56. Miglustat is the only approved therapy for NPC disease up to now. Other studies 
indicate that Sph accumulation is the first detectable biochemical change after NPC1 
inactivation and that addition of free Sph or dhSph to cells is enough to induce the NPC 
phenotype57. This Sph accumulation is then followed by a defect in calcium homeostasis of the 
acidic stores, leading to chronically lower calcium concentrations, which in turn leads to 
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defective vesicular fusion and accumulation of storage materials in the endosomal 
compartment57. This theory is supported by the fact that correcting the calcium phenotype 
through agents like curcumin reverses the cellular lipid storage and increases the lifespan of 
NPC mice57. The purpose and regulation of the NPC1 protein still remain unclear and further 
studies are needed to elucidate its cellular function, but strong hints point towards the 
importance of Sph and acidic store calcium homeostasis in this disease. 
1.3. The acidic compartment is a new player in intracellular calcium signaling  
Ionic calcium has long been recognized as an important cellular second messengers controlling a 
wide variety of cellular processes, such as neuronal transmission, insulin secretion, muscle 
contraction and proliferation, to name a few58. This diversity of different signals is possible 
because cells possess a number of different receptors and channels which react to and conduct 
calcium ions (see Figure 1.6). The cytoplasmic calcium concentration in resting cells is 
maintained at around 50 - 100 nM, but this is rapidly increased by activation of plasma 
membrane calcium channels, which lead to calcium influx from the extracellular space where 
the calcium concentration averages around 1.6 mM. Some of these channels react to 
membrane depolarization (such as voltage-gated calcium channels VGCC), whereas other 
plasma membrane calcium channels react to empty intracellular calcium stores and refill them 
without affecting cytosolic calcium (such as the ORAI channels). The mammalian transient 
receptor potential (Trp) channels are another family of calcium channels found mainly at the 
plasma membrane. The Trp channel family consists of 28 channels divided into six sub-families 
which are all activated either by chemical stimuli through molecules such as diacylglycerol or 
through physical stimuli like heat, low pH or mechanical stress59.  
Calcium is also stored in intracellular organelles, most prominently the ER and the sarcomere in 
muscle cells, which can reach calcium concentrations of 100 – 800 µM60. Second messengers 
such as myo-inositol 1,4,5-trisphosphate (InsP3) or cyclic ADP-ribose (cADPR) act on calcium 
channels in the ER, namely the InsP3-receptor and the ryanodine receptor (RyR) respectively and 
release the calcium into the cytoplasm (see Figure 1.6). Unlike the well-studied ER, the acidic 
compartments were only later discovered to act as intracellular calcium store. Measurements 
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on MDCK cells in 1996 showed an increase in cytosolic calcium after a glycyl-L-phenylalanine 2-
naphtylamide (GPN) induced osmotic lysis of acidic vesicles61. Since then, the concentration of 
calcium in acidic stores (which increases with decreasing pH during the maturation of 
endosomes) has been measured to have values in the range from 400 – 600 µM in lysosomes62.  
 
Figure 1.6 Schematic representation of the most important cellular calcium channels.  
Not all the components involved in lysosomal calcium homeostasis have been identified yet, but 
several calcium releasing channels have been characterized: a group of three channels with 
homology to the Trp channel family are known to localize to the endosomal / lysosomal system: 
TRPML1, TRPML2 and TRPML3. All of them are non-selective cation channels which have been 
reported to be activated by phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2)
63. The other, 
recently discovered family of acidic compartment calcium channels comprises two two-pore 
channels (TPC1 and TPC2). TPC1 was first discovered in plants64 and later shown to be the target 
of the calcium-mobilizing agent nicotinic acid adenine dinucleotide phosphate (NAADP) in 
mammalian cells65. There is still some controversy around whether TPCs are actually the cellular 
targets of NAADP. Strong evidence obtained via different approaches, including reconstitution 
of purified TPC in artificial membranes66, single-lysosome patch-clamp67, and patch-clamp on 
plasma-membrane anchored TPCs65 showed that TPCs were NAADP-gated Ca2+-permeant 
channels. Two studies68,69 challenged this notion by finding that a cell-permeant version of 
NAADP remained able to invoke calcium increase in fibroblasts from a TPC1/TPC2 double 
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knockout mouse. However, this knock-out mouse may not have been generated properly, 
resulting in an N-terminal truncation and potential residual activity of the TPCs70,71. While 
NAADP should therefore not be discarded as the primary TPC activator, other ligands have also 
been found to stimulate TPC in a convergent fashion: Mg2+, PI(3,5)P2 and p38/JNK kinases were 
shown to regulate TPC2 channel activity70,72,73.  
Functional calcium release from acidic stores is crucial for vesicle fusion along the 
endolysosomal system74 and non-functional calcium homeostasis therefore contributes to the 
lipid storage phenotype in NPC. Mutations in proteins involved in acidic store calcium 
homeostasis cause severe diseases such as mucolipidosis type IV75 or Hailey-Hailey disease76. It 
is therefore vital to study the mechanisms and regulatory steps involved in acidic store calcium 
filling and release in order to find treatments for these diseases.  
1.4. The lysosome is a signaling hub involved in the initial steps of autophagy 
The biological function of the lysosome was long reduced to merely the “trashcan” of the cell, 
where cellular material is degraded through the action of lysosomal hydrolases and lipases. This 
‘endpoint’ way of thinking was recently challenged when several observations were made 
showing that the cell actively monitors lysosomal content and changes transcriptional activity 
according to this information. It was shown that the mechanistic target of rapamycin kinase 
complex (mTORC1), which is a master regulator of cellular growth, associates with the lysosomal 
surface77 to sense amino acid levels in the lysosome via the vacuolar H+-ATPase (v-ATPase)78. In 
starvation conditions, when amino acid levels are low, mTORC1 is dissociated from the 
lysosome and thereby inactive78 (see Figure 1.7).  
This inactive mTORC1 can no longer phosphorylate the transcription factor EB (TFEB), allowing it 
to translocate to the nucleus79. TFEB was identified as a transcriptional regulator of a whole 
gene network involved in lysosomal biogenesis and autophagy termed CLEAR (coordinated 
lysosomal expression and regulation)80. Functionally, TFEB induces biogenesis of lysosomes and 
autophagosomes, enhances their fusion and promotes degradation of their cargo. Other 
lysosomal functions, such as lysosomal exocytosis, are also influenced by TFEB81. 
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Figure 1.7 Schematic representation of the egulation of TFEB in the context of cellular metabolism. Figure is adapted from 
82
.  
The mechanism by which mTORC1 inactivation leads to TFEB nuclear translocation was recently 
identified and includes lysosomal calcium release through the actions of TRPML1, which 
activates the phosphatase calcineurin leading to dephosphorylation and nuclear translocation of 
TFEB82. These new discoveries place the lysosome at the center for sensing the metabolic state 
of the cell and for regulating cellular processes accordingly. They also open new therapeutic 
avenues for treating lysosomal storage diseases or metabolic disorders. For example, 
overexpression of TFEB has already yielded promising results in diseases such as Pompe 
disease83, Parkinson’s disease84, Alzheimer’s disease85 and Huntington’s disease86. 
1.5. NPC1 and TPC2 are necessary for successful infection of host cells by the 
Ebola virus 
The biological importance of understanding the NPC pathway as well as TPC dependent calcium 
signaling was recently highlighted by several findings which implicated a role of both proteins in 
filovirus infection. The Ebola virus (EBOV) as well as the Marburg virus (MARV) belong to the 
class of filoviridae, a family of enveloped, negative-stranded RNA viruses which infect humans 
and non-human primates and cause haemorraghic fever with mortality rates of up to 90 %87. 
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The 2013-2015 Ebola outbreak in West Africa with over 10 000 confirmed deaths88 underlined 
the dire need to develop therapies, because there are currently no Ebola-specific treatments 
available89. Recently, however, several important steps have been made in the investigation of 
the molecular basis of Ebola virus infection (see Figure 1.8).   
The binding of the virion to the host cell is dependent upon a single viral transmembrane 
domain glycoprotein (GP), the structure of which was recently identified90. GP consists of two 
subunits: a receptor-binding subunit GP1 and a membrane fusion subunit GP2, which are 
organized into trimeric spikes on the virion surface. Upon internalization into host cells via 
macropinocytosis91,92, the GP is cleaved by endosomal proteases (cathepsin L, cathepsin B) to 
remove the heavily glycosylated C-terminal domain of GP190,93,94. The remaining N-terminal 
domain of GP1 interacts with a host factor promoting dissociation of GP1 and GP2, driving GP2-
mediated membrane fusion and subsequent release of the nucleocapsid into the 
cytoplasm90,93,95.  
 
Figure 1.8 A model of EBOV entry. Figure is adapted from 
96
.  
A genetic screen in human haploid cells recently identified several candidate proteins 
responsible for successful filovirus entry97: all six members of the homotypic fusion and vacuole 
protein-sorting (HOPS) complex, which is responsible for lysosomal function and fusion were 
identified along with the lysosomal transmembrane protein NPC1. This suggests that the 
lysosome plays a critical role in the late stages of viral entry. In parallel, it was shown that 
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binding of the N-terminal GP1 to NPC1 is crucial for infection, and that small-molecule inhibitors 
of NPC-GP1 binding are successful in preventing EBOV infection98. These new findings open up 
new avenues for Ebola therapy by directly targeting the NPC1 protein. The importance of NPC1 
in EBOV infection was further strengthened in follow-up studies identifying NPC1 as an 
intracellular filovirus receptor due to its ability to overcome species barriers: Expression of 
human NPC1 in non-permissive reptilian cells rendered them susceptible to filovirus entry and 
infection42. In the same study, the luminal loop C of the NPC1 protein (filovirus receptor domain 
in Figure 1.4) was shown to bind the proteolytically truncated GP1 domain of EBOV and proved 
necessary and sufficient for filovirus entry42. These findings were recently confirmed in vivo, 
showing that Npc1-/- and even Npc1+/- mice were protected from EBOV infection and that NPC1 
was directly required for filovirus entry irrespective of its role in cholesterol homeostasis99.  
Aside from NPC1, other cellular processes have been shown to be crucial for successful EBOV 
infection. An siRNA screen on HEK293 cells identified several host cell genes which play critical 
roles during infection, most prominently a network of calcium or calmodulin dependent 
kinases100. Follow-up studies identified TPC2 to be necessary for successful EBOV entry101. The 
authors further demonstrate that drugs blocking TPC2 activity improve survival of EBOV 
infected mice, opening yet another avenue for Ebola-specific antiviral therapy.  
1.6. Studying the specific contributions of lipids to cellular processes is 
challenging 
Given the vast diversity of different lipid species, it is somewhat surprising that only some of 
them, for example certain diacylglycerol102 and phosphatidic acid103 species as well as 
phosphatidylinositol phosphates104 and sphingosine-1-phosphate105, are recognized second 
messengers with clear modes of action. Others are merely implicated in different cellular 
processes19,106, without knowing their precise signaling effectors. Functions for many other 
known lipids are not elucidated yet. One reason might be that lipids are part of a complex 
network. They are transiently generated and quickly converted by a sophisticated lipid handling 
machinery consisting of hundreds of proteins107.  
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Ideally, one would follow the localization and concentration of the investigated lipids in the 
cellular system with high accuracy. These requirements effectively restrict the experimental 
approaches to fluorescence microscopy or – if applicable – electrophysiology. However, well 
performing biosensors which would allow such precise monitoring only exist for a few lipids, 
such as diacylglycerols108 and several phosphatidylinositol phosphates109–113. Most of these 
biosensors are based on translocation of a lipid binding domain, but these translocation-based 
probes recognize the respective lipid well at the plasma membrane and not at other 
organelles114. Following the cellular distribution of lipids through the use of fluorescently tagged 
lipids is problematic as well since they are easily mislocalized owing to the lipophilic properties 
of many fluorophores. To faithfully follow endogenous lipid behavior, it is essential to minimally 
interfere with the biophysical properties of the lipid molecules115.  
Another challenge in studying the biology of lipids is the need to specifically manipulate lipid 
levels in cellular systems. Simply adding lipids to the medium or feeding organisms with the 
lipids of interest may not lead to an intracellular elevation of the same lipid species because 
they may already be modified and/or degraded before reaching concentrations at which they 
would affect cellular signals. Standard molecular biology techniques such as overexpression or 
RNAi mediated knockdown of a key lipid metabolizing enzyme are not ideal because they 
require many hours to take effect. During this time, the cells may compensate by 
transcriptionally regulating other parts of the lipid signaling network. A faster method employs 
rapamycin-mediated translocation of constitutively active lipid metabolizing enzymes to certain 
organelles, generating a local pool of the lipid of interest. This method has been successfully 
applied to the study of phosphoinositide signaling112,116–119. However, rapamycin itself inhibits 
the mTOR kinase complex and thereby also perturbs cellular signals120. New developments in 
non-inhibitory rapamycin-analogues121,122, light inducible translocation123 or novel chemical 
dimerizers124 already seek to circumvent this drawback. Another way to precisely elevate 
certain lipid species is to deliver biologically inert lipid precursors (‘caged’ lipids) to the cells and 
to release the lipids inside the cells by illumination with light (see chapter 1.6.1).  
Lipids affect cellular signals by interacting with lipid binding proteins, either by recruiting 
proteins to certain membranes125,126 or by binding and activating cellular receptors127,128, yet 
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studying the interactions between lipids and proteins remains challenging. Very few tools allow 
for a large-scale mapping of lipid binding proteins.  Two such screens were performed using lipid 
arrays on solid support.  First, a phosphatidic acid derivate was coupled to an agarose-based 
matrix and incubated with brain cytosol129. Proteins which showed suppressed binding in 
presence of soluble phosphatidic acid were identified by mass spectrometry and included 
several proteins involved in intracellular traffic such as coatamer, Arf and kinesin. A more recent 
screen used an array of over 50 lipids immobilized on nitrocellulose, probed the binding of over 
170 tandem-affinity purification (TAP) tagged yeast proteins and identified 530 distinct lipid-
protein interactions130. This approach works well to capture proteins interacting with the lipid 
headgroup, but due to the solid support, the lipids are not present in their native state and 
cannot interact with deeper binding pockets of the proteins.  
To overcome this drawback, a microarray was established where lipids were presented on 
liposomes. The binding preferences of fluorescently tagged protein lysates to 120 liposomal 
membranes with different lipid compositions have been monitored by automated 
microscopy131. In another approach, lipids binding to 13 TAP-tagged yeast lipid transfer proteins 
expressed at endogenous levels were identified by TLC and mass spectrometry after affinity 
purification. The results show that two oxysterol binding protein homologs (Osh6 and Osh7) 
bind phosphatidylserine and mediate its transport from the ER to the plasma membrane132. 
Regrettably, all these methods are restricted to cytosolic proteins, because the detergent-based 
solubilization of the membrane necessary for integral membrane proteins also disrupts specific 
protein-lipid interactions. Given the wide variety of cellular lipids as well as integral membrane 
proteins, it is likely that specific interactions of lipids with membrane proteins occur within the 
lipid bilayer. One such example is the regulation of p24, an integral membrane protein of COPI 
vesicles, by a single molecular species of sphingomyelin (SM18:0). The interaction of SM18:0 
with p24 has been pinpointed to a four-residue motif within the transmembrane domain133. This 
highlights the need to systematically map protein-lipid interactions and to include integral 
membrane proteins in those screens. One promising avenue is the application of 
photoactivatable and clickable (bifunctional) lipid analogues, which allows for a proteome-wide 
screening of lipid binding proteins in living cells (see chapter 1.6.2).  
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1.6.1. Caged lipids are useful tools for studying intracellular signaling 
One way to increase the concentration of a specific lipid in living cells with high accuracy in time 
and space is to liberate caged lipids by a flash of light. We have recently reviewed caged lipids 
with respect to design considerations as well as applications in biological systems134 and the key 
aspects are only briefly discussed here. Caged lipids are obtained by masking a key group 
essential for the activity of the lipid with a photoremovable protecting group through chemical 
synthesis, thereby rendering the lipid inactive. The hydrophilic headgroup of lipids is crucial for 
interactions with the cellular machinery, and the functional groups (alcohol groups, amino 
groups, phosphates) are easily accessible for chemical modification. All reported caged lipids 
have therefore been modified at the headgroup, using either nitrobenzyl-derived or coumarin-
derived caging groups134 (see Figure 1.9).  
 
Figure 1.9 Chemical structure of two commonly used caging groups. 4,5-dimethoxynitrobenzyl (DMNB) and N,N-
diethylaminocoumarin (DEAC). 
The main differences in the cages result from their respective photophysical properties: the 
absorption spectra of coumarin-groups are red-shifted with respect to nitrobenzyl groups. This 
enables successful uncaging using the 405 nm laser of a standard microscope setup, while 
nitrobenzyl-modified lipids have to be uncaged with a special UV-laser because their absorption 
maximum lies at 365 nm134. Irradiating living cells at these wavelengths could lead to 
photodamage, which needs to be controlled for. Another difference is the inherent fluorescence 
of the coumarin groups which allows monitoring the loading of the compound either by 
fluorescence microscopy or via TLC. The photochemical mechanism of uncaging is another, 
fundamental distinction between the caging groups. While nitrobenzyl groups decay via an aci-
nitro intermediate135, coumarins are most likely cleaved by solvent-assisted photo-
heterolysis136, leaving different byproducts which could potentially influence the observed 
signal. It is therefore good practice to include a positive control compound using a caging group 
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with a different uncaging mechanism.  Another key consideration in the application of caged 
lipids is the delivery of the lipid to living cells. Due to their hydrophobic nature, caged lipids 
sometimes require addition of mild, non-ionic detergent. This does not hold true for uncharged 
lipids with only one hydrophobic tail (such as sphingosine or mono-acylglycerols), which cross 
the plasma membrane spontaneously without any detergent. The presence of charged groups 
on the lipids (such as phosphate, choline or ethanolamine) makes delivery over the plasma 
membrane impossible and requires more sophisticated delivery techniques. Microinjection is 
not recommended because it results in severe disturbances to the membrane which could make 
it impossible to observe any naturally occurring signaling events. The best strategy is to mask 
the charges on the headgroup by chemically attaching bioactivatable protecting groups such as 
butanoyl-, acetoxymethyl- or S-acetyl-thioethyl-groups, rendering the molecule neutral. After 
successful passing of the plasma membrane, intracellular esterases cleave these protecting 
groups, restoring the original charges. The biological activity of the lipid is then restored after 
uncaging with a flash of light (see Figure 1.10).  
 
Figure 1.10  Schematic diagram illustrating the application of caged, membrane-permeant lipids.  
Owing to the speed of lipid release after photo-uncaging, caged lipids are ideal tools to study 
highly dynamic processes in membrane biology in a non-invasive way. Somewhat surprisingly, 
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so far only 20 individual lipids have been reported in caged from, and even fewer have found 
application in studying biological questions134. An important example is the caged version of 
sphingosine-1-phosphate, which was first synthesized and used by the Spiegel group137 and later 
made commercially available. It proved crucial in distinguishing receptor-mediated S1P-
dependent pathways from those which result from intracellular S1P targets138–140. These results 
illustrate that, once made broadly available, caged lipids have the power to answer many 
biological questions, especially those where high temporal and spatial resolution is important.  
1.6.2. Proteome-wide identification of lipid-binding proteins by bifunctional lipids  
In vitro methods to study protein-lipid interactions rely on either purified proteins or cell lysates 
and are therefore limited to soluble proteins. In order to develop new methods for identifying 
protein-lipid interactions in the native environment, several advances in chemistry were 
necessary. First, a covalent bond between lipid and protein is essential to preserve the lipid-
protein complex during solubilization of membrane proteins. Such covalent bonds are created 
upon UV illumination of lipids modified with certain photoactivatable groups (Figure 1.11), 
which create a highly reactive intermediate (e.g. carbene or nitrene) and are able to insert into 
any chemical bond of the target proteins. 
 
Figure 1.11 Photoactivatable groups used in photoaffinity labeling experiments. 
Further requirements for such photoactivatable groups in use in the cellular system are mainly 
the stability in non-activating conditions, so that the reducing environment of the cell and 
cellular enzymes do not modify the group before photoactivation, as well as rapid photolysis 
rates in order to avoid long UV exposure times which are damaging to the sample. Additionally, 
the crosslinking reaction of the UV activated probes should proceed quickly and non-selectively 
with molecules in their direct environment, to increase specificity and reduce background 
crosslinking with small molecules such as water. Well-known photoactivatable groups which 
would fulfill these criteria such as benzophenones, aryl azides or aryl-trifluoromethyldiazirines 
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are too large to be incorporated into small molecules such as lipids without significantly 
changing their physicochemical properties. Smaller groups such as alkyl azides were employed 
in early studies of photoactivatable lipids141, but were later found to require too harsh 
photoactivation conditions to be useful in biological studies142. Alkyl diazirines however, show 
remarkable chemical stability even during peptide synthesis and incorporation into proteins in 
mammalian cells, as demonstrated by the application of alkyl diazirine-modified leucine and 
methionine for protein-protein crosslinking experiments143. 
The first lipids modified with alkyl diazirines were cholesterol144 and sphingosine145. Both lipids 
were also radiolabeled by incorporation of 3H to identify the captured protein-cholesterol or 
protein-sphingolipid complexes. One drawback of this design is that it does not allow for 
proteome-wide identifications, since every candidate protein has to be immunoprecipitated, 
purified and probed via autoradiography.  
The other important advance in chemistry was the introduction of click chemistry by Sharpless, 
Finn and Kolb146. Especially Cu(I) mediated cycloaddition between alkyne and azide groups147 
(Figure 1.12) opened up new possibilities for modifying lipids.  
 
Figure 1.12 Copper(I) catalyzed alkyne-azide cycloaddition. 
The alkyne group shows similar advantages to the diazirine group: it is small and interferes 
therefore only minimally with the structure of the modified lipid, it is stable in the cellular 
environment and unreactive with any naturally occurring functional group.  
A combination of both the diazirine as well as the alkyne functionality on the same lipid gives a 
powerful tool which enables the identification of protein-lipid complexes in the natural 
environment. As the lipid is only modified with small additional functionalities, it closely mimics 
its natural counterpart in localization and protein interaction. These interactors are then 
captured by covalent crosslinking upon UV irradiation. The major advantage of such a 
bifunctional design is the fact that functionalization of the probe (e.g. with biotin for a 
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subsequent avidin-mediated pulldown) happens after crosslinking to its interacting partners 
(see Figure 1.13). Therefore the bulky biotin modification does not inhibit protein-lipid 
interactions at all. 
A second advantage is the versatility of the functionalization. The same photoactivatable and 
clickable lipid can be used to probe the subcellular localization of said lipid at different time 
points, thereby following the metabolism and traffic within the cells (Figure 1.13, right-hand 
side). This is achieved by crosslinking of the lipid to its interaction partners and subsequent 
fixing of the cells. This new covalent bond makes rigorous washing steps possible, which reduces 
the background due to non-crosslinked lipids. Furthermore lipid mobility in the membranes, 
which is known to occur even with aldehyde fixation techniques148, is abolished by the covalent 
binding to large, crosslinked biomolecules. Bifunctional lipids are therefore best suited to 
faithfully display the subcellular localization of lipids, a challenge which has occupied the lipid 
biology field for decades115.  
 
Figure 1.13 Application of bifunctional lipids for mass spectrometry and confocal microscopy.  
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So far, only few photoactivatable and clickable lipid species have been reported. A major reason 
for this is certainly the substantial effort necessary for the lengthy synthesis of each individual 
lipid species. The introduction of the diazirine group in particular suffers from poor yields of 
around 30 %144,145. The first reported bifunctional lipids were phenylazide- and benzophenone 
derived phosphatidylcholines (PC) with an alkyl azide as a click handle149. They were used to 
probe PC binding partners on mitochondrial inner membranes.  
The first bifunctional lipid featuring the diazirine/alkyne combination was reported in 2009 with 
the application of a bifunctional cholesterol to map cholesterol-interacting proteins in living 
cells150. In stable isotopes of amino acid in culture (SILAC) screens, 265 proteins were identified 
which showed specific interaction with cholesterol as determined in competition assays. In a 
different approach, Haberkant et al.151 used a bifunctional C15 fatty acid precursor, which upon 
feeding to cells readily incorporated into all glycerolipids, but not into sphinoglipids. 
Crosslinking, affinity purification and mass spectrometry revealed 105 high-confidence 
glycerollipid-binding proteins. Additionally, this study introduced the power of visualizing lipids 
using bifunctional precursors in whole organisms by imaging the glycerolipid distribution in C. 
elegans.  
Another, very recent study employed a variety of different bifunctional lipids: arachidonyl-, 
stearoyl-, palmitoyl- and oleyl-containing endocannabinoids as well as bifunctional arachidonic 
acid to perform in-depth screens of the lipid interactome. Additionally, the geometry of protein 
binding on the lipid (e.g. interactions with the lipid headgroup vs binding of the lipid in a 
hydrophobic pocket) was probed by performing screens using precursors with varying position 
of the photoactivatable diazirine group (on the headgroup vs. on the lipophilic tail)152. 
Furthermore, the impact of different drugs on the lipid-interaction proteomes was profiled, 
showing the applicability of such bifunctional probes to map drug target and off-target effects 
as well as to identify new, potentially drugable proteins. The study progressed even further, 
screening functional ligands of these newly identified proteins (such as nucleobindin-1 (NUCB1)) 
and used these ligands to characterize the biochemical function of NUCB1 which is to facilitate 
transfer of N-acyl ethanolamides and N-acyl taurins to their respective metabolic enzymes152. 
The last study is an impressive example of the power of bifunctional lipids not only in 
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discovering novel lipid-interacting and potentially drugable proteins, but also in elucidating the 
biochemical functions of these newly discovered proteins.  
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Aim of the thesis 
Investigating the roles of lipids in cellular signaling is still limited by challenges such as the 
manipulation of lipid concentrations inside living cells or the identification of protein-lipid 
interactions. Sphingosine is a central lipid in the sphingolipid metabolic network, yet little is 
known about its signaling properties or its protein interactors other than metabolic enzymes. It 
has been implicated in apoptosis signaling and has been shown to accumulate in the lysosomal 
storage disorder Niemann-Pick disease type C, but the exact mode of action has not been 
elucidated so far. We envision that chemical biology can provide tools to overcome the 
difficulties faced in studying lipid signaling which will further the understanding of sphingosine 
mediated pathways and, eventually, lead to a treatment of Niemann-Pick type C.  
The main aim of this work is to manipulate sphingosine levels in living cells and monitor the 
downstream effects. Caged lipids provide an elegant, non-invasive method to increase their 
concentration with high spatial and temporal precision, permitting the study of fast-acting 
signaling events such as calcium signaling. Therefore the synthesis of caged sphingosine, a 
positive control equipped with a different caging group as well as a caged version of a closely 
resembling lipid, dihydrosphingosine as a negative control will be a major synthetic goal. In the 
first part, sphingosine-induced calcium signaling will be investigated in HeLa cells, but the assay 
will later be transferred to fibroblasts derived from patients suffering from Niemann-Pick C, as it 
is known that Niemann-Pick C cells feature chronic sphingosine accumulation as well as 
defective acidic store calcium homeostasis.  
In addition, we will improve on the bifunctional lipid technology so that protein interactomes of 
single lipid species can be captured. To this end, we will add a cage group to bifunctional 
sphingosine, characterize the resulting trifunctional probe and screen for proteins which 
uniquely interact with sphingosine. Furthermore, the trifunctional sphingosine will be a great 
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tool for studying the subcellular localization and transport of sphingosine in living cells using 
pulse-chase experiments. This probe will be applied to the study of NPC patient fibroblasts in an 
attempt to find a biomarker for predicting the severity of symptoms in NPC patients based on 
the extent of Sph storage.  
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Chapter 2 - Results and Discussion 
2.1. Caged sphingosine is a useful tool to investigate cellular signaling 
The specific effects of Sph on intracellular signaling pathways are difficult to tease apart, mainly 
due to a lack of tools to precisely manipulate Sph levels in living cells. As with other biologically 
active lipids, traditional methods of lipid manipulation have drawbacks which make it impossible 
to study acute downstream signals of Sph (see chapter 1.6.). Exogenously added free Sph, for 
instance, is both quickly metabolized to Cer and subsequently higher sphingolipids and it is 
broken down via the S1P-lyase pathway before it reaches intracellular concentrations which are 
comparable to an endogenously occurring signal. Therefore, it is challenging to attribute a 
certain signaling outcome to the lipid added and to exclude contributions of up- or downstream 
metabolites. On the other hand, overexpression of Sph-producing enzymes such as ceramidases 
often takes days, during which time the cell may turn on compensatory mechanisms to maintain 
low Sph concentration inside cells such as the up-regulation of the S1P-lyase pathway. One way 
to overcome this problem would be to use small molecules which penetrate the cell membrane 
easily and then quickly act on these enzymes. However, only a few molecules are known to 
specifically act on sphingolipid metabolizing enzymes, and all of them have inhibitory action153. 
No small molecule activator of any of the five known ceramidases has been reported so far.  
Another way to rapidly elevate Sph inside cells is to design caged variants of Sph, which 
circumvent ongoing sphingolipid metabolism and allow for the specific release of Sph during the 
experiment. The caging methodology is very successful and has been broadly applied to the field 
of neurotransmitters and other second messengers154. However, only two studies have ever 
reported the use of caged Sph. More than 15 years ago, Zehavi published the synthesis155 and 
application of caged Sph and dhSph in dorsal root ganglion neurons156. The caging group was a 
first-generation nitrobenzyl group directly attached to the amino group of the sphingoid 
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backbone, and uncaging was achieved by a xenon flash lamp with a bandpass filter of 365 nm ± 
110 nm. Both Sph and dhSph showed a Ca2+-activated inward rectifying current as measured by 
whole cell patch clamp156. These findings gave the first hint of a connection between 
sphingolipid and calcium signaling, but they have not been followed up. In the meantime, new 
caging groups with faster photolysis rates have been developed157 and advances in microscope 
hardware make it possible to uncage at single wavelengths, thereby avoiding potential 
photodamage likely to result from the shorter UV wavelengths of a bandpass filter. In this 
project, we have made use of these advances and synthesized new versions of caged Sph to 
study Sph-mediated calcium signaling in living cells. 
2.1.1. Design and synthesis of caged sphingosine 
For this work we chose to use a N,N-diethylamino-coumarin (DEAC) group as the principal 
caging group for Sph. This group allows for efficient and rapid uncaging at longer wavelengths 
than commercially available nitrobenzyl-caging groups158. An additional advantage of the DEAC 
group is its fluorescent properties which permit monitoring of DEAC-caged Sph (Sph-Cou) on the 
microscope in order to check labelling of the cells. To exclude any contribution of the cleaved 
group to the observed signal, we synthesized as a positive control Sph caged with a 4,5-
dimethoxy-nitrobenzyl (DMNB) group (Sph-NB). As a negative control dihydrosphingosine was 
chosen. dhSph is a naturally occurring, close structural analogue of Sph which differs only by 
one double bond from Sph. For the control experiments, dhSph was also caged with a DEAC 
group (dhSph-Cou).  
In order to prevent recognition and metabolism of the caged coumpounds by the cellular 
machinery, the caging group must be located at the head group of the lipids. In addition, the 
only functional groups on Sph and dhSph available for synthetic chemistry are within the head 
group. We therefore chose to attach the cage groups to the amino functionalities of Sph and 
dhSph since the higher reactivity of the amino group compared to the alcohols allowed us to 
perform protection group-free synthesis. Figure 2.1 shows the synthetic protocols used for the 
three compounds used in this study.  
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Figure 2.1 Synthesis of caged Sph derivates. N,N-diethylaminocoumarin-caged Sph (Sph-Cou), 4,5-dimethoxynitrobenzyl-caged 
Sph (Sph-NB) and N,N-diethylaminocoumarin-caged dhSph (dhSph-Cou).  
We chose to link Sph/dhSph to the cage groups by a carbamate linker. This leads to CO2 release 
after photolytic cleavage which drives the reaction forward by shifting the equilibrium to the 
side of the free lipid. The carbamate link was obtained by reacting the chloroformate derivates 
of the cage groups with the lipids at room temperature for 1 h, giving 45 – 95 % isolated yields. 
The target compounds were purified using column chromatography and the identity of the final 
caged lipids was confirmed using nuclear magnetic resonance (NMR) and high-resolution mass 
spectrometry (see chapter 3.2 and NMR spectra in Appendix A). 
2.1.2. Caged sphingosine is stable in the cellular environment 
We first used thin layer chromatography (TLC) to determine whether caged Sph was inert inside 
cells prior to uncaging. HeLa cells were incubated with 2 µM Sph-Cou for different time periods 
and some samples were subsequently illuminated with a mercury arc source equipped with a 
400 nm highpass filter for 2 min. The cells were pelleted and the cellular lipids were extracted 
according to the protocol developed by Thiele’s group159, using a mixture of chloroform / 
methanol / acetic acid. The extracts were developed on silica TLC plates and visualized using the 
fluorescence of the coumarin group. Figure 2.2 shows a time-dependent uptake of intact Sph-
Cou into cells. As expected, higher intensities were observed for longer incubation times. Photo-
cleavage was observed as a drop in intensity for each +UV condition. Comparing the intensities 
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of the non-irradiated with the irradiated bands, we estimated the extent of the photoreaction in 
this setup at 70 %.  
 
Figure 2.2 Stabilty of caged Sph in cells. TLC analysis of lipid extracts of HeLa cells incubated with 2 µM Sph-Cou. The background 
was subtracted using Fiji software.  
Most importantly, Figure 2.2 shows no additional DEAC-labelled lipids, even with one hour 
incubation periods. This indicates that the Sph-Cou is stable in the cellular environment and that 
the free alcohol groups on the Sph headgroup did not undergo further modification (for 
example with phosphates or cholines) by any sphingolipid metabolizing enzyme.  
However, this experiment does not rule out the possibility that the carbamate bond of Sph-Cou 
could have been cleaved by cellular enzymes. The loss of the coumarin group would make the 
resulting lipids invisible on TLC. To obtain a quantitative estimate of the Sph concentration 
inside cells, we subjected cellular extracts of Sph-Cou treated cells to lipidomic analysis as 
follows: Cells were labelled with 2 µM Sph-Cou for 15 min and subjected to UV treatment as 
described above. As controls, non-labelled HeLa cells as well as labelled but non-UV treated 
HeLa cells were collected. C17 standards were added to the cells for normalization after the 
extraction. Cellular lipids were extracted using a one-phase pyridine extraction protocol160 to 
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minimize loss of S1P and dhS1P, and were derivatized with the fluorescent label 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC)161. The sphingoid bases were analyzed 
on a TSQ Vantage and their amounts were normalized to their C17 counterparts. 
 
Figure 2.3 Comparative lipid analysis by mass spectrometry shows a specific increase in Sph upon uncaging. Values are 
normalized to the internal standards. Mass spectrometric analyses were perfomed by Auxiliadora Aguilera-Romero (University 
of Geneva, Switzerland).  
Figure 2.3 shows the relative amounts of Sph, S1P, dhSph and dhS1P detected in control, non-
UV treated (caged) and UV-treated (uncaged) conditions. The stability of the caged Sph in the 
cells was confirmed because comparable levels of Sph were measured in control and non-UV 
treated conditions, indicating that no cleavage of the carbamate linkage of Sph-Cou took place. 
Additionally, incubation with Sph-Cou did not perturb the lipid homeostasis in the cells because 
all investigated lipids showed similar concentrations compared to control conditions. Upon 
illumination of cells incubated with Sph-Cou, Sph levels were found at 3.4 times as high than in 
control samples. This increase was specific for Sph and was not observed for dhSph. The levels 
of S1P, however, increased in UV-treated conditions to 2.105 a.u., which corresponded to a 9.6 
fold increase over control. We attributed this increase to ongoing metabolism during and after 
the uncaging reaction, which was carried out using a mercury arc source for 2 min. This 
comparably long time was necessary to ensure complete uncaging of all cells in this setup. To 
minimize metabolism, cells were kept on ice throughout the experiment, however it seems that 
the time for the uncaging reaction as well as the following steps (collection of the cells and 
extraction of the lipids) was long enough that phosphorylation reactions occurred to a 
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significant extent even at 0 °C. The magnitude of the S1P increase (9.6 fold vs 3.4 fold for Sph) is 
explained by the generally low abundance of S1P in cells. Therefore, even if only a small portion 
of the liberated Sph was converted to S1P it resulted in a high increase. 
2.1.3. Sph release after uncaging transiently increases cytoplasmic calcium levels 
Intracellular calcium signaling has been intensively studied for a long time162. This has led to the 
development of a wide variety of different probes able to sense calcium concentrations inside 
cells163,164. The main types are small-molecule-based fluorescent calcium indicators, and 
genetically encoded, protein-based calcium sensors. In this work, especially with regards to 
eventually studying NPC-patient derived cells which cannot easily be transfected, we chose to 
work with a small-molecule based dye, namely Fluo-4 (Figure 2.4), which is delivered to cells 
using a lipophilic AM-ester modification that allows it to pass the plasma membrane165. 
Intracellular esterases then cleave off this modification and restore the active calcium sensing 
molecule. Fluo-4 undergoes fluorescence enhancement upon binding to Ca2+ 165. An increase in 
free cytoplasmic calcium is therefore reported by an increase in Fluo4 fluorescence intensity.  
 
Figure 2.4 Fluo4-AM is an intensiometric cytoplasmic calcium indicator.  
To check whether a sudden release of Sph following uncaging affects the cytoplasmic calcium 
concentration, HeLa cells were labelled with Fluo-4 for 30 min to allow for sufficient esterase 
cleavage as indicated by the manufacturer’s instructions. Cells were incubated with Sph-Cou for 
15 min before being put under the microscope. The uncaging experiment was performed on a 
confocal microscope by acquiring a baseline of 10 s before uncaging with a 405 nm laser 
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(375 nm laser for Sph-NB) in a local, circular area (~ 9 µm2) inside the cell for 3s for Sph-Cou and 
dhSph-Cou and for 6 s when Sph-NB was used. This microscope setup allowed for much shorter 
uncaging times compared to the whole-dish uncaging setup used for TLC and lipidomic 
experiments (chapter 2.1.2.). This should minimize the impact of any post-uncaging metabolism. 
The fluorescence of the Fluo-4 indicator after uncaging was monitored at a frequency of 1 frame 
per second. Cells loaded with Sph-Cou or Sph-NB responded with an immediate (1-5 s) and 
transient increase in cytoplasmic calcium, whereas neighboring, non-irradiated cells did not 
respond at all. This illustrates the high specificity in location that is possible with caged lipids. 
Figure 2.5a shows exemplary time-lapse confocal microscopy images of Fluo4-labelled HeLa 
cells after Sph-Cou in the indicated area within the cells. The experiments were repeated on 
different cells some distance away from the previously examined cell, so that only 4-5 cells were 
imaged in the same LabTek well. Whole-cell fluorescence intensity values of all uncaged cells 
were measured using the FluoQ macro for Fiji166 and averaged using R167.  
 
Figure 2.5 Local uncaging of Sph leads to calcium transients. A) Time-lapse confocal microscopy images of Fluo-4 labelled HeLa 
cells. B) Mean Fluo-4 fluorescence traces of cells loaded with Sph-Cou (17 cells), Sph-NB (15 cells), and dhSph-Cou (29 cells). 
C) Histogram of the maximum single-cell amplitudes. The threshold for responding cells  (vertical line) was set at 20 % amplitude 
increase over baseline.  
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Figure 2.5b shows the mean Fluo-4 intensity over time with the standard error of the mean 
plotted as error bars.  The calcium increase after Sph-Cou uncaging was also observed with the 
positive control Sph-NB. The only difference was the time of uncaging with was 6s for Sph-NB 
due to different photocleavage reactions. This resulted in a slightly slower onset of the 
response, which is partly explained by stronger bleaching of Fluo-4 when the 375 nm laser was 
used. On the other hand, the negative control compound dhSph-Cou did not evoke a calcium 
signal upon uncaging, indicating that the irradiation itself is not contributing to the increase in 
Fluo-4 fluorescence intensity. Furthermore, this illustrates that the Sph handling machinery 
follows such tight structural specifications that even a close analogue did not elicit a calcium 
signal. The promptness of the calcium increase seconds after Sph uncaging was a first hint that 
the observed response is due to Sph and not a downstream metabolite, which would take time 
to form. 
To analyze single cell responses in more detail, the maximal amplitudes of the intensity traces of 
each irradiated cell were extracted and plotted in a histogram fashion (Figure 2.5c) with a 
threshold for responding cells set at 20 % increase over baseline. While all cells responded with 
Sph-Cou, less than 15 % (4 out of 29 cells) responded under control conditions (dhSph-Cou). 
Moreover, under control conditions, the few responding cells gave rise to markedly reduced 
amplitudes, further demonstrating the validity of dhSph as a negative control compound in this 
experiment.  
To further ascertain that Sph is indeed the effector of this signal, we had to exclude any 
contribution of sphingosine-1-phosphate (S1P) formed post uncaging, as S1P is a potent 
calcium-mobilizing signaling lipid itself138,168,169. First attempts to silence both variants of the 
sphingosine kinase SK1 and SK2 using RNAi approaches were unsuccessful because cells did not 
survive the transfection. This is not particularly surprising as the sphingosine kinase/S1P lyase 
pathway is the only known way to degrade sphingolipids. A knockdown of the sphingosine 
kinases would lead to an accumulation of sphingolipids of which especially Sph and Cer are 
known to promote apoptosis12. We therefore turned to using several small molecule inhibitors 
of sphingosine kinases (Figure 2.6).  
Chapter 2 – Results and Discussion 
 
 
33 
 
 
Figure 2.6 Chemical structures of sphingosine kinase inhibitors. 
1) Dimethylsphingosine (DMS) is a natural sphingosine analogue in some cancer cells and 
a competitive inhibitor of both sphingosine kinases with IC 50 values of 60 µM for SK1 and 
20 µM for SK2170–172. However, it has been shown to have several non-specific off-target 
effects173,174.  
2) FTY720 is another sphingosine analogue, also known as Fingolimod, an 
immunosuppressant approved for treatment of multiple sclerosis. Its active, phosphorylated 
form acts on the S1P-receptors (S1PR), leads to S1P-R degradation and reduces circulating levels 
of T-lymphocytes175. Additionally, there is evidence that unphosphorylated FTY720 is an 
inhibitor of the catalytic activity of SK1176.  
Both of these described inhibitors would compete with the uncaged Sph for the binding to SK1 
or SK2, therefore we also chose a third, non-competitive inhibitor.  
3) SKI-II is not a Sph analogue and inhibits both SK1 and SK2, but is not active for other 
kinases. It acts as a mixed inhibitor for Sph and ATP binding on SK1177, however its action on SK2 
has not yet been studied.  
 
Figure 2.7 Inhibition of Sph kinases. A) Mean fluorescent traces of HeLa cells with and without SK-inhibitors. B) Histogram of the 
maximum amplitudes (20 % threshold, vertical line). 
Figure 2.7 presents the data for this set of experiments. It can be seen that HeLa cells treated 
with these inhibitors exhibited similar calcium traces with respect to onset and amplitude of 
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response compared to untreated cells, indicating that the uncaged Sph and not its S1P 
metabolite was responsible for eliciting this calcium response. Single cell analysis in Figure 2.7b 
showed slightly reduced response rates in the case of treated cells for all three inhibitors 
compared with untreated cells. This effect could stem from off-target effects of these inhibitors 
In spite of the minor effect of these inhibitors on calcium amplitudes, we concluded that rapid 
release of Sph directly leads to a transient increase in cytoplasmic calcium without involving 
S1P.  
Addition of free Sph to the medium did not evoke calcium transients at concentrations of up to 
5 µM. However, concentrations of free Sph greater than 6 µM killed cells frequently. The 
reasons for the lack of calcium response upon stimulation with free Sph have not been 
experimentally addressed. We hypothesize that cells have mechanisms for preventing the 
uptake of too high concentrations Sph. Any added lipid would also be subject to immediate 
metabolism (especially degradation through the S1P-lyase pathway). Only a rapidly generated 
Sph increase inside cells would lead to the observed calcium response.  
2.1.4.  Sph-induced calcium release originates at the acidic stores 
To determine how the increase in cytosolic calcium levels upon Sph release was achieved and 
where in the cell the calcium was released from, we performed several inhibition experiments: 
First, we complexed extracellular calcium by changing the medium to calcium-free buffer 
supplemented with 0.1 mM ethylene glycol tetraacetic acid (EGTA) and added 5 mM Ni2+, which 
blocks plasma membrane calcium channels in an unspecific way (PM block).  
 
Figure 2.8 Investigating the source of Sph-induced calcium. A) Mean fluorescent traces of HeLa cells in control conditions (41 
cells), in conditions blocking the plasma membrane calcium channels (PM block, 41 cells) or by blocking the InsP3 receptors at 
the ER using Xestospongin C (25 µM, 13 cells). B) Histograms of the maximum amplitudes with a baseline of 20 %.  
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We performed uncaging experiments under these conditions and observed that cells still 
reacted to the increase of Sph with calcium transients (Figure 2.8). Even though the mean 
amplitude of the calcium response was reduced and the response rate (derived from single cell 
maximum amplitudes, Figure 2.8b) was at 61 % in PM block conditions compared to 88 % in 
control conditions, the initial (0 – 6 s after uncaging) increase in calcium is identical to control 
conditions, suggesting that influx of calcium from the outside is not the primary route. It might, 
however, be required for propagation of the signal via calcium induced calcium influx through 
plasma membrane channels. This could account for reduced amplitudes and response rates in 
PM block conditions.   
In a separate experiment, the contribution of ER calcium store to the calcium response was 
investigated by using an inhibitor of the inositol trisphosphate receptor, Xestospongin C178. 
Uncaging Sph under these conditions led to similar calcium signals with only slightly reduced 
amplitudes but comparable response rates (Figure 2.8) to cells without inhibition. This 
suggested that the inositol trisphosphate receptor was not involved in Sph-induced calcium 
release. 
To further strengthen the hypothesis that ER calcium was not released after Sph uncaging, we 
performed pre-release experiments. Adding ATP to the medium at t = 10 s stimulated G-protein 
coupled receptors and subsequently ER calcium was released (Figure 2.9).  
 
Figure 2.9 Pre-release experiments. A) Mean fluorescence traces of HeLa cells stimulated with 10 µM ATP (11 cells) or 200 mM 
glycyl-L-phenylalanine-beta-naphthylamide (GPN). Uncaging was performed at t = 100 s as indicated by the horizontal bar. B) 
Histogram of the maximum amplitudes. The threshold for responding cells was lowered to 10 % amplitude change over 
baseline.  
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The increase in cytosolic calcium was monitored and Sph uncaging was performed after the 
transient had passed (at t = 100 s). As expected, Sph release led to a second calcium transient 
even after the ER store had been emptied, suggesting that another intracellular calcium store 
was involved. These findings further supported the hypothesis that indeed Sph, and not S1P was 
responsible for these calcium transients, since S1P has been shown to release calcium from the 
ER138.  
Another, important calcium store is comprised of acidic vesicles such as endosomes and 
lysosomes, which contain up to 600 µM calcium62. To investigate their involvement in the Sph-
induced calcium response, a separate pre-release experiment was performed. Glycyl-L-
phenylalanine-beta-naphthylamide (GPN) is hydrolyzed by cathepsin C in lysosomes and causes 
osmotic lysis of acidic vesicles, consequently releasing their calcium179. After adding GPN to 
HeLa cells, a calcium increase similar to ATP stimulation was observed. However, uncaging Sph 
after the transient had passed failed to induce a second signal (Figure 2.9, orange trace), 
thereby strongly supporting the acidic compartment as the principal organelle to release its 
calcium in response to stimulation with Sph. This result is a novel finding which links 
sphingolipid metabolism to lysosomal calcium signaling and potentially constitutes a first 
confirmed function for Sph in cellular signaling.  
2.1.5. Sph-induced calcium release from acidic stores requires TPC1 
The mechanisms responsible for acidic store calcium release are not yet well defined. Several 
channels located to endosomes and lysosomes have been identified, most importantly the two-
pore channels (TPC1 and TPC2) as well as mucolipin channel 1 (TRPML1). TPCs have recently 
been shown to be activated by nicotinic acid adenine dinucleotide phosphate (NAADP)180,181, by 
Mg2+ and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2)
72. PI(3,5)P2 has also been implicated 
in the regulation of TRPML1182. In this study, Sph-induced calcium release was investigated in 
cells devoid of TPCs or TRPML1 to see whether one of these channels was involved in this 
response as follows. First, we used fibroblasts derived from patients suffering from 
mucolipidosis type IV (MLIV), a disease characterized by mutations resulting in loss-of-function 
of TRPML175. Uncaging Sph in these cells did not attenuate the calcium signal, but led to calcium 
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transients with even higher mean amplitudes compared to fibroblasts derived from healthy 
controls (Figure 2.10a).  
 
Figure 2.10 Contribution of TRPML1 channel. A) Mean fluorescent traces of control and mucolipidosis type IV (MLIV) patient 
derived fibroblasts. B) Histogram of the maximum observed amplitudes compared to baseline with the threshold set at 10 % 
increase over baseline. 
MLIV patient derived fibroblasts exhibit a markedly different morphology to previously studied 
HeLa cells, mainly a bigger size. While the area and duration of uncaging was kept the same in 
all experiments across cell types, the calcium amplitudes were reduced in patient fibroblasts 
because the Fluo-4 intensities were averaged over a bigger area. The threshold of response for 
analyzing single cell responses was therefore reduced to 10 % increase over baseline compared 
to 20 % increase in HeLa cells (see vertical line in Figure 2.10b). Only one out of 20 control 
fibroblasts and one out of 34 MLIV patient-derived fibroblasts were non-responsive to Sph-
uncaging. We therefore concluded that TRPML1 does not mediate Sph-induced calcium efflux 
from the acidic stores.  
To investigate the contribution of two-pore channels, we employed embryonic fibroblasts 
derived from mice devoid of either TPC1, TPC2 or both (double knock-out, DKO)183. Again, an 
immediate calcium increase upon Sph uncaging was observed in WT mouse embryonic 
fibroblasts (Figure 2.10). TPC2 knock-out fibroblasts gave rise to comparable, if only slightly 
reduced amplitudes and response rates, indicating that TPC2 was probably not involved in the 
calcium response. 
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Figure 2.11 Two-pore channel knock-out studies. A) Mean fluorescent traces of primary mouse embryonic fibroblasts.                
B) Histograms of the maximum amplitudes compared to baseline, with a threshold at 10 % increase over baseline.  
TPC1 knock-out fibroblasts, on the other hand, gave a significantly reduced mean calcium 
response compared to wild type and TPC2 knock-out cells. Only 6 out of 25 TPC1KO cells 
showed a response upon uncaging, and the maximum amplitudes of these responders were 
markedly decreased compared to wild type and TPC2KO (Figure 2.11b). We infer that TPC1 is 
responsible for releasing calcium from the endolysosomes upon increase in Sph concentration. 
To verify this finding, we employed fibroblasts from a TPC double knock-out mouse and again 
performed uncaging experiments. DKO fibroblasts also showed a strongly reduced mean 
calcium response as well as a decreased response rate.  We therefore concluded that Sph-
induced release of calcium from the acidic stores was mediated by TPC1, which has been shown 
to localize to early, recycling, and late endosomes as well as lysosomes180.  
Furthermore, these results also show that Sph-induced calcium signaling is not restricted to one 
cell type (such as HeLa cells), but is a general feature of intracellular signaling and can also be 
observed in human patient derived cells or in primary mouse embryonic fibroblasts. 
Since two-pore channels are critically involved in NAADP-dependent calcium signaling180,184, we 
decided to investigate whether NAADP and Sph act on the same targets. However, NAADP is a 
highly charged and therefore non-membrane permeant compound. For this reason, we used a 
membrane permeant pharmacological antagonist of NAADP, Ned-19185, to study its effect on 
Sph-induced calcium release in HeLa cells (Figure 2.12).  
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Figure 2.12 NAADP antagonist Ned-19 does not influence Sph induced calcium signals. A) Mean fluorescent traces of Ned-19 
(100 µM) treated HeLa cells. B) Histogram of the distribution of maximum observed amplitudes with 20 % threshold.   
Ned-19 treated HeLa cells did not exhibit a markedly different calcium response after Sph 
uncaging, which is in line with previous observations that TPC1 is unresponsive to Ned-19186. 
This result also strengthens the hypothesis that Sph acted specifically on TPC1 and not on TPC2. 
2.1.6. Sph-mediated calcium release leads to the nuclear translocation of transcription 
factor EB (TFEB) 
The biological significance of the lysosome as a signaling hub has been well established in recent 
years187. Sabatini’s group found that the mTOR-complex, an important kinase which regulates 
cell growth, is translocated to the lysosome upon amino acid stimulation77. Another line of 
investigation found a new transcription factor,  (transcription factor EB, TFEB) to be a master 
regulator of lysosomal biogenesis80, which, in absence of nutrients, shuttles to the nucleus and 
targets several autophagy-mediating genes79. The mechanism of this TFEB nuclear translocation 
was very recently revealed: While lysosome-located mTOR phosphorylates TFEB and thus keeps 
it in the cytoplasm, cues such as starvation or exercise lead release of mTOR from the lysosomal 
surface and to calcium release from the lysosomal stores. This activates the phosphatase 
calcineurin, which binds and dephosphorylates TFEB and thereby promotes TFEB nuclear 
translocation82 (see also Figure 1.7). The authors also showed that the lysosomal calcium 
release is mediated by TRPML1, but they did not investigate the contribution of TPC1. Taken 
together, our findings also link acidic store calcium signaling to central cellular processes such as 
autophagy.  
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In this work, we investigated whether sphingosine-induced lysosomal calcium signaling is also 
able to induce TFEB nuclear translocation. To do this, we expressed a TFEB-GFP fusion in HeLa 
cells together with a genetically encoded calcium sensor R-GECO188. We performed uncaging 
experiments while simultaneously monitoring the calcium release and the subcellular 
localization of TFEB. As can be seen in Figure 2.13, uncaged cells showed an increase in cytosolic 
calcium as well as visible translocation of TFEB to the nucleus within 5 min after uncaging.  
 
Figure 2.13 Sph uncaging leads to TFEB translocation to the nucleus. Time-lapse confocal microscopy images of HeLa cells 
transfected with TFEB-GFP and R-GECO. Uncaging was performed in a small area in the cells for 3s (Sph-Cou) or 2 s (cg Ca
2+
).  
As a negative control, we increased the cytoplasmic calcium concentration by uncaging o-
nitrophenyl EGTA (“caged calcium”), a commercially available reagent which liberates calcium 
upon irradiation189. Releasing calcium in this way did not lead to TFEB nuclear translocation. 
Longer uncaging times of caged calcium led to a massive calcium increase in the cells which then 
induced TFEB translocation. This specific effect suggests that calcineurin senses calcium 
microdomains near the lysosomes and selectively dephosphorylates TFEB only upon a lysosomal 
calcium signal. Calcium release mediated ty TRPML1 has been reported to lead to TFEB 
tranlocation82. Our results confirm that lysosomal calcium signals induce nuclear translocation 
of TFEB and suggest that mediation by TPC1 has the same effect. We hypothesize that TFEB 
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translocation upon Sph stimulation is also able to increase transcription of autophagy-related 
genes as it was shown previously79,82,84. These results further underline the importance of 
understanding the mechanisms of lysosomal calcium signaling and their ties to other cellular 
processes.  
2.1.7. Calcium release is reduced in Niemann-Pick disease type C 
NPC was long thought of as a cholesterol storage disease. Indeed, cholesterol accumulation is 
still used for clinical diagnosis using filipin staining46 (Figure 1.5). However, it has become clear 
that the materials stored in NPC are much more complex than in other lysosomal storage 
disorders. Apart from cholesterol, sphingomyelin and glycosphingolipids, also sphingosine 
accumulates54.  Another distinct hallmark of NPC is a defective acidic store calcium homeostasis 
which is downstream of Sph accumulation and leads to lower concentrations of calcium in the 
acidic stores57. Elevation of cytosolic calcium levels using agents like curcumin corrected the 
NPC cellular phenotype and helped to prolong the lifespan of NPC mice57.  
To further investigate this link between Sph and acidic store calcium signaling in NPC, we 
performed Sph uncaging experiments in fibroblasts derived from healthy subjects (control) and 
from NPC patients. As expected, the release of acidic store calcium in NPC fibroblasts after Sph 
uncaging gave rise to lower cytosolic calcium amplitudes compared to control fibroblasts (Figure 
2.14). Previous measurements on NPC patient cells show reductions in acidic store calcium 
concentrations reduced by up to 70 %57.  
 
Figure 2.14 Calcium signaling in NPC disease. A) Mean fluorescent traces of control (25 cells) and NPC-patient derived fibroblasts 
(31 cells). B) Histogram of the distribution of maximum amplitudes with a response threshold set at 10% . 
Chapter 2 – Results and Discussion 
  
42 
 
These results from NPC patient fibroblasts are the first direct evidence of Sph action upstream 
of acidic calcium signaling in this disease. They further confirm our previous results showing that 
Sph releases calcium directly from acidic stores and not from other intracellular compartments.  
2.1.8. Sph localizes to late endosomes / lysosomes and accumulates in NPC 
Of all lipid materials stored in NPC, only cholesterol can be probed for its subcellular localization 
by use of the Filipin complex. The latter revealed cholesterol to accumulate in late endosomes / 
lysosomes of NPC patient cells (see Figure 1.5) and consequently colocalize with the LAMP-1 
antibody, as was shown previously190. The localization of sphingosine and higher sphingolipids is 
more difficult to study owing to a lack of tools. Even though fluorescent sphingolipids, e.g. 
sphingolipids modified with a small fluorescent group (usually nitrobenzoxadiazole, NBD or 
boron-dipyrromethene, BODIPY) are commercially available, these lipids do not faithfully 
represent the localization of endogenous sphingolipids since the NBD and BODIPY groups 
drastically alter their physical properties115. Bifunctional lipids are minimally modified and more 
closely mimic endogenous lipids, a fact which is useful in probing the subcellular localization of 
these lipids as shown using a bifunctional fatty acid precursor151. Per Haberkant synthesized a 
photoactivatable and clickable sphingosine (pacSph) and provided me with this compound to 
perform localization studies of Sph in NPC fibroblasts.  
 
Figure 2.15 Subcellular localization of Sph. Confocal images of N3-Alexa488-labelled TFS (green) and LAMP1 antibody (red) in 
human fibroblasts. The Pearson’s correlation coefficient r is shown in the top left corner of the merged image. Scale bar 
represents 10 µm.  
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To investigate the subcellular location of Sph, we incubated control and NPC fibroblasts with 
pacSph for a short time (10 min) to minimize conversion to higher sphingolipids. The lipids were 
photo-crosslinked before fixation and subsequently visualized via click-reaction with a 
fluorophore (Alexa488-azide). Figure 2.15 shows a clear localization of pacSph to LAMP1-
positive vesicles in both control and NPC fibroblasts.  
This is the first direct evidence of Sph localization at the acidic compartment, which was 
postulated for a long time since the other stored materials such as cholesterol and 
glycosphingolipids also accumulate in these vesicles191,192. A striking difference between control 
and NPC fibroblasts was the number and size of late endosomes / lysosomes and the 
concentration of Sph therein, all of which were markedly increased in the NPC cells. It is known 
that the acidic compartment, which is usually visualized by LysoTracker staining, is enlarged in 
NPC disease57,193. Our findings confirm that Sph is indeed present at higher concentrations in 
these vesicles compared to control cells, as revealed by the increased Alexa488-staining.  
A common hypothesis in the NPC field is that these lipids accumulate in the acidic 
compartments due to a post-endolysosomal trafficking block55. To check whether this block can 
be visualized using pacSph, we performed pulse-chase experiments. We labelled control and 
NPC fibroblasts with pacSph for 10 min as in the previous experiment (i.e. pulse), but instead of 
immediate crosslinking, cells were washed and incubated for further 10 min without pacSph (i.e. 
chase) before crosslinking and fixation. In this way, we followed the change of subcellular 
localization of Sph as it went through its metabolic path.  
Figure 2.16 shows that Sph in control fibroblasts no longer co-localized with the LAMP1 
antibody, but stained internal membranes, indicating release from the acidic compartments. 
Sph was likely transported to ceramide synthases at the ER33 as part of the sphingolipid 
metabolic pathway34. On the other hand, Sph in NPC fibroblasts still co-localized with LAMP1 
after 10 min chase and showed similar fluorescence intensities as at 0 min chase time. This 
points towards a Sph trafficking blockage at the late-endosomal / lysosomal stage and explains 
the increased Sph staining in NPC fibroblasts.  
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Figure 2.16 Subcellular localization of Sph after 10 min chase. Confocal images of N3-Alexa488-labelled TFS (green) and LAMP1 
antibody (red) in human fibroblast after 10 min chase. The Pearson’s correlation coefficient r is shown in the top left corner of 
the merged image. Scale bar represents 10 µm.  
 
2.1.9. Conclusion and outlook 
Sph is a known bioactive lipid, yet few of its actions have been characterized on a molecular 
level. One of the few identified targets of Sph apart from its metabolizing enzymes is protein 
kinase C (PKC), which it inhibits174. Several apoptotic effects of Sph have been attributed to this 
inhibition23. Sph is also involved in the pathophysiology of NPC disease. Its accumulation has 
been shown upstream of a reduction in lysosomal calcium concentration57. In this work, we 
investigated the actions of intracellular Sph on lysosomal calcium signaling. Caged Sph proved to 
be a valuable tool to investigate this process which could not have been studied with 
conventional means (exogenous lipid addition, RNAi-mediated knock-down, or small molecule 
modulators). We found that spontaneously generated intracellular Sph is capable of releasing 
calcium from acidic stores, while addition of Sph to the medium of the cells did not evoke such a 
calcium release. This effect was specific to Sph since even dhSph, a naturally occurring, close 
structural analogue, did not release calcium upon intracellular photo-release. We further 
excluded any contribution of the immediate Sph-metabolite S1P, which is known to increase 
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cytosolic calcium either via extracellular action on S1P G-protein coupled receptors169 or by 
intracellular release from the ER through a yet unidentified receptor138,194.  
Caged Sph was applied to three different cell lines: cultured HeLa cells, primary mouse 
embryonic fibroblasts and human patient-derived cells. Uncaging Sph stimulated a calcium 
transient in all cell types, indicating that this newly discovered connection between Sph and 
lysosomal calcium release is an important and general feature of intracellular signaling.  
We further pinpointed the endosomal/lysosomal channel TPC1 to be necessary for this 
response by employing embryonic fibroblasts from Tpc1-/- mice. The roles of two-pore channels 
have been widely debated in recent years. While many reports agree that TPC channels are 
NAADP-regulated Ca2+ channels65,66,180,181, others indicate a broader ion specificity of 
TPCs64,68,195 or alternative ligands such as PI(3,5)P2
68,69. Another report hinted towards a 
convergent regulation of TPC2 by Mg2+, NAADP, PI(3,5)P2 and two protein kinases (JNK and 
p38)72. Some of these findings were recently reconciled in a study showing that TPCs conduct 
both Ca2+ and Na+ ions and that TPCs are activated by NAADP as well as PI(3,5)P2
73,196. This work 
introduces Sph as a new small molecule activator of TPC.  
Several questions still remain concerning the mechanism of TPC1 activation. First, it is unclear if 
Sph has a direct interaction with TPC1 or if other, yet unidentified molecules mediate this 
response. Similarly, the site of Sph action needs to be addressed. Does the initiation of Sph-
induced calcium release take place outside the lysosome, from the lysosomal lumen or within 
the lysosomal membrane? Second, the crosstalk of Sph-induced TPC1 activation with NAADP-
induced TPC1 activation remains unclear. Since TPC1 is unresponsive to the small molecule 
NAADP-antagonist Ned-19186, other tools such as a membrane-permeant version of NAADP197 
should be employed to investigate how NAADP influences Sph action on TPC1.  
Sph-induced calcium signaling was also investigated in the context of NPC disease. The calcium 
release from the lysosomes in NPC patient fibroblasts was reduced compared to control 
fibroblasts. This is in line with other measurements performed with an intra-lysosomal calcium 
probe, showing that lysosomal calcium content is reduced in NPC due to an acidic store-filling 
defect57. Furthermore, we visualized the subcellular localization of Sph in NPC fibroblasts for the 
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first time. Using the bifunctional Sph probe synthesized by Per Haberkant, we localized Sph to 
late endosomes and lysosomes, which were more numerous and larger in NPC fibroblasts 
compared to control. The concentration of Sph inside these vesicles was also higher in NPC cells. 
This is in line with observations made for cholesterol using the Filipin staining (Figure 1.5) and 
indicates that both these lipids are stored in the same compartments. To investigate whether 
post-lysosomal traffic is impaired in NPC disease as suggested in literature55, we performed 
pulse-chase experiments and showed that Sph exited the endosomes/lysosomes in healthy 
controls, while it accumulated in NPC cells. It is hypothesized that permanently lowered acidic 
store calcium levels in NPC cells are responsible for the secondary accumulation of cholesterol, 
glycosphingolipids and sphingomyelin due to defective, calcium-dependent vesicle fusion57. Sph 
accumulation, however, occurs upstream of the calcium defect57. Our work gives the first 
evidence of a direct connection between Sph and lysosomal calcium efflux. Identification of the 
exact mechanism of Sph action on lysosomal calcium homeostasis could uncover new potential 
therapeutic targets for treatment of NPC. Another challenge is to identify the function of the 
NPC1 protein itself and how its inactivation leads to Sph accumulation. This would offer another 
point of therapeutic intervention.  
Few biological processes, such as vesicle fusion and secretion198 as well as induction of 
autophagy and lysosomal biogenesis82 have been shown to depend on lysosomal calcium efflux. 
The mechanism of autophagy induction was recently identified and involved the nuclear 
translocation of TFEB upon dephosphorylation by calcineurin, which in turn was activated by 
TRPML1-mediated lysosomal calcium efflux82. We also confirmed TFEB nuclear translocation 
upon lysosomal calcium efflux, in our case through TPC1 and stimulated by intracellular Sph. 
Since nuclear TFEB initiates transcription of autophagic genes, it is interesting to speculate that 
Sph-rich and potentially “leaky” lysosomes might lead to a permanent calcium signal and an 
over-induction of autophagy in the NPC disease. Indeed, increased autophagic flux and marked 
accumulation of autophagosomes are hallmarks of the NPC disease199. In NPC1-deficient cells, 
the inhibition of autophagy was found to have ameliorative effects200, which may be attributed 
to lowered lysosomal stress due to a reduced delivery of autophagic substrates. Caged Sph 
could be used in the future as a tool to investigate whether releasing Sph within cells, especially 
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neurons, which are particularly vulnerable in NPC disease, is capable of inducing an NPC-like 
phenotype by stimulating lysosomal calcium efflux.  
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2.2. Trifunctional sphingosine is a novel tool to identify protein-Sph 
interactions 
Sphingolipids have been shown to influence central cellular processes106,201 and their 
deregulation is implicated in severe diseases such as cancer27,202, diabetes and metabolic 
disorders203,204. However, the mechanism of action of these lipids is poorly understood, mostly 
due to a lack of tools to investigate their interaction with proteins in a systematic fashion. 
Several excellent techniques for in vitro studies of protein-lipid interactions have been 
developed recently131,205 but these rely on recombinant expression or cell lysates and are 
therefore limited to soluble proteins. To also investigate interactions of lipids with integral 
membrane proteins, and to examine these interactions in living cells, a bifunctional lipid 
technology was established206. Briefly, a lipid precursor is chemically modified with two 
additional functionalities: 
1) a photoactivatable diazirine group which, upon irradiation, creates a covalent bond 
between the lipid and the interacting protein and  
2) an alkyne group as a click handle for subsequent tagging and proteomic identification of 
the lipid-protein complexes.  
One drawback of this method is that upon addition to the cells, the bifunctional precursor is 
immediately subjected to lipid metabolism and so several lipid species are generated of which 
all carry the additional functionalities. The identified proteins may therefore interact with 
multiple members of the investigated lipid class. To pinpoint proteins interacting with a single 
lipid species, we added to the bifunctional lipid technology by developing a caged bifunctional 
Sph (i.e. “trifunctional” Sph). This compound was designed so that uncaging of the lipid inside 
cells followed by immediate photocrosslinking should prevent lipid metabolism before 
crosslinking. This technology should enable the identification of the protein interactome of a 
single, well defined lipid species.  
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2.2.1. Design and synthesis of trifunctional sphingosine 
For the synthesis of trifunctional sphingosine (TFS), we again chose to employ the DEAC group 
since its photochemical properties are compatible with the diazirine group. This strategy allows 
the uncaging reaction, which needs to precede the crosslinking at higher wavelengths 
(~ 400 nm) whereas the diazirine group is activated at 350 nm. The synthesis of trifunctional Sph 
was performed in a similar fashion to the synthesis of Sph-Cou (Chapter 2.1.1., see Figure 
2.17a), using the bifunctional Sph provided by Per Haberkant. André Nadler in our group 
synthesized a trifunctional diacylglycerol species (stearoyl-arachidonylglycerol, SAG) as well as a 
trifunctional fatty acid (stearic acid) which served as control compounds during the interaction 
studies (Figure 2.16 b) and c)).  
 
Figure 2.17 Synthesis of trifunctional lipids. a) Synthesis of trifunctional sphingosine (TFS). b) Synthesis of trifunctional 
diacylglycerol (TFDAG). c) Synthesis of trifunctional fatty acid (TFFA). b) and c) were carried out by André Nadler.  
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2.2.2. NMR feasibility studies 
In order to determine whether the two photoreactions required for the successful application of 
trifunctional lipids (uncaging and photocrosslinking) are indeed orthogonal, we performed 
nuclear magnetic resonance (NMR) studies on the pure compounds. We chose to use TFDAG, 
which has a well dispersed 1H-NMR spectrum where the relevant peaks were not overlapping 
with others and could therefore be easily monitored. Figure 2.18 shows a part of the spectrum 
of TFDAG with the relevant proton signals assigned in different colors. After collecting this 
spectrum, the NMR tube was subjected to a 2 min irradiation step using a mercury arc source 
(Newport) equipped with a 400 nm highpass filter. After this first irradiation step, i.e. the 
uncaging reaction, signals stemming from the CH2-groups next to the carbamate linker (red and 
blue peaks) changed their chemical shifts to match the corresponding signals of the bifunctional 
DAG (BFDAG) standard. This demonstrated a successful and complete uncaging reaction. More 
importantly, the green and purple resonances (from CH2 groups next to the diazirine group) did 
not change their chemical shifts, indicating that the diazirine was intact and that no 
photocrosslinking took place under the conditions used for uncaging.  
 
Figure 2.18 Two subsequent photoreactions are orthogonal. NMR spectra of TFDAG in CDCl3 before and after irradiation steps 
as indicated. This experiment was carried out by André Nadler. 
The NMR tube was then subjected to a second 2 min irradiation using the mercury arc source, 
this time equipped with a 345 nm highpass filter. During this second irradiation step, however, 
the green and purple resonances shifted considerably, proving that illumination with 345 nm 
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light is necessary for reaction of the diazirine. Notably, the alkyne bond, as monitored through 
the triplet at 2.22 ppm, remained unaffected by each illumination step.  
This experiment demonstrated that it is possible to perform two subsequent photoreactions on 
the same molecule and that the uncaging reaction can be carried out without affecting the 
crosslinkable group. This allowed us to precisely control the time of release and crosslinking of 
the lipid inside the cells. Additionally, it enabled us to perform very accurate pulse-chase 
experiments in order to follow the lipid metabolism in time and space either on TLC or with 
fluorescent microscopy.  
2.2.3. Trifunctional lipids are inert and stable in the cellular environment 
As with the caged Sph (chapter 2.1.), the success of this approach is dependent on the stability 
and the biological inactivity of the trifunctional lipids. We therefore tested whether the cage 
group was cleaved or whether the lipid precursors were metabolized before uncaging. Cells 
were incubated with trifunctional lipids for different times and the extracted cellular lipids were 
labelling by click-reaction with a fluorogenic compound. The most commonly used molecule for 
labeling lipid extracts is the commercially available 3-azido-7-hydroxycoumarin, which has 
already been used in several studies151,159.  
Unfortunately, the excitation and emission spectra of this compound are very similar to the 
DEAC group used in the synthesis of the trifunctional lipids. This complicates detection during 
TLC analysis and required the use of a new, orthogonal fluorophore. A longer-wavelength, 
fluorogenic fluorescein was reported recently207 and prepared by André Nadler in our group. p-
Azidofluorescein has a reported absorption maximum around 495 nm and an emission 
maximum around 518 nm207, whereas the DEAC group absorbs around 375 nm. 
Azidofluorescein labelled lipids were detected independently of whether or not they bear a 
DEAC group. Unfortunately, the fluorogenity of azidofluorescein is lower than that of the 
commercially available coumarin, so that unreacted azidofluorescein is still visible on the TLC 
(see Figure 2.19). As a control, click reactions were performed in absence of alkyne-containing 
lipids and the resulting bands migrating with Rf = 0.36 and Rf = 0.45 were therefore attributed as 
background bands stemming from unreacted azidofluorescein.  
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Figure 2.19 TFS is stable in the cellular environment. TLC analysis of lipid extracts of HeLa cells clicked to azidofluorescein. Pure 
TFS was subjected to +/- UV treatment, reacted with azidofluorescein and spotted as reference compounds (Std).  
Figure 2.19 shows the TLC analysis of lipid extracts of HeLa cells incubated with TFS for the 
indicated time. The lipids were visualized by click-reaction with azidofluorescein. In both 5 min 
and 15 min incubation conditions, only one band, which co-migrated with the TFS standard, was 
visible. Apart from the background bands, there are no additional azidofluorescein-labelled 
spots, indicating that the TFS is inert and that it is not metabolized to other lipids in its caged 
state within these timeframes. The same experiment for the other trifunctional lipids was 
performed by André Nadler and proved inertness also for TFDAG and TFFA.  
Having established the metabolic stability of all trifunctional lipids, we next determined loading 
conditions which would result in similar amounts of lipids inside the cells. HeLa cells were 
loaded with different concentrations of trifunctional lipids and their DEAC-fluorescence was 
monitored over time. Figure 2.20 displays the subcellular localization of the three trifunctional 
lipids in conditions which resulted in similar fluorescence intensities. It was notable that TFS was 
readily taken up by the cells, so that even a short incubation time of 5 min and a low 
concentration of 6 µM gave rise to fluorescence comparable of 100 µM TFDAG incubated for 
15 min. 
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Figure 2.20 Subcellular distribution of trifunctional lipids. Confocal images of HeLa cells incubated with the indicated 
concentrations of trifunctional lipids.  
As can be seen in Figure 2.20, the subcellular localization of all three lipids was determined by 
the properties of the DEAC cage and resulted in unspecific intracellular membrane staining and 
did not reflect the endogenous localization of the respective lipids. This unspecific uptake and 
labelling of cells by coumarin derivatives has already been reported208. With respect to the 
design of the proteomic screen, we decided to use the negative control TFFA at a concentration 
equal to that of TFDAG even though this gave slightly brighter staining of the cells. We reasoned 
that this would increase the specificity of the hits identified with TFS or TFDAG if even higher 
concentrations of TFFA failed to capture them.  
2.2.4. Trifunctional lipids are bioactive 
To investigate whether the lipids released after photouncaging are indeed biologically active 
(despite their diazirine and alkyne modifications), we performed pulse-chase experiments and 
monitored the resulting lipids by TLC. If the lipids were recognized by the cellular machinery, 
they would be quickly converted to other glycerolipids or sphingolipids. HeLa cells were labelled 
for 15 min, the lipids were liberated by illumination with 400 nm light and the cells were 
incubated for a further 15 min. The cellular lipids were then extracted and visualized through 
their azidofluorescein-adduct (Figure 2.21). The reference compounds were again treated with   
-/+ UV and taken through the same extraction procedure as the cellular extracts serving as 
standards. It is notable that the cage group of each pure, trifunctional lipid standards was partly 
cleaved during the extraction and click-reaction procedure as evident by the additional band in 
the –UV condition which co-migrated with the bright band of the +UV standard in each case. We 
quantified the extent of this cleavage as 22 % for TFS and 33 % for TFDAG and TFFA.  In this 
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experiment, however, this artefact was of no consequence since we were interested in the 
cellular lipid extracts after illumination and the standards were only used for co-migration 
analysis. Another complication was the fact that intact TFFA exhibited the same migration 
behavior as uncaged TFDAG (bifunctional DAG, BFDAG). Again, this did not hinder the 
interpretation of this particular experiment, as there was no more TFDAG in the cellular lipid 
extracts after illumination.  
 
Figure 2.21 Uncaged lipids take part in the cellular metabolism. TLC analysis of lipid extracts of HeLa cells clicked to 
azidofluorescein after 15 min chase. Standards of each lipid were subjected to -/+ UV treatment, reacted with azidofluorescein 
and spotted on the left-hand side as reference compounds.  
The lipids extracted after 15 min chase time showed additional bands for each trifunctional lipid 
pulse, indicating that the uncaged lipids were recognized by the lipid handling machinery and 
metabolized accordingly. The major lipid species in the TFS condition was the liberated 
(bifunctional) Sph (BFS), but we observed additional bands with slower migration behavior 
(arrow 1) that may indicate conversion to sphingomyelin. A very faint band migrating slightly 
faster than BFFA (marked by arrow 2) corresponded with the migration behavior of ceramide 
(Cer) in experiments done with 3-azido-7-hydroxycoumarin209. In such a short chase time, 
uncaged TFS already gave rise to multiple additional lipid species, indicating that the released 
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bifunctional Sph is a close mimic of endogenous Sph. This is in line with Per Haberkant’s studies. 
Similar observations were also made for TFDAG and TFFA, both of which gave rise to additional 
lipids (as indicated by arrows 3-6). DAG was converted to a fatty acid and a slow migrating 
species which we speculate to represent phosphatidylethanolamine (PE, arrow 4). However, we 
have no standards for PE and cannot prove this speculation. Cells pulsed with TFFA showed the 
highest level of metabolism and converted TFFA to DAG and mainly, phosphatidylcholine (PC, 
arrow 6). PC was identified by comparing its migration behavior to standards clicked to the 
commercial 3-azido-7-hydroxycoumarin in previous studies151,159.  
Another way to determine whether TFS mimics the behavior of endogenous Sph is to perform 
uncaging experiments and to monitor intracellular calcium signaling as described in chapter 
2.1.3.  As expected, TFS elicited an increase in cytosolic calcium immediately after uncaging in 
the same manner as Sph-Cou (Figure 2.22).  
 
Figure 2.22 Trifunctional Sph uncaging increases cytosolic calcium. Mean Fluo-4 fluorescence traces of HeLa cells incubated with 
Sph-Cou or TFS. Uncaging was performed in a small circular area within the cell for 3 s as indicated by the black bar. The 
standard error of the mean is plotted as error bars.   
The bioactivity of TFDAG was tested by André Nadler. He performed uncaging experiments and 
showed translocation of a DAG binding C1-domain (of PKCα) to the plasma membrane upon 
uncaging of TFDAG (data not shown). Taken together, the TLC and live-cell microscopy 
experiments showed clearly that the modification of the Sph backbone with two additional 
functionalities did not hinder its metabolism and that uncaging of TFS (and TFDAG) led to 
immediate signaling outcomes (calcium increase vs. C1-domain translocation). We therefore 
concluded that it was feasible to perform useful proteomic screens by uncaging trifunctional 
lipids in living cells followed by immediate crosslinking to their interacting proteins.   
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2.2.5. Design and outcome of proteomic screens 
The bifunctional lipid technology has already been successfully used for performing several 
proteomic screens150–152. For our study, we adapted the previous protocol to include extra 
illumination steps and to update the proteolytic digestion. Figure 2.22 shows the workflow of 
the screens as we performed them. Briefly, we incubated HeLa cells with TFS, TFDAG or TFFA at 
concentrations determined in chapter 2.2.3. After washing away excess lipid, we irradiated the 
dishes on ice for 2.5 min at 400 nm and immediately afterwards for another 2.5 min at 345 nm. 
This immediate change was achieved by switching the two highpass filters in front of the UV 
lamp with a lever. The cells were scraped, washed and lysed. The proteins were then subjected 
to a reduction/alkylation step using DTT/iodoacetamide to reduce cysteines and to ensure 
successful protease digestion. The protein concentration in each condition was determined 
using the Amido Black assay (see chapter 3.6.2.) and an equal amount of each condition was 
subjected to a click reaction with biotin-azide.  
 
Figure 2.23 Schematic overview of the proteomic screens performed with trifunctional lipids.  
Biotinylated protein-lipid complexes were enriched using neutravidin-agarose beads. After the 
elution step, a tryptic digest was performed on paramagnetic beads as recently described in 
Hughes et al.210 and the resulting peptides were separated using high-pH offline fractionation, 
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which increased proteome coverage by separating the peptide mixture in an orthogonal fashion 
to the LC-MS. 30 fractions were collected and pooled to 10 fractions, which were subjected to a 
desalting step and subsequently injected into an UPLC-MS/MS system.  
The screen was performed twice and yielded a total of 3263 proteins. The overlap between the 
two screens is depicted as a Venn diagram at the top of Figure 2.24 and shows a good overlap of 
1902 proteins identified in both screens. In order to investigate the specificity of the 
trifunctional lipid approach, we visualized the distribution of proteins identified with each of the 
different trifunctional lipids (Figure 2.24, bottom row). The majority of proteins in each screen 
were identified in all three conditions (red numbers) indicating that these proteins were either 
crosslinked non-specifically to all lipids due to close interaction in the membrane or that they 
were identified as background of the method due to non-specific binding to the neutravidin 
beads during pull-down. Conversely, proteins uniquely identified with one lipid may have been 
interacting with or binding to that lipid at the time of crosslinking. This high background is in line 
with previous observations209 and highlights the importance of using adequate control lipids in 
every screen. 
 
Figure 2.24 Number of proteins identified in two independent proteomic screens. 
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We narrowed the pool of candidate proteins by only looking at proteins identified in both 
screens. We visualized their distribution in a heatmap color-coded for their respective peptide 
spectral matches (PSM), a value indicating how often peptides belonging to the same protein 
were identified (Figure 2.25)  
 
Figure 2.25 Distribution of high-confidence proteins.  
It is apparent that the majority of identified proteins were found in all three conditions, 
indicative of a high background of unselective binding and crosslinking. However, 46 proteins 
were identified twice only with TFS, whereas 130 proteins were found in TFDAG experiments in 
both screens. These uniquely identified, ‘high confidence’ proteins were considered putative 
Sph or putative DAG binding proteins, respectively. It was still possible that some specific Sph or 
DAG-binding proteins were additionally identified in the control conditions with low PSM counts 
due false positive discovery rates in the protein identification procedure. We therefore 
introduced a threshold of 2.5-fold increased PSM count in one condition over the other two in 
order to include these proteins as well. This new threshold increased the number of putative 
Sph-binding proteins to 73 proteins and the number of putative DAG-binding proteins to 228 
proteins (see Appendix B). It was encouraging that among the putative Sph-binding proteins, we 
found enzymes involved in the sphingolipid pathway such as 3-ketodihydrosphingosine 
reductase and ceramide synthase 2, which is known to bind Sph as a substrate.  
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We next compared the list of putative Sph-binding proteins obtained with the TFS probe to 
previous screens using bifunctional Sph (=pacSph) performed by Per Haberkant209 (Figure 2.26, 
left-hand side). A quarter of high confidence TFS-binding proteins were uniquely identified with 
pacSph, further confirming the specificity of these protein-Sph interactions. Another quarter 
was identified with pacSph but also identified using pacFA as a control lipid, which was 
incorporated into multiple glycerolipids. It is possible that some of these proteins have dual 
specificity for Sph and certain glycerolipids (not SAG or arachidonic acid, which we excluded 
using the TFDAG and TFFA probes), but it is more likely that these proteins were unspecifically 
crosslinked to an abundant membrane glycerolipid such as PC while also specifically interacting 
with Sph. The majority of high-confidence TFS-binding proteins were not identified at all in any 
pacSph-screen. This exemplifies the major advantage of the trifunctional lipid concept: Since the 
bait lipid was not metabolized and only proteins interacting with Sph were crosslinked, the 
complexity of the proteome is reduced and proteomic analysis could therefore also detect 
proteins which were crosslinked at lower frequency and which would otherwise have failed 
detection due to more abundant proteins crosslinked to higher sphingolipids. A small 
percentage (10 %) of TFS-binding proteins were not identified with pacSph, but were crosslinked 
to pacFA. These proteins were either potential false positives in the TFS screen or they 
represent proteins which were crosslinked to Sph at low frequency and failed detection with 
pacSph, but were unspecifically crosslinked to glycerolipids such as PC.  
 
Figure 2.26 Prevalence of Sph binding proteins identified with TFS in the pacSph screen and vice versa. High confidence TFS-
binding proteins (n=73) were examined if they were identified solely with pacSph, in pacSph and control (=pacFA), only in 
control conditions (ctrl) or not identified at all in 3 screens performed by Per Haberkant
209
. On the other hand, high confidence 
pacSph-binding proteins (n=65) were identified either only with TFS, with TFS but also control lipids (=TFDAG or TFFA), only in 
control conditions or not identified at all. The number of proteins is indicated in parentheses. 
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On the other hand, we examined a list of 65 high-confidence proteins which were uniquely 
identified in all three pacSph screens to see whether they were also detected using the TFS 
probe (Figure 2.26, right-hand side). Indeed, a third of the proteins were also detected by TFS, 
but not by TFFA or TFDAG. This again demonstrated the reproducibility of this crosslinking 
approach and helped to recognize this subset as Sph-binding proteins. The identification of the 
nature of the lipid crosslinked to these proteins is a major challenge in the bifunctional lipid field 
which has not previously been addressed. The discrepancy of 5 proteins in the green subsets of 
Figure 2.26 is explained by lower confidence proteins which were identified in only one or two 
screens. These proteins were not counted as high confidence proteins but were still considered 
as TFS- or pacSph-binding proteins in the making of Figure 2.26. Another 20 high-confidence 
pacSph binding proteins were identified with the TFS probe and additionally with TFDAG, TFFA 
or both probes. Again, some of these represent potential dual specificity proteins for Sph and 
SAG or Sph and arachidonic acid, which could not be identified using the pacFA precursor. 
Others, as well as the 6 proteins in control conditions, could be false positive results from the 
pacSph screen. The portion of 17 proteins identified with pacSph but not with any of the 
trifunctional probes represent proteins interacting specifically with higher sphingolipids such as 
Cer, SM or GSL.  
2.2.6. The subcellular localization of Sph- and DAG-binding proteins matches with lipid 
localization 
In order to determine at which subcellular compartments these newly identified high-
confidence Sph-and DAG-binding proteins reside, we subjected them to an automatic GO-Term 
analysis using the BiomaRt package211 in R and extracted the cellular compartment annotations 
(Figure 2.27). It should be mentioned that each protein is usually annotated to more than one 
subcellular compartment GO-Term (e.g endoplasmic reticulum, endoplasmic reticulum 
membrane, integral component of membrane, nuclear membrane, membrane for ceramide 
synthase 2). Only a small subset of these terms was queried in the automated analysis (see y-
axis of Figure 2.27). Therefore, the percentage values on the x-axis do not add up to 100 %.  
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Figure 2.27 Localizations of high confidence proteins.  Cellular compartment annotations of GO-terms of putative Sph- (n=73) 
and DAG-binding proteins (n=228).  
This analysis revealed that most DAG-binding proteins resided in cytosolic and nuclear 
localizations and that they were almost completely absent from the endosomal/lysosomal 
system. Sph-binding proteins, on the other hand, were enriched along the endocytic pathway, 
with a higher percentage in endosomes/lysosomes compared to DAG-binding proteins. It is also 
worth noting that a substantial portion of putative Sph- and DAG-binders seem to be secreted 
to the extracellular space.  
In order to compare whether the localizations derived from GO-term annotations coincided 
with the localization of the lipids after uncaging, we probed the subcellular locations of TFS, 
TFDAG and TFFA immediately after crosslinking by fixing the cells, washing away non-
crosslinked lipids to reduce the background and subjecting the protein-lipid complexes to click-
reaction with Alexa488-azide (Figure 2.28). In agreement with the oucomes of GO-term 
annotations, Sph was observed in the perinuclear region as well as in vesicular structures which 
co-localized with the late endosomal/lysosomal marker LAMP1.  
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Figure 2.28 The subcellular localizations of Sph, DAG and FA are markedly different. Confocal images of HeLa cells. Alexa488-
azide-conjugated lipids are shown in gray (left hand side) and green (merged image). Late endosomes/lysosomes and the Golgi 
apparatus are visualized by the LAMP1 and GM130 antibodies, respectively in gray (middle image) and red (merged image).  The 
scale bars represent 10 µm.  
Surprisingly, the intensity of DAG staining was much reduced compared to Sph and FA in this 
experiment, even though the trifunctional lipids were added in such concentrations that similar 
loading was achieved (see chapter 2.2.3). We speculate that this was primarily due to an artifact 
in the fixation procedure we used, because it is known that methanol fixation can extract 
nuclear and cytosolic proteins212. It is likely that the majority of DAG was crosslinked to cytosolic 
proteins (according to the GO-annotations) and was therefore extracted during the fixation. 
DAG localized uniformly to internal membranes with a slightly higher fluorescent intensity in the 
Golgi area as shown by co-localization with the Golgi marker GM130. Similarly, TFFA showed 
staining of internal membranes with enriched intensities in the Golgi and perinuclear area. We 
concluded that the distribution of lipid-binding proteins corresponded to the distribution of the 
lipids themselves. This gave another hint towards the feasibility of the use of trifunctional lipids 
for identifying protein-lipid interactions in living cells.  
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2.2.7. Sph accumulates in the acidic compartments of NPC cellular models due to 
failed efflux 
A major advantage of the trifunctional lipids is the ability to liberate the active probe in a 
temporally and spatially precise way. In contrast to bifunctional lipids, which are taken up by 
cells in their active form, and are therefore immediately metabolized, all trifunctional lipid 
molecules are liberated at once with a flash of light, giving a precise starting point for pulse-
chase experiments in subcellular localization studies. Additionally, the lipids are liberated inside 
the cells, thereby bypassing the endocytic machinery or extracellular checkpoints. We decided 
to make use of these advantages to study the subcellular localization of Sph in the context of 
NPC disease, since Sph may be the first and potentially causative change following NPC 
inactivation57. Using bifunctional Sph, we showed in chapter 2.1.8 that Sph accumulated in the 
late endosomes / lysosomes of NPC cells and that Sph did not escape these vesicles over time. A 
weakness of the bifunctional Sph method was that the endolysosomal localization was observed 
solely because the compound was taken up by endocytosis and then trapped in these vesicles 
due to protonation of the free amino group at low pH.  
Using the TFS probe, the Sph localization in HeLa cells was examined and it was found that Sph 
indeed localized to the perinuclear region as well as to late endosomes / lysosomes at 0 min 
chase time (i.e. the time between uncaging and crosslinking) (see Figure 2.29). At chase times of 
10 min or 30 min, the TFS probe no longer showed co-localization with LAMP1, but labelling of 
ER and Golgi (co-localization data not shown). This is in line with observations made by Per 
Haberkant using the bifunctional Sph209 and indicates that Sph escaped from the acidic vesicles 
during this time and relocated to the ER where different ceramide synthases process Sph to 
Cer33. The Golgi staining represented further metabolism of Cer to SM and GlcCer, which is 
known to occur at the Golgi apparatus34. This experiment showed that even when Sph was 
released from anywhere within the cell, it rapidly re-localized to the endosomes/lysosomes, 
indicating a transport mechanism (either active transport or passive diffusion) of Sph to its 
endogenous localization.  
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Figure 2.29 Sph is retained at endolysosomes in a cellular model of NPC disease. Confocal microscopy images of HeLa cells 
incubated with TFS (clicked to Alexa488-azide, green in the merged image). Late endosomes/lysosomes are shown in red in the 
merged image. For each condition, the distribution of free cholesterol was visualized by Filipin staining. The scale bars represent 
10 µm. Pearson coefficient is indicated in top left corner of the merged image.  
We next induced the NPC cellular phenotype in HeLa cells by employing the amphiphilic, 
hydrophobic amine U18666A, which partially disrupts NPC1 function213. The distribution of Sph 
was detected via the TFS probe (Figure 2.29, middle panel). At 0 min chase, Sph was visibly 
enriched in late endosomes / lysosomes, which were larger than in control conditions. Longer 
chase times of 10 min and 30 min, respectively still showed a marked late endosomal / 
lysosomal staining, indicating a defect in the efflux of Sph from the acidic compartments. Similar 
results were obtained by knock-down of NPC1 using an RNAi approach, which again gave rise to 
larger and more numerous endolysosomal vesicles compared to control conditions. The 
successful induction of the NPC phenotype in both cases (U18666A and siRNA) was confirmed 
by cholesterol staining using Filipin. Taken together, these results showed that Sph accumulated 
in late endosomes / lysosomes of NPC due to failed Sph efflux. The TFS probe enabled us to 
faithfully visualize the distribution of Sph in cells for the first time and we continued to use it in 
other models of NPC to check for Sph accumulation.  
Another, commonly used model of the NPC disease is Chinese hamster ovary (CHO) cells, which 
are deleted of the NPC1 locus (M12)214. As control, we used M12 cells which are stably 
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overexpressing the NPC1 protein (CHO/NPC1)214. M12 cells have been shown to accumulate 
cholesterol and to mimic the NPC phenotype, whereas CHO/NPC1 cells do not show increased 
Filipin staining even though the total cholesterol content of these cells is higher214. In order to 
investigate whether M12 cells reproduce the full NPC phenotype (i.e. also accumulated Sph), we 
probed the subcellular localization of Sph in these cells versus CHO/NPC1 cells using the TFS 
probe (Figure 2.30) at a chase time of 10 min because this already showed a clear difference 
between control and NPC condition.  
 
Figure 2.30 Sph also accumulated in CHO model of NPC. Confocal microscopy images of CHO/NPC1 and M12 cells labelled with 
TFS at chase times of 10 min. Scale bars represent 10 µm.  
As expected, M12 cells accumulated Sph in enlarged late endosomes / lysosomes typical for the 
NPC cellular phenotype. In contrast, NPC1 overexpressing cells showed a mostly perinuclear / 
Golgi staining, indicating that Sph escaped from the acidic compartments and was transported 
to the Golgi for further modification, in line with observations made in HeLa cells. We concluded 
that the deletion of the NPC1 locus in CHO cells led to accumulation of Sph as well as 
cholesterol214 in the late endosomes / lysosomes of these cells. This defect could be rescued by 
overexpression of the NPC1 protein, which restored Sph traffic and metabolism. 
 
2.2.8. The rate of Sph transport in NPC patients correlated with the severity of their 
symptoms 
The clinical presentation of the NPC disease can vary dramatically in age of onset and severity of 
the neurological phenotypes215 and prediction of disease progression is challenging. Genotype-
phenotype correlation is limited because most patient mutations are heterozygous. However, 
some of the over 200 known NPC mutations have been shown to correlate with disease 
severity41,43,216. The correlation between cellular trafficking defects or lipid accumulation with 
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clinical presentation is very poor and many efforts have been made to identify biomarkers for 
NPC which would allow prediction and monitoring disease progression217–219. Here we 
investigated the Sph accumulation in fibroblasts derived from skin biopsies of NPC patients 
exhibiting a range of neurological symptoms to see whether the extent of Sph accumulation 
correlated with the severity of the disease. The confocal microscopy images are shown in 
Figure 2.31.  
 
Figure 2.31 Lysosomal Sph efflux varied with NPC disease severity. Confocal microscopy images of NPC patient fibroblasts at 
various chase times. Cell lines were taken from patients exhibiting very mild symptoms (PH) to and intermediary phenotype 
(WF) and the severest phenotype seen to date (SGM). The scale bars represent 10 µm.  
The initial Sph localization (at 0 min chase) was similar in all patient cells as well as in control 
fibroblasts and showed Sph mostly in late endosomes/lysosomes as well as in the perinuclear 
area. No significant difference in fluorescence intensity or number of labelled vesicles could be 
observed. However, all patient cells showed brighter lysosomal staining compared to control 
cells. 
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The rate efflux of Sph from these acidic vesicles, however, differed markedly between the 
different cell lines. At 10 min chase and 30 min chase, no more vesicular staining was observed 
in control cells. The fluorescent signal stemmed from internal membranes with a slight 
enrichment in Golgi staining, in line with observations made in HeLa and CHO cells (chapter 
2.2.7.). Surprisingly, NPC PH cells (derived from a patient with mild clinical symptoms) did not 
show strong retention of Sph in late endosomes/lysosomes as observed in other NPC models 
(CHO/NPC1 or HeLa cells treated with U18666A or NPC1 siRNA). At 10 min chase, the 
fluorescent intensity in the endolysosomal vesicles was much reduced compared to 0 min and 
most of the staining stemmed from internal membranes, just as observed in control cells. After 
30 min, only a few vesicles remained fluorescent and NPC PH cells resembled control cells with 
respect to the uniformity of internal membrane staining. It appears the NPC1 mutations in this 
patient (R978C point mutation, IVS21-2 A>G splice site mutation) did not critically affect the 
capabilities of the acidic vesicles to efflux Sph (and potentially other lipids).  
In contrast, cells derived from patients with more severe phenotypes (WF and SGM) retained 
Sph accumulation in late endosomes / lysosomes after 30 min chase, indicative of a failed efflux 
of Sph from the acidic compartment. These findings constituted a promising first step towards 
establishing the TFS Sph efflux assay as a new diagnostic tool predicting the severity of the NPC 
disease in different patients. Further efforts employing cells from more patients and optimized 
chase times should confirm whether the rate of Sph transport from the late endosomes / 
lysosomes correlates with the severity of neurological symptoms observed in NPC patients.  
2.2.9. Ultrastructural examinations of NPC  
In order to examine the storage defect in NPC cells more closely, we investigated patient and 
control fibroblasts on the ultrastructural level using cryo-electron microscopy (cryo-EM). All EM 
sample preparation and analysis steps in this chapter were performed by Martina Schifferer in 
our group.   
First, we analyzed samples by Transmission Electron Tomography (TEM). Control and NPC-WF 
fibroblasts were high-pressure frozen, embedded in Lowicryl and thick-sectioned (300 nm) and 
visualized by TEM. Figure 2.32 reveals a high abundance of very large (> 500 nm diameter) 
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multivesicular bodies (MVB) in both control and NPC-WF cells. While the electron density in 
control MVBs was more homogenously distributed, NPC cells showed a striking enrichment of 
electron dense material in intraluminal vesicles (ILV).  
 
Figure 2.32 NPC cells show multivesicular bodies with high electron density. TEM images of control and NPC-WF fibroblasts. The 
scale bars represent 500 nm.  
A close-up of NPC MVBs (Figure 2.32, bottom right image) revealed tight packing of many 
electron-dense ILVs, indicative of ILVs filled with storage material. These electron-dense vesicles 
may be the site of lipid accumulation in NPC disease.  
To investigate whether Sph was indeed present in the ILVs, we used correlative light and 
electron microscopy (CLEM) on NPC-WF cells. We visualized Sph localization by clicking a 
fluorescent dye (Alexa594-azide) to the crosslinked TFS probe in PFA-fixed cells before high-
pressure freezing. Samples were embedded in Lowicryl, thick sectioned and incubated with 
50 nm Tetraspecks, both fluorescent and electron dense beads serving as landmarks for 
correlation fluorescent and electron microscopy images220. Figure 2.33 shows a representative 
correlation and confirms that Sph was present in MVBs of NPC-WF cells. Its distribution was not 
homogenous over the whole MVB, but enriched in single ILVs.  
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Figure 2.33 Sph is localized to intraluminal vesicles in NPC. CLEM images of NPC-WF fibroblasts labelled with TFS. The scale bars 
represent 500 nm. 
 
This is further evidence consistent with the widely accepted hypothesis that fusion events are 
hindered in the NPC disease55,57. Sph and other storage materials are retained at the late 
endosomal / lysosomal stage and cannot be metabolized further. We hypothesize that 
accumulation of such ILVs in the late endosomes / lysosomes of NPC cells leads to lysosomal 
stress and weaken lysosomal membrane stability. Several of the storage lipids in NPC such as 
Sph221 and SM222 have already been shown to contribute to lysosomal destabilization. This 
might also explain the observation that inhibition of autophagy ameliorated the NPC phenotype 
in NPC1-null cells200, because this reduced the delivery of substrates to compromised 
lysosomes. 
2.2.10. Conclusion and outlook 
The bifunctional lipid technology is currently one of the best methods to screen for soluble and 
transmembrane spanning lipid-binding proteins in a native cellular environment. Due to the 
synthetic effort necessary for creating these lipids, only few studies have been reported so 
far150–152. However, the power and applicability of this concept is gaining attraction as a whole 
new class of drugable proteins has been identified recently using bifunctional 
endocannabinoids152.  Additionally, bifunctional lipids are optimally suited to probe the 
subcellular localization of lipids since the fluorescent group is only added after crosslinking and 
fixation and therefore does not alter the physicochemical properties of the lipid probe. This has 
been successfully demonstrated in cultured cells as well as in whole organisms151.  
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The only drawback of this method comes from its biggest advantage: The bifunctional probe 
mimics endogenous lipids so closely that it takes part in cellular metabolism and is converted to 
multiple lipid species, thereby  yielding mixed protein interactomes of different lipid probes. 
Here, we developed a novel method which retained all the advantages of bifunctional lipids and 
additionally circumvented ongoing lipid metabolism before crosslinking and identification of 
interacting proteins, by adding a caging group to bifunctional lipids. This technology ensured the 
inactivity of these trifunctional probes during delivery to the cells. Two subsequent 
photoreactions carried out on the same molecule allowed for the liberation of the active probe 
to its binding partners immediately before crosslinking. We demonstrated the orthogonality of 
the uncaging and photo-crosslinking reaction by NMR spectroscopy and showed that the 
liberated species are highly bioactive by live-cell microscopy.  
One possible concern was the mislocalization of the trifunctional probe due to the lipophilic 
properties of the DEAC cage group. Indeed, all investigated trifunctional lipids exhibited the 
same non-discriminatory endomembrane staining before uncaging, which does not represent 
endogenous lipid localization. However, the conditions used for proteomic screens (2 min 
uncaging immediately followed by 2 min crosslinking) resulted in complete rearrangement of 
the trifunctional lipids inside the cells so that TFS was crosslinked mostly at endosomes and 
lysosomes while TFDAG exhibited cytosolic and ER staining. This hints towards a rapid transport 
mechanism of the liberated species to their endogenous locations, either passively by diffusion 
or actively via the action of lipid transfer proteins. Interestingly, we found several known 
transfer proteins (such as STARD3, STARD7 or PITPβ) and some unknown lipid transfer proteins 
in the Sph interactome, indicating that Sph either regulates these proteins or is transported by 
these proteins. Further experiments are needed to confirm these hypotheses.  
Analysis of the protein interactomes of three different trifunctional lipids revealed a high 
overlap of proteins which were identified in all three conditions. This high background has been 
reported in other studies151,152 and stemmed either from unspecific crosslinking of membrane 
proteins to the surrounding lipid layer, or from non-specific binding of the proteins to 
neutravidin beads during the enrichment step. Therefore, it is imperative to employ control 
lipids to exclude these background proteins. Additionally, these non-specific proteins also 
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impeded the identification of proteins crosslinked at lower numbers due to the cut-off at the 
mass spectrometer. The same effect was observed in experiments with bifunctional lipids which 
were incorporated into many bifunctional metabolites. The increased complexity of the 
proteome led to the loss of proteins present in low copy numbers. We showed this effect by 
comparing high confidence TFS binding proteins with high confidence pacSph binding proteins. 
Almost half of the putative TFS-binding proteins were not identified at all when using pacSph. In 
conclusion, we developed a novel method to obtain protein interactomes of single lipid species 
with a much higher coverage than by using bifunctional lipids.  
Interestingly, we also found TPC1, but not other lysosomal calcium channels such as TPC2 or 
TRPML1 crosslinked to TFS. This provides evidence of a direct interaction between Sph and TPC1 
and explains the immediate effect of Sph on lysosomal calcium signaling. The TFS probe was 
further used to determine the binding site of Sph to TPC1. However, the TFS-Sph interaction 
was only detected in one screen and with low spectral counts and therefore needs to be further 
validated in future experiments.  
We also demonstrated the power of trifunctional lipids as probes to investigate the subcellular 
localization and transport of lipids through the cell. Using TFS, we confirmed the late 
endosomal / lysosomal localization of Sph and its enrichment in different cellular models of the 
NPC disease, showing it was not an artifact from the endocytic uptake of the previously used 
bifunctional Sph. The TFS probe was also used in precise pulse-chase experiments to follow the 
efflux of Sph from the acidic compartments. This new assay was used to examine the 
differences between fibroblasts derived from NPC patients with varying disease severity. We 
showed that fibroblasts derived from the patient with the mildest phenotype had the ability to 
efflux Sph from the endolysosomes almost as fast as control cells, while NPC patients with more 
severe symptoms showed accumulation of Sph in acidic vesicles. More in-depth investigations 
involving cells from more patients and finer chase times should confirm the suitability of this 
assay as a biomarker for predicting NPC disease severity based on the extent of Sph storage.  
Finally, we employed TFS to investigate Sph localization in NPC fibroblasts by correlative light- 
and electron microscopy. This is the first report visualizing the localization of a lipid on the 
ultrastructural level. We showed an accumulation of Sph in intraluminal vesicles of 
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multivesicular bodies / late endosomes in NPC fibroblasts, an observation which is consistent 
with the long-standing hypothesis that NPC cells exhibit a trafficking block at the late endosomal 
/ lysosomal stage55,57. Apart from the insights into the pathophysiology of NPC, we also believe 
that this new method will find application in many more areas where the ultrastructural 
localization of lipids is of interest.  
 73 
 
 
 
Chapter 3 - Experimental methods 
3.1. Reagents 
Common laboratory chemicals were purchased from commercial sources (Acros, Fluka, Merck, 
Sigma-Aldrich or VWR) at highest available grade and were used without further purification. D-
erythro sphingosine and D-erythro dihydrosphingosine, the sphingosine kinase inhibitor SKI-II, 
Xestospongin C and GPN were obtained from Biomol (Hamburg, DE). 7-Diethylamino-4-
hydroxymethylcoumarin was a kind gift from Rainer Müller (EMBL Heidelberg, DE). Deuterated 
solvents for NMR analysis were purchased from Deutero (Karlsruhe, DE). Sphingosine kinase 
inhibitor N,N-dimethylsphingosine was obtained from Sigma-Aldrich. NAADP-antagonist Ned-19 
was purchased from Tocris Biosciences (Bristol, UK). FTY720 was a kind gift from Dr. Fran Platt 
(University of Oxford, UK). The fluorescent calcium indicator Fluo-4-AM and Alexa488-azide 
were obtained from Life Technologies (Thermo Fisher Scientific, Waltham, USA).  
3.2. Chemical synthesis 
3.1.1. General synthetic procedures 
All reactions were carried out using dry solvents under inert atmosphere in the dark. Thin layer 
chromatography (TLC) was performed on plates of silica gel (Merck, 60 F254) and visualized 
using UV light (254 nm or 366 nm) or a solution of phosphomolybdic acid in EtOH (10 % w/v). 
Preparative column chromatography was carried out using Merck silica gel 60 (grain size 0.063 – 
0.200 nm) under a pressure of <1.5 bar. 1H-NMR spectroscopic measurements were conducted 
on a 400 MHz Bruker UltraShieldTM spectrometer at 25°C. 13C-NMR measurments were 
performed on a 500 MHz Bruker UltraShieldTM spectrometer at 25°C and were broadband 
hydrogen decoupled. 1H- and 13C-NMR spectra are shown in Appendix A. Chemical shifts are 
given in ppm referenced to the residual solvent peak. J values are given in Hz and splitting 
patterns are designated using s for singlet, d for doublet, t for triplet, q for quartet, m for 
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mulitplet and b for broad signal. High-resolution mass spectra were recorded on a Finnigan LCQ 
quadrupole ion trap at the Organic Chemistry Institute of the University of Heidelberg 
3.1.2. 7-(Diethylamino)-coumarin-4-yl)-methyl-chloroformate223 
 
A solution of 7-diethylamino-4-hydroxymethylene-coumarin (48 mg, 194 µmol) in 2 mL dry THF 
was cooled to 0°C. DIPEA (0.1 µL, 575 µmol) and phosgene (300 µL, 610 µmol) were added 
dropwise and stirred in the dark for 2 h at 0 °C. The reaction mixture was extracted with 
EtOAc/H2O (1:1, 75 mL), the layers were separated, the organic layer was washed with brine 
and dried using Na2SO4. The solvent was removed under reduced pressure and the product was 
dried further under high vacuum conditions. 7-(Diethylamino)-coumarin-4-yl]-methyl 
chloroformate was used without further purification. 
3.1.3. (7-(Diethylamino)-2-oxo-2H-chromen-4-yl ((2R,3S,E)-1,3-dihydroxyoctadec-4-en-
2-yl)carbamate) 
 
To a solution of D-erythro-sphingosine (30 mg, 100 µmol) in 2 mL dry THF, TEA (70 µL, 
500 µmol) and a solution of 7-diethylamino-coumarin-4-yl-methyl chloroformate (46 mg, 
148 µmol) in 1 mL dry THF were added. The mixture was stirred at RT for 1 h in the dark. EtOAc 
(50 mL) was added to stop the reaction and the mixture was washed twice with citric acid (5 % 
w/v, 25 mL) and twice with saturated NaHCO3. The organic layer was dried with Na2SO4 and the 
solvent was removed under reduced pressure. The residue was purified by repeated flash 
chromatography (first column: eluent: DCM/MeOH 13:1, second column: eluent: 
cyclohexane/EtOAc 1:5 (+1 % TEA)). Sph-Cou was obtained as yellow oil (26 mg, 45 µmol, 45 % 
over two steps)  
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1H NMR (400 MHz, CDCl3) δ = 7.29 (d, J=8.9, 1H), 6.58 (d, J=8.7, 1H), 6.50 (s, 1H), 6.14 (s, 1H), 
5.96 (d, J=8.3, 1H), 5.80 (dd, J=14.6, 7.2, 1H), 5.55 (dd, J=15.2, 6.1, 1H), 5.22 (s, 2H), 4.39 (s, 1H), 
4.05 – 3.96 (m, 1H), 3.76 (d, J=11.6, 1H), 3.68 (q, J=3.8, 1H), 3.40 (q, J=7.0, 3H), 3.06 (s, 1H), 2.05 
(dd, J=13.5, 6.6, 2H), 1.41 – 1.10 (m, 28H), 0.87 (t, J=6.6, 3H). 13C NMR (126 MHz, CDCl3) δ = 
162.15, 156.18, 155.60, 150.40, 134.45, 128.70, 126.78, 124.43, 108.98, 106.16, 98.13, 74.75, 
74.17, 66.85, 62.21, 61.89, 55.73, 44.96, 32.29, 31.93, 29.70, 29.67, 29.64, 29.51, 29.37, 29.22, 
29.10, 22.70, 14.12, 12.40.  
HRMS for C33H53N2O6
+  calculated: 573.39036; found: 573.39027 
3.1.4. (2,4-Dimethoxy-6-nitrophenyl-((2R,3S,E)-1,3-dihydroxyoctadec-4-en-2-yl)- 
carbamate) 
 
A solution of D-erythro-sphingosine (30 mg, 100 µmol) in 2 mL dry THF and TEA (70 µL, 
500 µmol) was stirred during dropwise addition of 4,5-dimethoxy-2-nitrobenzyl-chloroformate 
(41 mg, 150 µmol) in 2 mL dry THF. The mixture was stirred at RT for 1h in the dark. EtOAc 
(50 mL) was added and the mixture was washed twice with citric acid (5 % w/v, 25 mL) and 
twice with saturated NaHCO3. The organic layer was dried with Na2SO4 and the solvent was 
removed under reduced pressure. The residue was purified by chromatography (eluent: 
cyclohexane/EtOAc 1:5 (+1 % TEA)). Sph-NB was a colorless oil (51,4 mg, 95 µmol, 95 %).  
1H NMR (400 MHz, CDCl3) δ = 7.70 (s, 1H), 7.02 (s, 1H), 5.84 – 5.75 (m, 2H), 5.55 (d, J=6.0, 1H), 
5.51 (s, 2H), 4.38 (s, 1H), 4.01 (s, 1H), 3.98 (s, 3H), 3.95 (s, 3H), 3.73 (d, J=11.5, 1H), 3.67 (s, 1H), 
2.39 (s, 2H), 2.12 – 1.96 (m, 2H), 1.42 – 1.13 (m, 22H), 0.87 (t, J=6.7, 3H) 13C NMR (101 MHz, 
CDCl3) δ = 155.99, 134.47, 128.58, 110.07, 108.15, 74.81, 63.78, 62.24, 56.52, 56.50, 56.40, 
55.57, 32.28, 31.94, 31.92, 29.71, 29.68, 29.62, 29.48, 29.36, 29.22, 29.08, 22.71, 22.69, 14.13.  
HRMS for C28H47N2O8Na
+ calculated: 561.31519, found: 561.31557 
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3.1.5. (7-(Diethylamino)-2-oxo-2H-chromen-4-yl-((2R,3S)-1,3-dihydroxyoctadecan-2-yl) 
carbamate) 
 
To a solution of D-erythro-dihydrosphingosine (10 mg, 33 µmol) in 1 mL dry THF, DIPEA (23 µL, 
230 µmol) and a solution of [7-(diethylamino)-coumarin-4-yl)-methyl chloroformate (15 mg, 
50 µmol) in 0,5 mL dry THF were added. The mixture was stirred at RT for 1,5 h in the dark. 
EtOAc (20 mL) was added to stop the reaction and the mixture was washed twice with citric acid 
(5 % w/v, 10 mL) and twice with saturated NaHCO3. The organic layer was dried with Na2SO4 and 
the solvent was removed under reduced pressure. The residue was purified by repeated flash 
chromatography (first column: eluent: DCM/MeOH 13:1, second column: eluent: 
cyclohexane/EtOAc 1:5). dhSph-Cou was obtained as yellow oil (14.5 mg, 25 µmol, 76 % over 
two steps) 
1H NMR (400 MHz, CDCl3) δ = 7.27 (d, J=8.9 Hz, 1H), 6.56 (dd, J=9.0, 2.3, 1H), 6.49 (d, J=2.3, 1H), 
6.14 (s, 1H), 6.08 (d, J=8.4, 1H), 5.22 (s, 2H), 4.07 (dd, J=11.4, 2.3, 1H), 3.82 (d, J=11.7, 2H), 3.66 
(s, solvent THF), 3.62 (dd, J=8.1, 3.3, 1H), 3.40 (q, J=7.0, 4H),2,30 (t, J=7.6, solvent),  1.67 – 1.45 
(m, 4H), 1.36 – 1.13 (m, 30H), 0.87 (t, J=6.7, 3H) 13C NMR (126 MHz, CDCl3) δ = 162.34, 156.17, 
155.52, 150.60, 130.02, 129.77, 124.41, 108.83, 106.12, 105.90, 97.90, 74.36, 62.24, 61.83, 
55.13, 51.44, 44.82, 34.55, 31.94, 29.71, 29.67, 29.61, 29.59, 29.37, 27.23, 25.99, 24.96, 22.70, 
14.12, 12.43. 
HRMS for C33H55N2O6
+ calculated: 575.40601; found: 575.40626 
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3.1.6. (7-(Diethylamino)-2-oxochromen-4-yl)methyl-((2S,3R,E)-1,3-dihydroxy-13-(3-
(pent-4-yn-1-yl)-3H-diazirin-3-yl)tridec-4-ene-2-yl)carbamate 
 
A solution of 20 mg (59.7 µmol) photoactivatable and clickable sphingosine (Per Haberkant) in 
1.5 mL THF was cooled to 0 °C and 52 µL DIPEA (0.3 mmol) was added.  [7-(diethylamino)-
coumarin-4-yl)-methyl chloroformate (28 mg, 0.09 mmol) in 1 mL dry THF were added and 
stirred at room temperature for 1 h. The product was extracted with 30 mL EtOAc and 30 mL 
citric acid (5 % w/v) and washed twice with 30 mL citric acid, once with NaHCO3 and once with 
brine. The organic phase was dried over Na2SO4 and the solvent was removed under reduced 
pressure. The residue was purified by flash chromatography (first column: eluent: 
cyclohexane/EtOAc 1:1, second column: eluent: DCM/MeOH 14:1) which gave the title 
compound as a yellow oil (35 mg, 57.5 mmol, 96 % yield).  
1H NMR (500 MHz, CDCl3) δ = 7.29 (d, J=9.0, 1H), 6.58 (dd, J=8.9, 2.2, 1H), 6.50 (d, J=2.2, 1H), 
6.14 (s, 1H), 5.89 (d, J=6.8, 1H), 5.84 – 5.75 (m, 1H), 5.55 (dd, J=15.2, 6.1, 1H), 5.23 (s, 2H), 4.39 
(s, 1H), 4.02 (dd, J=11.2, 2.8, 1H), 3.77 (dd, J=11.5, 3.0, 1H), 3.69 (dd, J=7.8, 3.3, 1H), 3.66 – 3.59 
(m, 1H), 3.41 (q, J=7.0, 4H), 2.56 (s, 2H), 2.15 (td, J=6.9, 2.6, 2H), 2.05 (dd, J=13.9, 7.0, 3H), 1.94 
(t, J=2.6, 1H), 1.48 (dd, J=9.1, 6.6, 3H), 1.39 – 1.29 (m, 9H), 1.28 – 1.15 (m, 28H), 1.10 – 1.02 (m, 
5H), 0.91 – 0.77 (m, 4H) 
13C NMR (126 MHz, CDCl3) δ = 162.34, 156.17, 155.63, 150.63, 134.39, 128.68, 124.40, 108.87, 
105.92, 97.91, 83.49, 77.28, 77.03, 76.77, 74.72, 68.88, 62.12, 61.88, 55.67, 44.83, 32.85, 32.24, 
31.85, 29.71, 29.31, 29.28, 29.17, 29.10, 29.02, 28.46, 23.81, 22.77, 17.97, 14.12, 12.43. 
HRMS calculated for C34H49N4O6
+:  609.36521, found: 609.36508 
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3.2. Buffers and media 
3.2.1. Bacterial culture media 
LB medium 
Autoclaved Luria-Bertani (LB) medium was prepared by the media kitchen at EMBL according to 
following composition and stored at room temperature.  
1 % (w/v) bacto trypton 
 0.5 % (w/v) bacto yeast extract 
 170 mM NaCl  
The pH was adjusted to 7.6 using NaOH and the medium was supplemented with antibiotics 
(100 µg/mL ampicillin, 33 µg/mL chloramphenicol or 30 µg/mL kanamycin) immediately prior to 
use.  
 LB agarose plates 
LB agarose plates were prepared by the media kitchen with 1.5 % (w/v) bacto agar in LB, 
supplemented with antibiotics (100 µg/mL ampicillin, 33 µg/mL chloramphenicol or 30 µg/mL 
kanamycin) and stored at 4 °C. 
 SOC medium 
Super Optimal broth with Catabolite repression (SOC) medium was prepared by the media 
kitchen according to following composition, pH adjusted to 7.0, autoclaved and stored at 4°C.  
20 mM glucose 
10 mM MgCl2  
10 mM MgSO4 
2.5 mM KCl 
10 mM NaCl 
2 % (w/v) bacto tryptone 
0.5 % (w/v) bacto yeast extract 
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3.2.2. Buffers and solutions 
 PBS 
 137 mM NaCl 
2.7 mM KCl 
 2 mM KH2PO4 
 10 mM Na2PO4 
 1 mM EDTA 
PBS was prepared by the media kitchen at EMBL. It was adjusted to pH 7.4 using HCl and sterile 
filtered.  
Imaging buffer 
20 mM HEPES 
115 mM NaCl 
1.2 mM MgCl2 
1.2 mM K2HPO4 
1.8 mM CaCl2  
The pH of the imaging buffer was adjusted to 7.4 using 1 M NaOH or 1 M HCl solution. Before 
each experiment, glucose was added to a final concentration of 0.2 % (w/v).  
 Lysis buffer 
 50 mM HEPES 
 50 mM NaCl 
 1 % (w/v) SDS 
 1x protease inhibitor cocktail (PIC)  
The pH of the lysis buffer was adjusted to 8.5 before addition of SDS. One tablet of PIC was 
added to 50 mL lysis buffer immediately before use.  
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Amido Black solution 
 0.02 % (w/v) amido black 
 40 % (v/v) methanol 
 10 % (v/v) glacial acetic acid 
 50 % (v/v) H2O 
PHEM buffer 
60 mM PIPES  
5 mM HEPES 
10 mM EGTA  
2 mM MgCl2  
The buffer was adjusted to pH 6.9, sterile filtered and refrigerated before use.  
Borate buffer (for lipidomics analysis) 
200 mM boric acid  
10 mM tris(2-carboxyethyl)-phosphine  
10 mM ascorbic acid  
33.7 µM 15N13C valine 
The boric acid solution was adjusted to pH 8.8 before addition of the other components and 
sterile filtration.  
3.2.3. Eukaryotic cell media 
Standard culture medium 
Dulbecco’s Modified Eagle Medium (DMEM) (4.5 g/L glucose, Gibco/Life Technologies) 
 10 % fetal calf serum (Sigma-Aldrich, Lot.-No. 032M3395)  
 2 mM L-glutamine (Gibco/Life Technologies)  
 1 % penicillin/streptomycin (Gibco/ Life Technologies)  
 
Chapter 3 – Experimental methods 
 
 
81 
 
HeLa cell culture medium 
DMEM (1 g/L glucose, Gibco/Life Technologies)  
 10 % fetal calf serum (Sigma-Aldrich, Lot.-No. 032M3395)  
 1 % primocin (InvivoGen) 
All media were sterile filtered and stored at 4 °C.  
3.3. Cell culture 
3.3.1. Eukaryotic cell lines 
HeLa (human cervical adenocarcinoma cells, No. CCL-2)  
ATCC / LGC Standards GmbH (Wesel, DE) 
TPC1-KO (mouse embryonic fibroblasts from Tpcn1-/- mouse)  
TPC2-KO (mouse embryonic fibroblasts from Tpcn2-/- mouse) 
DKO (mouse embryonic fibroblasts from a Tpcn1-/-, Tpcn2-/- double knockout mouse) 
Ctrl MEF (mouse embryonic fibroblasts from a WT mouse)  
Dr. Antony Galione (Department of Pharmacology, University of Oxford, UK) 
Ctrl FB (human fibroblasts derived from healthy donor) 
NPC-PH (human fibroblasts derived from NPC patient (#17))  
NPC-WF (human fibroblasts derived from NPC patient (#22)) 
NPC-SGM (human fibroblasts derived from NPC patient (#25))   
Dr. Forbes D. Porter (Section of Molecular Dysmorphology, NIHCD, Betheseda, USA) 
CHO WT (Chinese hamster ovary cells) 
CHO null (NPC1 null Chinese hamster ovary cells)  
CHO OE (NPC1 overexpressing chinese hamster ovary cells)  
Dr. Daniel Ory (Washinton University School of Medicine, St. Louis, USA) 
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Ctrl FB (human fibroblasts derived from healthy donor)  
MLIV (human fibroblasts derived from mucolipidosis type IV patient)   
Dr. Frances Platt (Department of Pharmacology, University of Oxford, UK)  
All cells were kept in appropriate growth medium in a humidified incubator at 37 °C with 5 % 
CO2 and were passaged 2 – 3 times per week. For live-cell imaging experiments, cells were 
seeded in 8-well Labtek dishes (Nunc/Thermo Scientific) 48 h prior to the experiment.  
3.3.2. Transfection 
For imaging experiments, cells in 8-well Labteks were transfected 24 h prior to the experiment 
using Fugene HD reagent (Promega), OPTIMEM medium (Gibco/Life Technologies) and 100 ng 
TFEB-GFP plasmid as well as 50 ng R-GECO plasmid per well according to the manufacturer’s 
instructions.  
3.4. Live-cell microscopy  
3.4.1. Cell loading  
Cells in 8-well Labteks at 70 – 80 % confluency were labelled with 100 µL of 5 µM Fluo4 AM 
(Molecular Probes) solution in imaging buffer at 37 °C for 30 min. 15 min prior to the start of the 
experiment, caged lipids (Sph-Cou, Sph-NB, dhSph-Cou or TFS) were added to a final 
concentration of 2 µM. The cells were then washed and kept in imaging buffer at 37 °C for the 
duration of the experiment.  
3.4.2. Confocal time lapse microscopy and photoactivation 
The fluorescence of the calcium indicator Fluo4 was monitored on a dual scanner confocal laser 
scanning microscope (Olympus FluoView 1200) using a 63x oil objective at 488 nm excitation 
and emission settings between 500 - 550 nm at an intverval of 1 s per frame. A baseline of 10 
frames (= 10 s) was captured before photoactivation (‘uncaging’) in a circular region (10 pixel 
units diameter, 8.9 µm2) inside the cells using the tornado function of the Olympus software. 
Coumarin-uncaging was carried out using the 405 nm laser line set to 50 % intensity for 3 s at 2 
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µs per pixel. For nitrobenzyl-uncaging, the 375 nm laser line was set to 100 % intensity and 
activated for 5 s at 2 µs per pixel.  
3.4.3. Image analysis 
For calcium measurements, time lapse images were analyzed using Fiji software (W. Rasband, 
NIH, USA) with the FluoQ macro 166 set to the following parameters:  
Background subtraction method:  Mean of an interactively selected ROI 
Noise reduction / smoothing method: None 
Threshold method:  Interactively with ImageJ’s built-in threshold window 
ROI segmentation:  Semi-automatically with binary mask modification 
Calculate amplitude changes: Using maximum observed amplitude change 
The maximum amplitude values were calculated by subjecting the raw traces to a central 
moving average. The maximal amplitude xresponse
max  of these smoothed traces was used to 
calculate the amplitude change in percent %∆𝑥
𝑚𝑎𝑥according to following formula: 
%∆𝑥
𝑚𝑎𝑥=
𝑥𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒
𝑚𝑎𝑥 − ?̅?𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
|?̅?𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒|
∗ 100 
The resulting intensity series/amplitude values represent mean values of whole cells and were 
further analyzed using R software167.  
3.4.4. Data anaylsis 
The intensity/amplitudes values derived from the FluoQ macro were loaded in R and grouped 
according to lipid and condition (cell lines, inhibitors used). Single cell traces belonging to the 
same groups were summarized using a custom function called summarySE (see Appendix C.1) 
which calculated the mean as well as the standard error of the mean of all traces for every time 
point. Line and bar graphs were generated using the ggplot2 package in R224.  
3.5. Lipid analyses 
3.5.1. Thin layer chromatographic analysis of caged lipids 
HeLa cells were grown in 6 cm dishes (Nunc) to 85 – 95 % confluency and labelled with indicated 
concentrations of Sph-Cou in imaging buffer for the designated times. Cells were washed with 
PBS and scraped in 300 µL PBS. 600 µL MeOH and 150 µL CHCl3 were added and the mixture 
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was vortexed and centrifuged at 14 000 rpm for 3 min. The supernatant was transferred in a 
new vial, 300 µL CHCl3 and 600 µL acetic acid (0.1 % v/v in water) were added and the mixture 
was vortexed and centrifuged at 14 000 rpm for 4 min. The (upper) aqueous phase as discarded 
and the organic phase was dried in a speed-vac at 30 °C for 15 min. The lipids were redissolved 
in 30 µL CHCl3 and applied onto a 10 x 10 cm HPTLC Silica 60 glass plate (VWR) using the 
automatic Camaq system. TLC plates were developed using CHCl3/MeOH/H2O/AcOH 65:25:4:1 
for 6 cm and then cyclohexane/ethylacetate 1:1 for 9 cm. Lipids containing the fluorescent cage 
group were visualized using a geldoc system.  
3.5.2. Thin layer chromatographic analysis of clickable lipids 
Cells were grown in 60 cm dishes to 85 – 95 % confluency and labelled with the snapshot probes 
or pacSph at 1 – 6 µM for the indicated times. After washing with PBS, the cells were transferred 
onto an ice block and UV-irradiated using a 450 – 1000 W high-pressure mercury lamp 
(Newport, USA) equipped with glass filters removing wavelengths below 345 nm and below 400 
nm. The cells were irradiated with > 400 nm for 2.5 min and then immediately irradiated with > 
350 nm for another 2.5 min. The cells were washed again and scraped in 300 µL PBS and mixed 
with 600 µL MeOH and 150 µL CHCl3. The mixture was vortexed and centrifuged at 14 000 rpm 
for 3 min and the supernatant was transferred into a new vial. 300 µL CHCl3 and 600 µL acetic 
acid (0.1 % v/v in water) were added, the mixture was again vortexed and centrifuged (14 000 
rpm, 4 min) and the aqueous phase was discarded. The organic phase was dried in a speed-vac 
at 30 °C for 15 min. The lipids were dissolved in 7 µL CHCl3 and 30 µL click-mixture (5 µL 
44.5 mM 3-azido-7-hydroxycoumarin, 500 µL of 10 mM [acetonitrile]4CuBF4 and 2 mL EtOH) was 
added. The reaction vial is vortexed and incubated in a heating block at 42 °C with no shaking 
for 3 -4 h until all solvent is condensed under the lid. The tube is then vortexed and the mixture 
is applied onto a 10 x 10 cm HPTLC Silica 60 glass plate (VWR) using the automatic Camaq 
system.   TLC plates were developed using CHCl3/MeOH/H2O/AcOH 65:25:4:1 for 6 cm and then 
cyclohexane/ethylacetate 1:1 for 9 cm. Lipids containing the fluorescent coumarin group were 
visualized using a geldoc system.  
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3.5.3. Lipidomics analysis of Sph and metabolites 
HeLa cells were grown in 6 cm dishes (Nunc) to 85 – 95 % confluency and labelled with 2 µM 
Sph-Cou in imaging buffer or only in imaging buffer for 15 min. After washing with PBS,  cells 
were transferred onto an ice block and UV-irradiated  with > 400 nm  light for 2 min and then 
immediately pelleted (by centrifugation with 3000 rpm for 1 min) and snap-frozen in liquid 
nitrogen. The pellets were resuspended in extraction solvent EtOH/H2O/diethylether/pyridine 
(15:15:5:1) supplemented with ammonium hydroxide (2.1.10-3 N) and internal standards (C17-
sphingosine, C17-sphinganine, C17-sphingosine-1-phosphate and C17-sphinganine-1-
phosphate) were added. The pellets were vortexed at 4 °C for 10 min and incubated on ice for 
20 min. Cell debris was pelleted by centrifugation at 20000 g for 2 min at 4 °C. The extraction 
was repeated one more time skipping the incubation on ice. Supernatants were combined and 
dried under vaccum in a Centrivap (Labconco, Kansas City, USA).  
The lipid extract was resuspended in borate buffer and derivatized by reaction for 15 min at 
55 °C with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC, 2.85mg/ml in acetonitrile) 
The AQC reagent was synthesized according to Cohen et al225. Samples were analyzed after 
overnight incubation at 24 °C using a reverse-phase C18 column (HPLC EC 100/2 Nucleoshell 
RP.18 2.7µm) on an Accela high-performance liquid chromatography system (ThermoFisher 
Scientific, Waltham, MA), coupled to a TSQ Vantage (ThermoFisher Scientific, Waltham, USA). 
MRM-MS was used to identify and quantify lipid species. The relative amounts of Sph and its 
metabolites were normalized to 15N13C-valine, the internal standard for the derivatization 
process.  
3.6. Proteomic screen 
3.6.1. Cell labelling and crosslinking 
HeLa cells were grown in three 10 cm dishes for each condition and labelled with 4 mL of 100 
µM TFFA for 15 min, 100 µM TFDAG for 15 min and 6 µM TFS probe for 5 min. The cells were 
then UV-irradiated for 2.5 min at wavelengths above 400 nm follwed by a second irradiation at 
wavelenghts above 345 nm and washed with ice-cold PBS. The cells were scraped off in 2 mL 
PBS and centrifuged at 3000 rpm for 10 min at 4 °C. The cell pellet was resuspended in 300 µL 
PBS, 600 µL MeOH and 150 µL CHCl3 were added, vortexed and centrifuged at  14 000 rpm for 3 
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min. The protein pellet was resuspended in 100 µL PBS and 100 µL lysis buffer were added, and 
shaken at 95 °C for 5 min. After cooling down, 2 µL benzonase was added and incubated for 30 
min at 37 °C. Next, 100 µL of 200 mM DTT (in 200 mM HEPES) was added and incubated at 45 °C 
for 30 min and then 20 µL of 400 mM iodoacetamide (in 200 mM HEPES) was added and shaken 
at 24 °C for 30 min. Finally, 20 µL 200 mM DTT were added to quench the reaction. The proteins 
were precipitated by addition of 600 µL MeOH and 150 µL CHCl3 and resuspended in 152.5 µL 
PBS/1 % (w/v) SDS/2x PIC by shaking at 37 °C for >1 h. 5 µL of the solution was removed for 
protein determination, the three lysates belonging to the same condition were pooled and 
stored at - 20 °C.  
3.6.2. Protein determination using Amido Black 
A serial dilution of BSA was prepared with 0, 2.5, 5, 7.5, 10, 25 and 50 µg BSA in 100 µL water. 
The samples were diluted to 100 µL. To all samples, 400 µL amido black solution was added, 
vortexed, incubated at room temperature for 5 min and centrifuged at 14 000 rpm for 5 min. 
The supernatant was aspirated and the pellets were washed twice with 500 µL MeOH/AcOH 
10/1. The pellets were dissolved in 300 µL 0.1 N NaOH and 150 µL were spotted onto a 96 well 
plate. The absorbance at 550 nm was recorded on a Synergy 4 microplate reader (BioTek, 
Winooski, USA).  
3.6.3. Biotinylation and pull-down 
The volume of the lysate was adjusted to 1 mg of protein and diluted to 630 µL. 30 µL of each 
reagent for click reaction (2.5 mM TBTA in DMSO, 25 mM CuSO4 in water, 25 mM biotin azide in 
water, 25 mM ascorbic acid in water) was added and the mixture was shaken at 37 °C for > 3 h. 
The proteins were precipitated twice using CHCl3/MeOH (1/4), redissolved in 160 µL PBS/1 % 
SDS and diluted with 240 µL RPVS to reach a final SDS concentration of 0.4 % (w/v). After 
centrifugation at 1000 rpm for 3 min, the supernatant was transferred into a new vial and mixed 
with 10 µL NeutrAvidin agarose resin (Thermo Scientific), which were washed three times with 
180 µL PBS/0.2 % SDS. The lysate was incubated with the resin for 1 h at room temperature and 
the supernatant was removed. The resin was washed 15 times with PBS/1 % SDS and the 
proteins were eluted with 50 µL elution buffer (100 mM Tris pH 6.8, 4 % SDS, 4 % β-
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mercaptoethanol) at room temperature for 1 h. The supernatant was taken after heating to 
95 °C for 30 min.  
3.6.4. On-bead tryptic digest (adapted from Hughes et al.210) 
20 µL of hydrophilic and hydrophobic Sera-Mag Speed beads (Thermo Scientific) were mixed 
and kept in 100 µL water. The protein lysate was mixed with 5 µL fomic acid (5 % (v/v) in water) 
and 5 µL beads. Acetonitril was added immediately to a final concentration of greater than 50 
%.  The mixture was incubated 8 min at room temperature and was then placed on a magnetic 
rack for further 2 min. The supernatant was removed and discarded. The beads were washed 
twice with 200 µL EtOH (70 % (v/v) in water) and once with 180 µL acetonitrile. The dry beads 
were then reconstituted in 10 µL digestion solution (50 mM HEPES pH 8.0 + 1 µg trypsin/LysC 
(Promega, mass spec grade)) and incubated for 14 h at 37 °C. The peptides were recovered by 
adding 190 µL acetonitrile to the beads, incubating at room temperature for 8 min and for 
further 2 min on the magnetic rack. The supernatant was removed and discarded. The beads 
were washed with 180 µL acetonitrile and 200 µL EtOH (90 % (v/v) in water). Beads were 
reconstituted in 9 µL DMSO (4 % (v/v) in water) and sonicated for 5 min. The supernatant was 
removed and transferred to a deactivated glass vial containing 1 µL formic acid (10 % (v/v) in 
water).  
3.6.5. High pH reverse phase offline fractionation (adapted from Bock et al.226) 
The peptide mixture was basified by addition of 10 µL 200 mM NH4OH and 2 µL pure NH4OH 
and injected into an Agilent 1200 Infinity high-performance liquid chromatography (HPLC) 
system equipped with a peltier-cooled autosampler and fraction collector (both set at 10 °C for 
all samples). The column was a Gemini C18 column (3 µm, 110 Å, 100 x 1.0 mm, Phenomenex) 
with a Gemini C18, 4 x 2.0 mm SecurityGuard cartrigdge (Phenomenex) as a guard column. The 
solvent system consisted of two mobile phases: Phase A was 20 mM ammonium formate (pH 
10.0) and phase B was acetonitrile (100 %). Sepearation was achieved at a flow rate of 0.1 
mL/min using the following linear gradient: 100 % A for 2 min., from 100 % A to 35 % B in 59 
min., 100 % A and reequilibration for 13 min. Thirty-two fractions were collected which were 
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then pooled into 10 fractions and dried under vacuum centrifugation and reconstituted in 10 µL 
0.1 % formic acid.  
3.6.6. Peptide cleanup and enrichment 
An Oasis HLB microelution plate (Waters) was washed twice with 200 µL 80 % acetonitrile/0.05 
% formic acid and then equilibrated twice with 200 µL formic acid (0.05 % (v/v) in water) per 
well. The samples were loaded and the flowthrough was discarded. Samples were then washed 
twice with 200 µL formic acid (0.05 % (v/v) in water). Elution was achieved with 50 µL 80 % 
acetonitrile/0.05 % formic acid. The eluate was dried under vacuum centrifugation and 
reconstituted in DMSO (4 % (v/v) in water) + 1 % formic acid.  
3.6.7. LC-MS/MS 
Peptides were separated using the nanoAcquity UPLC system (Waters) fitted with a trapping 
(nanoAcquity Symmetry C18, 5 μm, 180 μm x 20 mm) and an analytical column (nanoAcquity 
BEH C18, 1.7 μm, 75 μm x 200 mm). The outlet of the analytical column was coupled directly to 
an LTQ Orbitrap Velos Pro (Thermo Fisher Scientific) using the Proxeon nanospray source. 
Solvent A was water, 0.1 % formic acid and solvent B was acetonitrile/0.1% formic acid. The 
samples (7 μL) were loaded with a constant flow of solvent A at 5 μL/min onto the trapping 
column. Trapping time was 6 minutes. Peptides were eluted via the analytical column a constant 
flow of 0.3 μL/min. During the elution step, the percentage of solvent B increased in a linear 
fashion from 3 % to 7 % in 10 min, then increased to 25 % in 20 min and finally to 40 % in a 
further 10 min. The peptides were introduced into the mass spectrometer via a Pico-Tip Emitter 
360 μm OD x 20 μm ID; A 10 μm tip (New Objective) and a spray voltage of 2.2 kV were applied. 
The capillary temperature was set at 300 °C. Full scan MS spectra with mass range 300-1700 m/z 
were acquired in profile mode in the FT with resolution of 30 000. The filling time was set at 
maximum of 500 ms with limitation of 106 ions. The most intense ions (up to 15) from the full 
scan MS were selected for sequencing in the LTQ. Normalized collision energy of 40 % was used, 
and the fragmentation was performed after accumulation of 3 x 104 ions or after filling time of 
100 ms for each precursor ion (whichever occurred first). MS/MS data were acquired in centroid 
mode. Only multiply charged (2+, 3+, 4+) precursor ions were selected for MS/MS. The dynamic 
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exclusion list was restricted to 500 entries with a maximum retention period of 30 s and relative 
mass window of 10 ppm. In order to improve the mass accuracy, a lock mass correction using a 
background ion (m/z 445.12003) was applied. 
3.6.8. Data analysis 
Proteome Discoverer 1.4 (version 1.4.1.14, Thermo Scientific) was used as raw data post-
processing interface with the possibility to select scan events for peptide/protein identification. 
Identification was performed using a species specific Uniprot database (Homo sapiens 
taxonomy, 2012, 86945 entries). Mascot (version 2.2.07, Matrix Sciences, London) was used as 
search engine. Variable amino acid modification was oxidized methionine. 
Carbamidomethylation of cysteines was set as fixed modification.  Trypsin was selected as the 
enzyme, with one potential missed cleavage. Peptide and fragment ion tolerance was 
respectively 10 ppm and 0.5 Da. False Discovery Rates (FDR) of 5% (relaxed) and 1% (strict), 
validated based on q-value, were calculated by Proteome Discoverer based on the search 
against the corresponding randomized database.   Results were filtered on upload for only high 
peptide confidence, peptide length greater than 6 amino acids and a minimum mascot peptide 
ion score of 20.   
3.7. Visualization of protein-lipid complexes in cells 
Cells were seeded onto 11 mm coverslips placed in wells of a 24-well plate and labeled with 4 
µM pacSph in imaging buffer for 10 min. Cells were washed, overlaid with 1 mL imaging buffer 
and UV-irradiated on ice for 2.5 min at wavelength > 400 nm and for further 2.5 min at 
wavelengths of > 345 nm. Cells were immediately fixed with MeOH at -20°C for 20 min. Not 
crosslinked lipids were extracted by washing three times with 1 mL of CHCl3/MeOH/AcOH 
10:55:0.75 (v/v) at RT. Cells were then incubated with 50 µl of click mixture (1 mM ascorbic acid, 
100 μM TBTA, 1 mM CuSO4 and 2 μM Alexa 488 azide in PBS) for 1 h at RT in the dark. Cells 
were then washed with PBS and incubated with 50 µl of primary antibody (rabbit α-LAMP1, Cell 
Signaling, 1:100 or mouse α-GM130, abcam, 1:200 in PBS supplemented with 4 % BSA and 
0.02 % Triton) overnight at 4°C. Coverslips were again washed in PBS and incubated with 
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secondary antibody (α-rabbit conjugated to AlexaFluor555, α-mouse conjugated to 
AlexaFluor555Cell Signaling, 1:800) for 1 h, washed and mounted in DAPI-containing mounting 
medium (Vectashield, Vector Laboratories). Microscopy images were captured at room 
temperature using a confocal laser scanning microscope (Zeiss LSM780) with a 63x oil objective. 
Settings were as follows: DAPI-channel (405 nm excitation (ex), 409 - 475 nm emmission (em); 
green channel: 488 nm ex, 489 - 550 nm em; red channel: 561 nm ex, 569 - 655 nm em). Images 
were further processed using Fiji software (http://fiji.sc/Fiji). 
3.8. Visualization of Sph via correlated light- and electron microscopy 
NPC or wt cells were seeded on carbon coated Sapphire discs (3mm diameter, thickness 0.05 
mm, Engineering Office M. Wohlwend GmbH, Sennwald, Switzerland) for 24 h. Uncaging and 
crosslinking was performed as described in chapter 3.7. Cells were then fixed in 4 % PFA in 
PHEM buffer for 10 min and permeabilized with 0.001 % Saponin in PHEM buffer for 5 min 
before click reaction for 1 h in the dark (see also chapter 3.7.). The samples were processed 
within 1 h for high-pressure freezing (HPF) using the HPM 010 (Bal-Tec), placed between two 
aluminium carriers and a gold slot grid spacer (Plano GmbH, Wetzlar, Germany).  
The freeze substitution was performed in a temper temperature-controlling device (AFS2, Leica) 
in acetone supplemented with 0.1 % (w/v) uranyl acetate for 24 h at -90 °C. The temperature 
was raised to -45 °C within 10 h, held at that temperature, washed three times with acetone 
and infiltrated by Lowicryl HM20 (Polysciences Europe GmbH, Eppelheim, Germany) for 4 h 
periods at increasing concentrations (10 %, 25 %, 50 %, 75 %). The temperature was 
subsequently raised to -25 °C (5 °C/hour) and the final Lowicryl concentration of 100 % was held 
and washed every 10 h for three times. The blocks were finally polymerized by UV light 
incubation for 48 h at 20 °C. 
Thick sections (300 nm) were cut using a Leica Utracut UCT microtome mounted with a diamond 
knife (Diatome, Biel, Switzerland). Each section was placed on a carbon-coated copper grid 
(Plano GmbH, Wetzlar, Germany), incubated for 8 min in a drop of 1:200 with 50 nm fluorescent 
microspheres in PBS (TetraSpecks, Lifetechnologies) followed by 3 times washing in water. 
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The grids were sandwiched between two coverslips (Menzel-Gläser, No. 1) filled with 30 µL 
water and sealed by vaccum grease. Samples were imaged using a Metamorph (Molecular 
Devices) operated widefield fluorescence microscope (Olympus IX81) equipped with an X-Cite 
120PC light source (EXFO Life 2 Sciences), an Olympus PlanApo 100x 1.45 NA oil immersion 
objective, Orca-ER camera (Hamamatsu Photonics), electronic shutters and filter wheels (Sutter 
Instruments Co.). 470/22 nm and 556/20 nm excitation filters were used in combination with 
emission filters 520/35 nm for Tetraspecks and 624/40 nm for Alexa594. 
The grids were incubated with gold fiducial markers (15 nm) and placed into a single-tilt holder 
on a Tecnai TF30 microscope (FEI) at 300 kV using Serial EM for electron tomography. Images 
were acquired at -60 to +60 ° (1 ° increment) recorded by a 4K Eagle camera (FEI) at a pixel size 
of 5.068 nm and reconstructed using IMOD (versions 4.1.4). Fluorescent and electron 
tomography images were correlated based on the fluorescent and gold fiducials using a 
MATLAB script220.  
 
 92 
 
 
 
Bibliography 
1. Zechner, R., Kienesberger, P. C., Haemmerle, G., Zimmermann, R. & Lass, A. Adipose triglyceride lipase and 
the lipolytic catabolism of cellular fat stores. J. Lipid Res. 50, 3–21 (2009). 
2. Van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. 
Nat. Rev. Mol. Cell Biol. 9, 112–124 (2008). 
3. Sud, M. et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35, 527–532 (2007). 
4. Wymann, M. P. & Schneiter, R. Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 9, 162–176 (2008). 
5. Ekroos, K. et al. Charting molecular composition of phosphatidylcholines by fatty acid scanning and ion trap 
MS3 fragmentation. J. Lipid Res. 44, 2181–2192 (2003). 
6. Ohvo-Rekilä, H., Ramstedt, B., Leppimäki, P. & Peter Slotte, J. Cholesterol interactions with phospholipids in 
membranes. Prog. Lipid Res. 41, 66–97 (2002). 
7. Hofmann, A. F. Bile Acids: The Good, the Bad, and the Ugly. News Physiol Sci 14, 24–29 (1999). 
8. Beato, M. Gene regulation by steroid hormones. Cell 56, 335–344 (1989). 
9. Wehling, M. Nongenomic actions of steroid hormones. Trends Endocrinol. Metab. 5, 347–353 (1994). 
10. Hanada, K. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim. Biophys. Acta - 
Mol. Cell Biol. Lipids 1632, 16–30 (2003). 
11. Hannun, Y. A. & Obeid, L. M. Many ceramides. J. Biol. Chem. 286, 27855–62 (2011). 
12. Woodcock, J. Sphingosine and ceramide signalling in apoptosis. IUBMB Life 58, 462–466 (2006). 
13. Teichgräber, V. et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility 
in cystic fibrosis. Nat. Med. 14, 382–391 (2008). 
14. Sentelle, R. D. et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat. 
Chem. Biol. 8, 831–838 (2012). 
15. Gómez-Muñoz, A., Kong, J. Y., Salh, B. & Steinbrecher, U. P. Ceramide-1-phosphate blocks apoptosis 
through inhibition of acid sphingomyelinase in macrophages. J. Lipid Res. 45, 99–105 (2004). 
Bibliography 
 
 
93 
 
16. Granado, M. H. et al. Ceramide 1-phosphate (C1P) promotes cell migration. Involvement of a specific C1P 
receptor. Cell. Signal. 21, 405–412 (2009). 
17. Warnock, D. E. et al. Determination of plasma membrane lipid mass and composition in cultured Chinese 
hamster ovary cells using high gradient magnetic affinity chromatography. J. Biol. Chem. 268, 10145–10153 
(1993). 
18. Ramstedt, B. & Slotte, J. P. Membrane properties of sphingomyelins. FEBS Lett. 531, 33–37 (2002). 
19. Lingwood, C. A. Glycosphingolipid functions. Cold Spring Harb. Perspect. Biol. 3, 1–26 (2011). 
20. Cox, T. M. Gaucher disease: clinical profile and therapeutic developments. Biologics 4, 299–313 (2010). 
21. Zarate, Y. A. & Hopkin, R. J. Fabry’s disease. Lancet 372, 1427–1435 (2008). 
22. Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5, 
554–565 (2004). 
23. Cuvillier, O. Sphingosine in apoptosis signaling. Biochim. Biophys. Acta 1585, 153–62 (2002). 
24. Suzuki, E., Handa, K., Toledo, M. S. & Hakomori, S. Sphingosine-dependent apoptosis: a unified concept 
based on multiple mechanisms operating in concert. Proc. Natl. Acad. Sci. U. S. A. 101, 14788–93 (2004). 
25. Vanier, M. T. Niemann-Pick disease type C. Orphanet J. Rare Dis. 5, 16 (2010). 
26. Spiegel, S. & Milstien, S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 
11, 403–415 (2011). 
27. Pyne, N. J. & Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 10, 489–503 (2010). 
28. Spiegel, S. & Milstien, S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4, 
397–407 (2003). 
29. Bandhuvula, P. & Saba, J. D. Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. 
Trends Mol. Med. 13, 210–217 (2007). 
30. Hagen, N. et al. Subcellular origin of sphingosine 1-phosphate is essential for its toxic effect in lyase-
deficient neurons. J. Biol. Chem. 284, 11346–11353 (2009). 
31. Hagen-Euteneuer, N., Lütjohann, D., Park, H., Merrill, A. H. & Van Echten-Deckert, G. Sphingosine 1-
phosphate (S1P) lyase deficiency increases sphingolipid formation via recycling at the expense of de Novo 
biosynthesis in neurons. J. Biol. Chem. 287, 9128–9136 (2012). 
32. Bektas, M. et al. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J. Biol. Chem. 
285, 10880–10889 (2010). 
33. Levy, M. & Futerman, A. H. Mammalian ceramide synthases. IUBMB Life 62, 347–356 (2010). 
34. Hannun, Y. A. & Obeid, L. M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. 
Mol. Cell Biol. 9, 139–150 (2008). 
Bibliography 
 
94 
 
35. Sandhoff, K. & Kolter, T. Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. 
Soc. Lond. B. Biol. Sci. 358, 847–861 (2003). 
36. Tafesse, F. G., Ternes, P. & Holthuis, J. C. M. The multigenic sphingomyelin synthase family. J. Biol. Chem. 
281, 29421–29425 (2006). 
37. Hanada, K. et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426, 803–809 
(2003). 
38. Swanton, C. et al. Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to 
Paclitaxel and Other Chemotherapeutic Drugs. Cancer Cell 11, 498–512 (2007). 
39. Carstea, E. D. et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. 
Science 277, 228–231 (1997). 
40. Babalola, J. O. et al. Development of an assay for the intermembrane transfer of cholesterol by Niemann-
Pick C2 protein. Biol. Chem. 388, 617–626 (2007). 
41. Scott, C. & Ioannou, Y. A. The NPC1 protein: Structure implies function. Biochim. Biophys. Acta - Mol. Cell 
Biol. Lipids 1685, 8–13 (2004). 
42. Miller, E. H. et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. 
EMBO J. 31, 1947–1960 (2012). 
43. Millat, G., Marçais, C. & Tomasetto, C. Niemann-Pick C1 Disease: Correlations between NPC1 Mutations, 
Levels of NPC1 Protein, and Phenotypes Emphasize the Functional Significance of. Am. J. … 1373–1385 
(2001). 
44. Infante, R. E. et al. Purified NPC1 protein II. Localization of sterol binding to a 240-amino acid soluble 
luminal loop. J. Biol. Chem. 283, 1064–1075 (2008). 
45. Kwon, H. J. et al. Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and 
Transfer of Cholesterol. Cell 137, 1213–1224 (2009). 
46. Sokol, J. et al. Type C Niemann-Pick disease Lysosomal accumulation and defective intracellular mobilization 
of low density lipoprotein cholesterol. J. Biol. Chem. 263, 3411–3417 (1988). 
47. Malathi, K. et al. Mutagenesis of the putative sterol-sensing domain of yeast Niemann Pick C-related 
protein reveals a primordial role in subcellular sphingolipid distribution. J. Cell Biol. 164, 547–556 (2004). 
48. Puri, V. et al. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage 
diseases. Nat. Cell Biol. 1, 386–388 (1999). 
49. White, N. M., Corey, D. a. & Kelley, T. J. Mechanistic similarities between cultured cell models of cystic 
fibrosis and Niemann-pick type C. Am. J. Respir. Cell Mol. Biol. 31, 538–543 (2004). 
50. Trushina, E. et al. Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of 
cholesterol in vitro and in vivo. Hum. Mol. Genet. 15, 3578–3591 (2006). 
51. Patterson, M. C. et al. The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in 
Niemann-Pick disease type C. Neurology 43, 61–64 (1993). 
Bibliography 
 
 
95 
 
52. Walter, M., Chen, F. W., Tamari, F., Wang, R. & Ioannou, Y. a. Endosomal lipid accumulation in NPC1 leads 
to inhibition of PKC, hypophosphorylation of vimentin and Rab9 entrapment. Biol. cell 101, 141–152 (2009). 
53. Liscum, L. et al. Identification of a pharmaceutical compound that partially corrects the Niemann-Pick C 
phenotype in cultured cells. J. Lipid Res. 43, 1708–1717 (2002). 
54. Te Vruchte, D. et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal 
transport. J. Biol. Chem. 279, 26167–75 (2004). 
55. Mukherjee, S. & Maxfield, F. R. Lipid and cholesterol trafficking in NPC. Biochim. Biophys. Acta - Mol. Cell 
Biol. Lipids 1685, 28–37 (2004). 
56. Lachmann, R. H. et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick 
disease type C. Neurobiol. Dis. 16, 654–658 (2004). 
57. Lloyd-Evans, E. et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes 
deregulation of lysosomal calcium. Nat. Med. 14, 1247–55 (2008). 
58. Berridge, M. J., Lipp, P. & Bootman, M. D. The versatility and universality of calcium signalling. Nat. Rev. 
Mol. Cell Biol. 1, 11–21 (2000). 
59. Nilius, B., Owsianik, G., Voets, T. & Peters, J. A. Transient receptor potential cation channels in disease. 
Physiol. Rev. 87, 165–217 (2007). 
60. Burdakov, D., Petersen, O. H. & Verkhratsky, A. Intraluminal calcium as a primary regulator of endoplasmic 
reticulum function. Cell Calcium 38, 303–310 (2005). 
61. Haller, T., Dietl, P., Deetjen, P. & Völkl, H. The lysosomal compartment as intracellular calcium store in 
MDCK cells: a possible involvement in InsP3-mediated Ca2+ release. Cell Calcium 19, 157–165 (1996). 
62. Christensen, K. A., Myers, J. T. & Swanson, J. A. pH-dependent regulation of lysosomal calcium in 
macrophages. J. Cell Sci. 115, 599–607 (2002). 
63. Feng, X. et al. Drosophila TRPML forms PI(3,5)P2-activated cation channels in both endolysosomes and 
plasma Membrane. J. Biol. Chem. 289, 4262–4272 (2014). 
64. Peiter, E. et al. The vacuolar Ca2+-activated channel TPC regulates germination and stomatal movement. 
Nature 434, 404–408 (2005). 
65. Brailoiu, E. et al. An NAADP-gated two-pore channel targeted to the plasma membrane uncouples 
triggering from amplifying Ca2+ signals. J. Biol. Chem. 285, 38511–38516 (2010). 
66. Pitt, S. J. et al. TPC2 is a novel NAADP-sensitive Ca2+ release channel, operating as a dual sensor of luminal 
pH and Ca2+. J. Biol. Chem. 285, 35039–35046 (2010). 
67. Schieder, M., Rötzer, K., Brüggemann, A., Biel, M. & Wahl-Schott, C. a. Characterization of two-pore channel 
2 (TPCN2)-mediated Ca2+ currents in isolated lysosomes. J. Biol. Chem. 285, 21219–21222 (2010). 
68. Wang, X. et al. TPC proteins are phosphoinositide- activated sodium-selective ion channels in endosomes 
and lysosomes. Cell 151, 372–83 (2012). 
Bibliography 
 
96 
 
69. Cang, C. et al. mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic 
state. Cell 152, 778–90 (2013). 
70. Ruas, M. et al. Expression of Ca2+-permeable two-pore channels rescues NAADP signalling in TPC-deficient 
cells. EMBO J. 1–16 (2015). 
71. Morgan, A. J. & Galione, A. Two-pore channels (TPCs): current controversies. Bioessays 36, 173–83 (2014). 
72. Jha, A., Ahuja, M., Patel, S., Brailoiu, E. & Muallem, S. Convergent regulation of the lysosomal two-pore 
channel-2 by Mg2+, NAADP, PI(3,5)P2 and multiple protein kinases. EMBO J. 33, 501–511 (2014). 
73. Jentsch, T. J., Hoegg-beiler, M. B. & Vogt, J. Departure gate of acidic Ca 2 + confirmed. EMBO J. 2, 1–3 
(2015). 
74. Holroyd, C., Kistner, U., Annaert, W. & Jahn, R. Fusion of endosomes involved in synaptic vesicle recycling. 
Mol. Biol. Cell 10, 3035–3044 (1999). 
75. Bargal, R. et al. Identification of the gene causing mucolipidosis type IV. Nat. Genet. 26, 118–123 (2000). 
76. Hu, Z. et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat. Genet. 24, 
61–65 (2000). 
77. Sancak, Y. et al. Ragulator-rag complex targets mTORC1 to the lysosomal surface and is necessary for its 
activation by amino acids. Cell 141, 290–303 (2010). 
78. Zoncu, R. et al. mTORC1 Senses Lysosomal Amino Acids through an Inside-out Mechanism that Requires the 
Vacuolar H+-ATPase. Science (80-. ). 334, 678–683 (2011). 
79. Settembre, C. et al. TFEB links autophagy to lysosomal biogenesis. Science 332, 1429–1433 (2011). 
80. Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473–477 
(2009). 
81. Medina, D. L. et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev. Cell 
21, 421–430 (2011). 
82. Medina, D. L. et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat. 
Cell Biol. 17, 288–299 (2015). 
83. Spampanato, C. et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO 
Mol. Med. 5, 691–706 (2013). 
84. Decressac, M. et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein 
toxicity. Proc. Natl. Acad. Sci. U. S. A. 110, E1817–26 (2013). 
85. Polito, V. a et al. Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription 
factor EB. EMBO Mol. Med. 6, 1–19 (2014). 
86. Tsunemi, T. et al. PGC-1  Rescues Huntington’s Disease Proteotoxicity by Preventing Oxidative Stress and 
Promoting TFEB Function. Sci. Transl. Med. 4, 142ra97–142ra97 (2012). 
Bibliography 
 
 
97 
 
87. Feldmann, H. & Geisbert, T. W. Ebola haemorrhagic fever. Lancet 377, 849–862 (2011). 
88. World Health Organization. Ebola data and statistics. Situat. Summ. (2015). at 
<http://apps.who.int/gho/data/view.ebola-sitrep.ebola-summary-latest?lang=en> 
89. Martínez-Romero, C. & García-Sastre, A. Against the clock towards new Ebola virus therapies. Virus Res. 
(2015). doi:10.1016/j.virusres.2015.05.025 
90. Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621–
635 (2009). 
91. Nanbo, A. et al. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-
dependent manner. PLoS Pathog. 6, (2010). 
92. Mulherkar, N., Raaben, M., de la Torre, J. C., Whelan, S. P. & Chandran, K. The Ebola virus glycoprotein 
mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology 419, 72–83 
(2011). 
93. Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the 
Ebola virus glycoprotein is necessary for infection. Science 308, 1643–1645 (2005). 
94. Hood, C. L. et al. Biochemical and structural characterization of cathepsin L-processed Ebola virus 
glycoprotein: implications for viral entry and immunogenicity. J. Virol. 84, 2972–2982 (2010). 
95. Brecher, M. et al. Cathepsin Cleavage Potentiates the Ebola Virus Glycoprotein To Undergo a Subsequent 
Fusion-Relevant Conformational Change. J. Virol. 86, 364–372 (2012). 
96. Falzarano, D. & Feldmann, H. Delineating Ebola entry. Science (80-. ). 347, 947–948 (2015). 
97. Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 
340–343 (2011). 
98. Côté, M. et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. 
Nature 477, 344–348 (2011). 
99. Herbert, A. S. et al. Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis In Vivo. MBio 
6, 1–12 (2015). 
100. Kolokoltsov, A. A., Saeed, M. F., Freiberg, A. N., Holbrook, M. R. & Davey, R. A. Identification of novel 
cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. Drug Dev. Res. 
70, 255–265 (1009). 
101. Sakurai, Y. et al. Two-pore channels control Ebola virus host cell entry and are drug targets for disease 
treatment. Science (80-. ). 347, 995–998 (2015). 
102. Carrasco, S. & Mérida, I. Diacylglycerol, when simplicity becomes complex. Trends Biochem. Sci. 32, 27–36 
(2007). 
103. Wang, X., Devaiah, S. P., Zhang, W. & Welti, R. Signaling functions of phosphatidic acid. Prog. Lipid Res. 45, 
250–278 (2006). 
Bibliography 
 
98 
 
104. Delmas, P., Coste, B., Gamper, N. & Shapiro, M. S. Phosphoinositide lipid second messengers: New 
paradigms for calcium channel modulation. Neuron 47, 179–182 (2005). 
105. Alvarez, S. E., Milstien, S. & Spiegel, S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends 
Endocrinol. Metab. 18, 300–7 (2007). 
106. Young, M. M., Kester, M. & Wang, H.-G. Sphingolipids: regulators of crosstalk between apoptosis and 
autophagy. J. Lipid Res. 54, 5–19 (2013). 
107. Eyster, K. The membrane and lipids as integral participants in signal transduction: lipid signal transduction 
for the non-lipid biochemist. Adv. Physiol. Educ. 31, 5–16 (2007). 
108. Nishioka, T. et al. Rapid Turnover Rate of Phosphoinositides at the Front of Migrating MDCK Cells. 19, 
4213–4223 (2008). 
109. Axe, E. L. et al. Autophagosome formation from membrane compartments enriched in phosphatidylinositol 
3-phosphate and dynamically connected to the endoplasmic reticulum. J. Cell Biol. 182, 685–701 (2008). 
110. Quinn, K. V, Behe, P. & Tinker, A. Monitoring changes in membrane phosphatidylinositol 4,5-bisphosphate 
in living cells using a domain from the transcription factor tubby. J. Physiol. 586, 2855–2871 (2008). 
111. Brombacher, E. et al. Rab1 guanine nucleotide exchange factor SidM is a major phosphatidylinositol 4-
phosphate-binding effector protein of Legionella pneumophila. J. Biol. Chem. 284, 4846–4856 (2009). 
112. Varnai, P., Thyagarajan, B., Rohacs, T. & Balla, T. Rapidly inducible changes in phosphatidylinositol 4,5-
bisphosphate levels influence multiple regulatory functions of the lipid in intact living cells. J. Cell Biol. 175, 
377–382 (2006). 
113. Oatey, P. B. et al. Confocal imaging of the subcellular distribution of phosphatidylinositol 3,4,5-
trisphosphate in insulin- and PDGF-stimulated 3T3-L1 adipocytes. Biochem. J. 344 Pt 2, 511–518 (1999). 
114. Martelli, A. M. et al. Intranuclear 3′-phosphoinositide metabolism and Akt signaling: New mechanisms for 
tumorigenesis and protection against apoptosis? Cell. Signal. 18, 1101–1107 (2006). 
115. Van Meer, G. & Liskamp, R. M. J. Brilliant lipids. Nat. Methods 2, 14–15 (2005). 
116. Fili, N., Calleja, V., Woscholski, R., Parker, P. J. & Larijani, B. Compartmental signal modulation: Endosomal 
phosphatidylinositol 3-phosphate controls endosome morphology and selective cargo sorting. Proc. Natl. 
Acad. Sci. U. S. A. 103, 15473–15478 (2006). 
117. Zoncu, R. et al. A Phosphoinositide Switch Controls the Maturation and Signaling Properties of APPL 
Endosomes. Cell 136, 1110–1121 (2009). 
118. Ueno, T., Falkenburger, B. H., Pohlmeyer, C. & Inoue, T. Triggering Actin Comets Versus Membrane Ruffles: 
Distinctive Effects of Phosphoinositides on Actin Reorganization. Sci. Signal. 4, ra87–ra87 (2011). 
119. Suh, B.-C., Inoue, T., Meyer, T. & Hille, B. Rapid chemically induced changes of PtdIns(4,5)P2 gate KCNQ ion 
channels. Science 314, 1454–1457 (2006). 
120. Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and 
ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011). 
Bibliography 
 
 
99 
 
121. Inoue, T., Heo, W. Do, Grimley, J. S., Wandless, T. J. & Meyer, T. An inducible translocation strategy to 
rapidly activate and inhibit small GTPase signaling pathways. Nat. Methods 2, 415–418 (2005). 
122. Xu, T., Johnson, C. a, Gestwicki, J. E. & Kumar, A. Conditionally controlling nuclear trafficking in yeast by 
chemical-induced protein dimerization. Nat. Protoc. 5, 1831–1843 (2010). 
123. Kennedy, M., Hughes, R. & Peteya, L. Rapid blue-light-mediated induction of protein interactions in living 
cells. Nat. Methods 7, 973–975 (2010). 
124. Feng, S. et al. A rapidly reversible chemical dimerizer system to study lipid signaling in living cells. Angew. 
Chemie - Int. Ed. 53, 6720–6723 (2014). 
125. Baron, C. L. & Malhotra, V. Role of diacylglycerol in PKD recruitment to the TGN and protein transport to 
the plasma membrane. Science 295, 325–328 (2002). 
126. Kagan, J. C. & Medzhitov, R. Phosphoinositide-Mediated Adaptor Recruitment Controls Toll-like Receptor 
Signaling. Cell 125, 943–955 (2006). 
127. Lee, M. et al. Sphingosine-1-phosphate as a ligand for the G-protein-coupled receptor EDG-1. Science (80-. 
). 279, 1552–1555 (1998). 
128. Pasternack, S. M. et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of 
human hair growth. Nat. Genet. 40, 329–334 (2008). 
129. Manifava, M. et al. Differential Binding of Traffic-related Proteins to Phosphatidic Acid- or 
Phosphatidylinositol (4,5)-Bisphosphate-coupled Affinity Reagents. J. Biol. Chem. 276, 8987–8994 (2001). 
130. Gallego, O. et al. A systematic screen for protein-lipid interactions in Saccharomyces cerevisiae. Mol. Syst. 
Biol. 6, 430 (2010). 
131. Saliba, A.-E. et al. A quantitative liposome microarray to systematically characterize protein-lipid 
interactions. Nat. Methods 11, 47–50 (2014). 
132. Maeda, K. et al. Interactome map uncovers phosphatidylserine transport by oxysterol-binding proteins. 
Nature 501, 257–61 (2013). 
133. Contreras, F.-X. et al. Molecular recognition of a single sphingolipid species by a protein’s transmembrane 
domain. Nature 481, 525–529 (2012). 
134. Höglinger, D., Nadler, A. & Schultz, C. Caged lipids as tools for investigating cellular signaling. Biochim. 
Biophys. Acta 1841, 1085–96 (2014). 
135. Il’ichev, Y. V., Schwörer, M. a. & Wirz, J. Photochemical Reaction Mechanisms of 2-Nitrobenzyl Compounds: 
Methyl Ethers and Caged ATP. J. Am. Chem. Soc. 126, 4581–4595 (2004). 
136. Schade, B. et al. Deactivation Behavior and Excited-State Properties of (Coumarin-4-yl)methyl Derivatives. 
1. Photocleavage of (7-Methoxycoumarin-4-yl)methyl-Caged Acids with Fluorescence Enhancement. J. Org. 
Chem. 64, 9109–9117 (1999). 
137. Qiao, L., Kozikowski, A. P., Olivera, A. & Spiegel, S. Synthesis and evaluation of a photolyzable derivative of 
sphingosine 1-phosphate--caged SPP. Bioorg. Med. Chem. Lett. 8, 711–714 (1998). 
Bibliography 
 
100 
 
138. Meyer zu Heringdorf, D. et al. Photolysis of intracellular caged sphingosine-1-phosphate causes Ca2+ 
mobilization independently of G-protein-coupled receptors. FEBS Lett. 554, 443–449 (2003). 
139. Hopson, K. P., Truelove, J., Chun, J., Wang, Y. & Waeber, C. S1P activates store-operated calcium entry via 
receptor- and non-receptor-mediated pathways in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 
300, C919–C9126 (2011). 
140. Usatyuk, P. V et al. Photolysis of caged sphingosine-1-phosphate induces barrier enhancement and 
intracellular activation of lung endothelial cell signaling pathways. Am. J. Physiol. Lung Cell. Mol. Physiol. 
300, L840–L850 (2011). 
141. Chakrabarti, P. & Khorana, G. A new approach to the study of phospholipid-protein interactions in 
biological membranes. Synthesis of fatty acids and phospholipids containing photosensitive groups. 
Biochemistry 14, 5021–5033 (1975). 
142. Gupta, C. M. et al. Intermolecular crosslinking of fatty acyl chains in phospholipids: use of photoactivable 
carbene precursors. Proc. Natl. Acad. Sci. U. S. A. 76, 2595–2599 (1979). 
143. Suchanek, M., Radzikowska, A. & Thiele, C. Photo-leucine and photo-methionine allow identification of 
protein-protein interactions in living cells. Nat. Methods 2, 261–267 (2005). 
144. Thiele, C., Hannah, M. J., Fahrenholz, F. & Huttner, W. B. Cholesterol binds to synaptophysin and is required 
for biogenesis of synaptic vesicles. Nat. Cell Biol. 2, 42–49 (2000). 
145. Haberkant, P. et al. Protein-sphingolipid interactions within cellular membranes. J. Lipid Res. 49, 251–262 
(2008). 
146. Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click Chemistry：Diverse Chemical Function from a Few Good 
Reactions. Angew. Chemie - Int. Ed. 40, 2004–2021 (2001). 
147. Tornøe, C. W., Christensen, C. & Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-Triazoles by 
regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 67, 
3057–3064 (2002). 
148. Tanaka, K. A. K. et al. Membrane molecules mobile even after chemical fixation. Nat. Methods 7, 865–866 
(2010). 
149. Gubbens, J. et al. Photocrosslinking and Click Chemistry Enable the Specific Detection of Proteins 
Interacting with Phospholipids at the Membrane Interface. Chem. Biol. 16, 3–14 (2009). 
150. Hulce, J. J., Cognetta, A. B., Niphakis, M. J., Tully, S. E. & Cravatt, B. F. Proteome-wide mapping of 
cholesterol-interacting proteins in mammalian cells. Nat. Methods 10, 259–64 (2013). 
151. Haberkant, P. et al. In vivo profiling and visualization of cellular protein-lipid interactions using bifunctional 
fatty acids. Angew. Chem. Int. Ed. Engl. 52, 4033–8 (2013). 
152. Niphakis, M. J. et al. A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell 161, 1668–
1680 (2015). 
153. Canals, D., Perry, D. M., Jenkins, R. W. & Hannun, Y. A. Drug targeting of sphingolipid metabolism: 
Sphingomyelinases and ceramidases. Br. J. Pharmacol. 163, 694–712 (2011). 
Bibliography 
 
 
101 
 
154. Mayer, G. & Heckel, A. Biologically active molecules with a ‘light switch’. Angew. Chem. Int. Ed. Engl. 45, 
4900–4921 (2006). 
155. Zehavi, U. Synthesis of potentially caged sphingolipids, possible precursors of cellular modulators and 
second messengers. Chem. Phys. Lipids 90, 55–61 (1997). 
156. Scott, R. H., Pollock, J., Ayar, A., Thatcher, N. M. & Zehavi, U. Synthesis and use of caged sphingolipids. 
Methods Enzymol. 312, 387–400 (2000). 
157. Givens, R., Rubina, M. & Wirz, J. Applications of p-hydroxyphenacyl (pHP) and coumarin-4-ylmethyl 
photoremovable protecting groups. Photochem. Photobiol. Sci. 11, 472–488 (2012). 
158. Hagen, V. et al. [7-(Dialkylamino)coumarin-4-yl]methyl-caged compounds as ultrafast and effective long-
wavelength phototriggers of 8-bromo-substituted cyclic nucleotides. ChemBioChem 4, 434–442 (2003). 
159. Thiele, C. et al. Tracing fatty acid metabolism by click chemistry. ACS Chem. Biol. 7, 2004–11 (2012). 
160. Guan, X. L., Riezman, I., Wenk, M. R. & Riezman, H. Yeast lipid analysis and quantification by mass 
spectrometry. Methods Enzymol. 470, (Elsevier Inc., 2010). 
161. Lester, R. L. & Dickson, R. C. High-performance liquid chromatography analysis of molecular species of 
sphingolipid-related long chain bases and long chain base phosphates in Saccharomyces cerevisiae after 
derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate. Anal. Biochem. 298, 283–292 
(2001). 
162. Clapham, D. E. Calcium signaling. Cell 131, 1047–58 (2007). 
163. Rudolf, R., Mongillo, M., Rizzuto, R. & Pozzan, T. Looking forward to seeing calcium. Nat. Rev. Mol. Cell Biol. 
4, 579–586 (2003). 
164. Paredes, R. M., Etzler, J. C., Watts, L. T., Zheng, W. & Lechleiter, J. D. Chemical calcium indicators. Methods 
46, 143–151 (2008). 
165. Gee, K. R. et al. Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium 27, 
97–106 (2000). 
166. Stein, F., Kress, M., Reither, S., Piljic, A. & Schultz, C. FluoQ : A Tool for Rapid Analysis of Multiparameter 
Fluorescence Imaging Data Applied to Oscillatory Events. ACS Chem. Biol. 1862–1868 (2013). 
doi:10.1021/cb4003442 
167. R Development Core Team. R: A Language and Environment for Statistical Computing. (2014). 
168. Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G. & Brown, S. Sphingosine 1-phosphate receptor signaling. 
Annu. Rev. Biochem. 78, 743–68 (2009). 
169. Lee, M. et al. Sphingosine-1-Phosphate as a Ligand for the G Protein-Coupled Receptor EDG-1. Science (80-. 
). 279, 1552–1555 (1998). 
170. Yatomi, Y. et al. N,N-Dimethylsphingosine Inhibition of Sphingosine Kinase and Sphingosine 1-Phosphate 
Activity in Human Platelets. Biochemistry 35, 626–633 (1996). 
Bibliography 
 
102 
 
171. Edsall, L. C., Brocklyn, J. R. Van, Cuvillier, O., Kleuser, B. & Spiegel, S. N, N-dimethylsphingosine is a potent 
competitive inhibitor of sphingosine kinas but not protein kinase C: Modulation of cellular levels of 
sphingosine 1-phosphate and ceramide. Biochemistry 37, 12892–12898 (1998). 
172. French, K. J. et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine 
kinase-2. J. Pharmacol. Exp. Ther. 333, 129–139 (2010). 
173. Igarashi, Y. et al. Effect of Chemically Well-Defined Sphingosine and Its N-Methyl Derivatives on Protein 
Kinase C and src Kinase Activities. Biochemistry 28, 6796–6800 (1989). 
174. Hannun, Y. A., Loomis, C. R., Merrill, A. H. & Bell, R. M. Sphingosine inhibition of protein kinase C activity 
and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 261, 12604–12609 (1986). 
175. Gräler, M. H. & Goetzl, E. J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-
protein-coupled receptors. FASEB J. 18, 551–553 (2004). 
176. Tonelli, F. et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its 
proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-
independent prostate cancer cells. Cell. Signal. 22, 1536–42 (2010). 
177. Lim, K. G. et al. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: 
Functional differences between sphingosine kinase 1a and 1b. Int. J. Biochem. Cell Biol. 44, 1457–1464 
(2012). 
178. Gafni, J. et al. Xestospongins: Potent Membrane Permeable Blockers of the Inositol 1,4,5-Trisphosphate 
Receptor. Neuron 19, 723–733 (1997). 
179. Berg, T. O., Strømhaug, E., Løvdal, T., Seglen, O. & Berg, T. Use of glycyl-L-phenylalanine 2-naphthylamide, a 
lysosome-disrupting cathepsin C substrate, to distinguish between lysosomes and prelysosomal endocytic 
vacuoles. Biochem. J. 300 ( Pt 1, 229–236 (1994). 
180. Brailoiu, E. et al. Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling. J. Cell 
Biol. 186, 201–9 (2009). 
181. Calcraft, P. J. et al. NAADP mobilizes calcium from acidic organelles through two-pore channels. Nature 459, 
596–600 (2009). 
182. Dong, X. et al. PI(3,5)P(2) controls membrane trafficking by direct activation of mucolipin Ca(2+) release 
channels in the endolysosome. Nat. Commun. 1, 38 (2010). 
183. Ruas, M. et al. TPC1 has two variant isoforms, and their removal has different effects on endo-lysosomal 
functions compared to loss of TPC2. Mol. Cell. Biol. 34, 3981–92 (2014). 
184. Durlu-Kandilci, N. T. et al. TPC2 proteins mediate Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)- 
and agonist-evoked contractions of smooth muscle. J. Biol. Chem. 285, 24925–24932 (2010). 
185. Naylor, E. et al. Identification of a chemical probe for NAADP by virtual screening. Nat. Chem. Biol. 5, 220–6 
(2009). 
186. Pitt, S. J., Lam, A. K. M., Rietdorf, K., Galione, A. & Sitsapesan, R. Reconstituted human TPC1 is a proton-
permeable ion channel and is activated by NAADP or Ca2+. Sci. Signal. 7, 1–11 (2014). 
Bibliography 
 
 
103 
 
187. Settembre, C. & Ballabio, A. Lysosome: regulator of lipid degradation pathways. Trends Cell Biol. 24, 743–
750 (2014). 
188. Zhao, Y. et al. An Expanded Palette of Genetically Encoded Ca2+ Indicators. Science (80-. ). 333, 1888–1891 
(2011). 
189. Ellis-Davies, G. C. & Kaplan, J. H. Nitrophenyl-EGTA, a photolabile chelator that selectively binds Ca2+ with 
high affinity and releases it rapidly upon photolysis. Proc. Natl. Acad. Sci. U. S. A. 91, 187–191 (1994). 
190. Coxey, R. a, Pentchev, P. G., Campbell, G. & Blanchette-Mackie, E. J. Differential accumulation of cholesterol 
in Golgi compartments of normal and Niemann-Pick type C fibroblasts incubated with LDL: a cytochemical 
freeze-fracture study. J. Lipid Res. 34, 1165–1176 (1993). 
191. Kobayashi, T. et al. Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol 
transport. Nat. Cell Biol. 1, 113–118 (1999). 
192. Zhang, M. et al. Sterol-modulated Glycolipid Sorting Occurs in Niemann-Pick C1 Late Endosomes. J. Biol. 
Chem. 276, 3417–3425 (2001). 
193. Xu, M. et al. δ-tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol 
storage disorders. J. Biol. Chem. 287, 39349–39360 (2012). 
194. Mattie, M., Brooker, G. & Spiegel, S. Sphingosine-1-phosphate, a putative second messenger, mobilizes 
calcium from internal stores via an inositol trisphosphate-independent pathway. J. Biol. Chem. 269, 3181–
3188 (1994). 
195. Rybalchenko, V. et al. Membrane potential regulates Nicotinic Acid Adenine Dinucleotide Phosphate 
(NAADP) dependence of the pH- and Ca2+-sensitive organellar two-pore channel TPC1. J. Biol. Chem. 287, 
20407–20416 (2012). 
196. Ruas, M. et al. Purified TPC isoforms form NAADP receptors with distinct roles for Ca(2+) signaling and 
endolysosomal trafficking. Curr. Biol. 20, 703–9 (2010). 
197. Parkesh, R. et al. Cell-permeant NAADP: A novel chemical tool enabling the study of Ca2+ signalling in intact 
cells. Cell Calcium 43, 531–538 (2008). 
198. Patel, S. & Docampo, R. Acidic calcium stores open for business: expanding the potential for intracellular 
Ca2+ signaling. Trends Cell Biol. 20, 277–86 (2010). 
199. Pacheco, C. D., Kunkel, R. & Lieberman, A. P. Autophagy in Niemann-Pick C disease is dependent upon 
Beclin-1 and responsive to lipid trafficking defects. Hum. Mol. Genet. 16, 1495–1503 (2007). 
200. Elrick, M. J., Yu, T., Chung, C. & Lieberman, A. P. Impaired proteolysis underlies autophagic dysfunction in 
Niemann-Pick type C disease. Hum. Mol. Genet. 21, 4876–4887 (2012). 
201. Bartke, N. & Hannun, Y. A. Bioactive sphingolipids: metabolism and function. J. Lipid Res. 50 Suppl, S91–6 
(2009). 
202. Morad, S. a F. & Cabot, M. C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 13, 51–65 
(2013). 
Bibliography 
 
104 
 
203. Hla, T. & Dannenberg, A. J. Sphingolipid signaling in metabolic disorders. Cell Metab. 16, 420–434 (2012). 
204. Summers, S. a. & Nelson, D. H. A Role for Sphingolipids in Producing the Common Features of Type 2 
Diabetes, Metabolic Syndrome X, and Cushing’s Syndrome. Diabetes 54, 591–602 (2005). 
205. Sloan, C. D. K., Marty, M. T., Sligar, S. G. & Bailey, R. C. Interfacing lipid bilayer nanodiscs and silicon 
photonic sensor arrays for multiplexed protein-lipid and protein-membrane protein interaction screening. 
Anal. Chem. 85, 2970–2976 (2013). 
206. Haberkant, P. & Holthuis, J. C. M. Fat & fabulous: Bifunctional lipids in the spotlight. Biochim. Biophys. Acta 
(2014). doi:10.1016/j.bbalip.2014.01.003 
207. Shieh, P., Hangauer, M. J. & Bertozzi, C. R. Fluorogenic Azidofluoresceins for Biological Imaging. J. Am. 
Chem. Soc. 134, 17428–17431 (2012). 
208. Rivolta, I. et al. Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. J. Physiol. 
Pharmacol. 62, 45–53 (2011). 
209. Haberkant, P. et al. Bifunctional Sphingosine for Cell-Based Analysis of Protein-Sphingolipid Interactions. In 
preparation (2015). 
210. Hughes, C. S. et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol. Syst. Biol. 
10, 1–14 (2014). 
211. Smedley, D. et al. The BioMart community portal: an innovative alternative to large, centralized data 
repositories. Nucleic Acids Res. 1–10 (2015). doi:10.1093/nar/gkv350 
212. Hoetelmans, R. W. et al. Effects of acetone, methanol, or paraformaldehyde on cellular structure, visualized 
by reflection contrast microscopy and transmission and scanning electron microscopy. Appl. 
Immunohistochem. Mol. Morphol. 9, 346–351 (2001). 
213. Karten, B., Vance, D. E., Campenot, R. B. & Vance, J. E. Trafficking of cholesterol from cell bodies to distal 
axons in Niemann Pick C1-deficient neurons. J. Biol. Chem. 278, 4168–4175 (2003). 
214. Millard, E. E., Srivastava, K., Traub, L. M., Schaffer, J. E. & Ory, D. S. Niemann-Pick type C1 (NPC1) 
overexpression alters cellular cholesterol homeostasis. J. Biol. Chem. 275, 38445–38451 (2000). 
215. Vanier, M. T. & Millat, G. Niemann-Pick disease type C. Clin. Genet. 64, 269–281 (2012). 
216. Fernandez-Valero, E. M. et al. Identification of 25 new mutations in 40 unrelated Spanish Niemann-Pick 
type C patients: Genotype-phenotype correlations. Clin. Genet. 68, 245–254 (2005). 
217. Cologna, S. M. et al. Quantitative Proteomic Analysis of Niemann-Pick Disease, Type C1 Cerebellum 
Identifies Protein Biomarkers and Provides Pathological Insight. PLoS One 7, (2012). 
218. Porter, F. D. et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for 
Niemann-Pick C1 disease. Sci. Transl. Med. 2, 1–12 (2010). 
219. Fan, M. et al. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J. Lipid 
Res. 54, 2800–14 (2013). 
Bibliography 
 
 
105 
 
220. Kukulski, W. et al. Correlated fluorescence and 3D electron microscopy with high sensitivity and spatial 
precision. J. Cell Biol. 192, 111–119 (2011). 
221. Kågedal, K., Zhao, M., Svensson, I. & Brunk, U. T. Sphingosine-induced apoptosis is dependent on lysosomal 
proteases. Biochem. J. 359, 335–343 (2001). 
222. Kirkegaard, T. et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal 
pathology. Nature 463, 549–553 (2010). 
223. Subramanian, D. et al. Activation of membrane-permeant caged PtdIns(3)P induces endosomal fusion in 
cells. Nat. Chem. Biol. 6, 324–326 (2010). 
224. Wickham, H. ggplot2: elegant graphics for data analysis. (2009). 
225. Cohen, S. A. & Michaud, D. P. Synthesis of a fluorescent derivatizing reagent, 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate, and its application for the analysis of hydrolysate amino acids via high-
performance liquid chromatography. Anal. Biochem. 211, 279–287 (1993). 
226. Bock, T. et al. An integrated approach for genome annotation of the eukaryotic thermophile Chaetomium 
thermophilum. Nucleic Acids Res. 42, 13525–13533 (2014).  
 
 106 
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AA amino acid 
AcOH acetic acid 
AM acetoxymethyl 
ATP adenosine triphosphate 
BFDAG bifunctional diacylglycerol 
BFS bifunctional sphingosine 
BODIPY boron-dipyrromethene 
bp base pair 
BSA bovine serum albumin 
C1P ceramide-1-phosphate 
cADPR cyclic adenosine diphosphate ribose 
CDase ceramidase 
CDS glucosylceramide synthase 
Cer  ceramide   
CerK ceramide kinase 
CerS ceramide synthase 
CERT ceramide transfer protein 
CHO chinese hamster ovary (cells) 
CLEAR coordinated lysosomal expression and regulation (network) 
CoA coenzyme A 
DAG diacylglycerol 
DCM dichloromethane 
DEAC N,N-diethylaminocoumarin 
DES sphingolipid desaturase 
dhCer dihydroceramide 
dhSph dihydrosphingosine, sphinganine 
DIPEA diisopropylethylamine 
DKO double knock out 
DMEM Dulbecco's Modified Eagle Medium 
DMNB 4,5-dimethoxy-nitrobenzyl 
DMS dimethylsphingosine 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic acid 
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DTT dithiothreitol 
EBOV Ebola virus 
EDTA ethylene diamine tetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
ER endoplasmic reticulum 
EtOAc ethylacetate 
FDR false discovery rate 
GalCer galactosylceramide 
GBA glucosylceramidase 
GluCer glucosylceramide   
GM130 cis-Golgi matrix protein 130 
GO gene ontology 
GP  glycoprotein 
GPN glycyl-L-phenylalanine 2-naphtylamide 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HOPS homotypic fusion and vacuole protein-sorting 
HPLC high performance liquid chromatography 
HPTLC high performance thin layer chromatography 
HRMS high resolution mass spectrometry 
HSAN1 hereditary sensory and autonomic neuropathy type I 
InsP3R inositol-triphophate receptor 
KDSR 3-ketodihydrosphingosine reductase 
LAMP-1 lysosomal associated membrane protein 1 
LB Luria-Bertani 
LC liquid chromatography 
LE late endosome 
MARV Marburg virus 
MeOH methanol 
MLIV mucolipidosis type IV 
MS mass spectrometry 
mTORC mechanistic target of rapamycin complex 
NAADP nicotinic acid adenine dinucleotide phosphate 
NBD nitrobenoxadiazole 
NMR nuclear magnetic resonance 
NPC Niemann-Pick type C 
NTP nucleotide triphosphate 
OD optical density 
Osh oxysterol binding protein homolog 
pacSph photoactivatable and clickable sphinogsine 
PBS phosphate buffered saline 
PC phosphatidylcholine 
PCR polymerase chain reaction 
PE phosphatidylethanolamine 
PI(3,5)P2 phophatidylinositol (3,5)-bisphosphate 
List of Abbreviations 
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PIC protease inhibitor cocktail 
PM plasma membrane 
PSM peptide spectral matches 
RNAi ribonucleic acid interference 
ROI region of interest 
RT room temperature 
RyR ryanodine receptor 
S1P sphingosine-1-phosphate 
S1PL sphingosine-1-phosphate lyase 
S1PR sphingosine-1-phosphate receptor 
SAG stearoyl-arachinoylglycerol 
SDS sodium dodecylsulfate 
siRNA small interfering ribonucleic acid 
SKI-II sphingosine kinase inhibitor II 
SM  sphingomyelin   
SMase sphingomyelinase 
SMS sphingomyelin synthase 
SOC super optimal broth with catabolite repression 
Sph sphingosine 
SK sphingosine kinase 
SPT serine palmitoyl transferase 
SSD sterol sensing domain 
TAP tandem affinity purification 
TBE Tris buffered EDTA 
TEA triethylamine 
TFDAG trifunctional diacylglycerol 
TFEB transcription factor EB 
TFFA trifunctional fatty acid 
TFS trifunctional sphingosine 
THF tetrahydrofuran 
TLC thin layer chromatography 
TPC two-pore channels 
Trp transient receptor potential  
UPLC ultra performance liquid chromatography 
UV ultraviolet 
vATPase vacuolar H+-adenylpyrophosphatase 
VGCC  voltage gated calcium channels 
WT wild type 
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Appendix B – Results of proteomic screens 
B.1. List of high confidence Sph-binding proteins 
description size 
[aa] 
function localization 
Prolow-density lipoprotein receptor-related protein 1 GN=LRP1  4544 endocytosis of apoptotic cells PM 
DnaJ homolog subfamily C member 1 GN=DNAJC1  554 protein synthesis, DNA binding ER, nucleus 
SUN domain-containing protein 2 GN=SUN2  717 cytoskeleton, nucleoskeleton nucleus 
Leucyl-cystinyl aminopeptidase GN=LNPEP  1025 Zn binding, peptide hormone degradation membrane 
Endothelin-converting enzyme 1 GN=ECE1 PE=2 SV=1 770 catalysis of endothelin conversion, binds Zn PM 
C-type mannose receptor 2 GN=MRC2  1479 internalizes glycosylated ligands  membrane 
Cation-dependent mannose-6-phosphate receptor GN=M6PR 277 endosome to lysosome transport lysosome 
3-ketodihydrosphingosine reductase GN=KDSR 332 de novo synthesis, nucleotide binding ER 
Protein sel-1 homolog 1 GN=SEL1L 794 ER quality ctrl, notch signaling ER 
Transmembrane emp24 domain-containing protein 2 GN=TMED2  201 secretory pathway Golgi, endosome 
Proactivator polypeptide = Prosaposin GN=PSAP 524 GlcCer hydrolysis lysosome 
Ceramide synthase 2 GN=LASS2  380 suppresses growth of cancer cells ER   
Isoform 3 of Transmembrane protein 87A GN=TMEM87A 555 
 
membrane 
C-X-C chemokine receptor type 4 GN=CXCR4  352 activation increases Ca2+ und MAPK PM 
Translocating chain-associated membrane protein 1 GN=TRAM1  374 protein translation, targeting ER 
Golgi integral membrane protein 4 GN=GOLIM4  696 protein transport from endosome to Golgi Golgi, endosome 
Vacuole membrane protein 1 GN=VMP1  406 autophagy vesicle 
Putative peripheral benzodiazepine receptor-related protein GN=TSPO 169 porphyrin, Heme-binding, lipid transport mitochondria 
UPF0420 protein C16orf58 GN=C16orf58  460 
 
membrane 
Lysosomal Pro-X carboxypeptidase GN=PRCP  496 peptide cleavage, blood coagulation lysosome 
Translocase of inner mitochondrial membrane domain-containing 
protein 1 GN=TIMMDC1  
285 chaperone of mitochondrial complex 1 mitochondria 
B-cell receptor-associated protein 29 GN=BCAP29 230 protein transport ER 
Isoform 4 of Clusterin GN=CLU  449 blood coagulation, myelin maintenance secreted 
Isoform 3 of Atlastin-2 GN=ATL2 583 GTPase, ER biogenesis ER 
Cathepsin B GN=CTSB 339 thiol protease lysosome 
Transmembrane protein 59 GN=TMEM59 323 autophagy regulation in S.aureus LE/lysosome 
Carbohydrate sulfotransferase 3 GN=CHST3 479 carbohydrate metabolism Golgi 
Phosphatidylinositol transfer protein alpha isoform GN=PITPNA 270 PI, PC transporter cytoplasm 
Secretory carrier-associated membrane protein 2 GN=SCAMP2  329 post-Golgi recycling pathway Golgi 
Beta-hexosaminidase subunit alpha  GN=HEXA  529 GM2 degradation lysosome 
Reticulocalbin-2 GN=RCN2 317 binds calcium ER 
Inter-alpha-trypsin inhibitor heavy chain H3 GN=ITIH3 890 trypsin inhibitor secreted 
Isoform 5 of Amyloid-like protein 2 GN=APLP2 763 trypsin inhibitor, hemostasis,  PM, nucleus 
Protein S100-A8  = Calprotectin GN=S100A8  93 Ca2+, Zn2+ and arachidonic acid binding cytoplasm 
Heme-binding protein 1 GN=HEBP1  189 porphyrin-binding, circadian rhythm cytoplasm 
Protein S100-A9 GN=S100A9 114 Ca2+, Zn2+ and arachidonic acid binding cytoplasm, 
secreted Putative disease resistance protein GN=SLC30A5 765 zinc transporter Golgi 
Mitochondrial cardiolipin hydrolase GN=PLD6 252 stimulated by Ca2+ and Mn2+ MOM 
Beta-hexosaminidase subunit beta GN=HEXB 556 GM2 degradation lysosome 
Glycerophosphodiester phosphodiesterase 1 GN=GDE1  331 binds Mg,  cytoplasm, PM 
DnaJ homolog subfamily C member 3 GN=DNAJC3  504 UR, ER stress, chaperone ER 
ADP-ribosylation factor-like protein 6-interacting protein 6 GN=ARL6IP6 226 
 
membrane 
Protocadherin Fat 1 GN=FAT1 4588 polarization, migration, binds Ca2+ PM, nucleus 
Ras-related protein Rab-31 GN=RAB31  194 GTPase, secretory pathway Golgi, endosome 
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-
sialyltransferase 4 GN=ST3GAL4  
333 protein glycosylation Golgi, secreted 
CD276 antigen GN=CD276 534 T-cell mediated immune response plasma 
membrane CDGSH iron-sulfur domain-containing protein 1 GN=CISD1 108 oxidative phosphorylation itochondria 
Mitochondrial import inner membrane translocase subunit Tim22 
GN=TIMM22 
194 protein import, targeting to mitochondria mitochondria 
Isoform 4 of Mitochondrial fission factor GN=MFF  342 peroxisomal fission, synaptic vesicles mitochondria 
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Transmembrane protein 160 GN=TMEM160  188 
 
membrane 
Protein FAM8A1 GN=FAM8A1 413 
 
membrane 
Protein PRRC1 GN=PRRC1 620 cytokinesis regulator cytoskeleton 
Transmembrane emp24 domain-containing protein 3 GN=TMED3  217 early secretory pathway Golgi, ER 
Protein C5orf15 GN=C5orf15  265 keratinocyte-associated Tmem2 membrane 
Connective tissue growth factor GN=CTGF 349 proliferation in chondrocytes secreted 
Protein FAM3A GN=FAM3A  230 cytokine like protein secreted 
Isoform 3 of UBX domain-containing protein 8 GN=UBXN8 270 ER quality control ER 
Polypeptide N-acetylgalactosaminyltransferase 3 GN=GALNT3 633 protein glycosylation, binds Ca2+ and Mn2+ Golgi 
Peroxisomal membrane protein PEX16 GN=PEX16  336 peroxisome biogenesis peroxisome 
Lysosome-associated membrane glycoprotein 2 GN=LAMP2 410 protection of lys membrane lysosome 
StAR-related lipid transfer protein 3 GN=STARD3  445 cholesterol transport LE /lysosome 
2-hydroxyacylsphingosine 1-beta-galactosyltransferase GN=UGT8 541 GalCer synthesis membrane 
Galectin-3-binding protein GN=LGALS3BP 585 cell adhesion, host defense secreted 
Isoform 3 of Solute carrier family 35 member F2 GN=SLC35F2 374 solute transporter membrane 
Sodium/hydrogen exchanger 6 GN=SLC9A6  669 calcium homeostasis endosomes 
Transmembrane protein with metallophosphoesterase domain 
GN=TMPPE  
453 binds 2-divalent metal cations membrane 
Isoform K of Membrane cofactor protein GN=CD46 392 cofactor for serine protease vesicle 
Peptidyl-glycine alpha-amidating monooxygenase GN=PAM 973 amidation of peptides secreted 
Carboxypeptidase D GN=CPD 1380 binds Zn, peptidase activity membrane 
D-glucuronyl C5-epimerase GN=GLCE  617 glycan metabolism, heparin biosynthesis Golgi 
Isoform 5 of Polycystin-2 GN=PKD2 968 calcium channel in cillia cillium  
Collagen alpha-1(V) chain GN=COL5A1  1838 type v collagen, binds calcium secreted 
Isoform 3 of Tax1-binding protein 1 GN=TAX1BP1 789 TNF-induced apoptosis cytosol 
 
 
  
 
 
  B.2. List of high-confidence DAG-binding proteins 
description 
size 
[aa] 
function localization 
Guanine nucleotide-binding protein subunit beta-2  GN=GNB2 340 Ca-channel activatoin cytoplasm 
Guanine nucleotide-binding protein subunit beta-1  GN=GNB1  340 Ras signal transduction cytoplasm 
DNA replication licensing factor MCM3  GN=MCM3 808 DNA replication initiation nucleus 
Mitochondrial import receptor subunit TOM40 GN=TOMM40  361 mitochondrial transport mitochondria 
Microtubule-associated protein 4  GN=MAP4  1152 promotes microtubule assembly cytoskeleton 
Isoform 2 of Tyrosine-protein kinase BAZ1B  GN=BAZ1B 1483 chromatin remodeling nucleus 
40S ribosomal protein S27-like  GN=RPS27L 84 endopeptidase activator nucleus, ribosome 
Isoleucine--tRNA ligase, cytoplasmic  GN=IARS 1262 tRNA editing cytoplasm 
Isoform 3 of Palladin  GN=PALLD  1383 actin binding cytoskeleton 
40S ribosomal protein S3a  GN=RPS3A  264 regulation of TF DDITT3 nucleus 
Eukaryotic translation initiation factor 3 subunit D  GN=EIF3D 548 protein synthesis cytoplasm 
ATP-dependent RNA helicase DDX1  GN=DDX1 740 double-strand break repair cytoplasm, nucleus 
Bifunctional purin biosynthesis protein PURH GN=ATIC 592 purine biosynthesis cytoplasm 
Phosphoglycerate kinase 1  GN=PGK1  417 polymerase alpha cofactor cytoplasm 
Threonine--tRNA ligase, cytoplasmic  GN=TARS  723 threonine-tRNA ligation cytoplasm 
2-oxoglutarate dehydrogenase complex, mitochondrial  GN=DLST 453 L-lysine degradation mitochondria 
Isoform 4 of Plasminogen activator inhibitor 1 RNA-binding protein   408 mRNA stability cytoplasm, nucleus 
Nucleolar protein 58  GN=NOP58  529 biogenesis of boxC/D snoRNAs nucleus 
Serine palmitoyltransferase 2  GN=SPTLC2 562 sphingolipid synthesis ER 
Serine/threonine-protein phosphatase 2A subunit A GN=PPP2R1A  589 chromosome segregation Cytoplasm 
Zinc finger CCCH domain-containing protein 15  GN=ZC3H15  426 inhibits DRG1 degradation cytoplasm, nucleus 
NADH-ubiquinone oxidoreductase, mitochondrial  GN=NDUFS1  727 cellular respiration mitochondria 
THO complex subunit 2  GN=THOC2  1593 mRNA export nucleus 
Transgelin-2  GN=TAGLN2  199 epithelial cell differentiation vesicle 
Probable ATP-dependent RNA helicase DDX27  GN=DDX27  796 RNA unwinding nucleus 
Ras-related C3 botulinum toxin substrate 1  GN=RAC1  192 GTPase PM, cytoplasm 
Macrophage-capping protein  GN=CAPG 348 calcium binding cytoplasm, nucleus 
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Dihydroxyacetone phosphate acyltransferase  GN=GNPAT  680 gylcerophospholipid metabolism peroxisome 
Cell division cycle 27, isoform CRA_c  GN=CDC27  823 cell division nucleus 
Isoform 3 of Protein AHNAK2  GN=AHNAK2  5795 interacts with DYSF nucleus 
Zinc finger CCCH domain-containing protein 14  GN=ZC3H14 736 mRNA stability in neurons nucleus 
DNA-directed RNA polymerase I subunit RPA1  GN=POLR1A  1720 RNA transcription nucleus 
Phosphoglycerate kinase  GN=PGK1 242 glycolytic process cytoplasm 
60S ribosomal protein L10  GN=RPL10 163 protein translation ribosome 
Isoform 2 of Nuclear pore complex protein Nup50  GN=NUP50 468 nuclear protein import nucleus 
Dihydropyrimidinase-related protein 3  GN=DPYSL3 570 cytoskeleton remodeling cytoplasm 
Asparagine--tRNA ligase, cytoplasmic  GN=NARS 548 protein translation cytoplasm 
Isoform 4 of A-kinase anchor protein 2  GN=AKAP2  859 cell polarity, PKA binding cytoplasm 
Pescadillo homolog  GN=PES1 571 maturation of rRNA nucleus 
NUP153 variant protein GN=NUP153 variant protein 1475 nuclear transport nucleus 
Probable ATP-dependent RNA helicase DHX36 GN=DHX36 797 RNA processing cytoplasm, nucleus 
Isoform 2 of Triosephosphate isomerase  GN=TPI1 286 gluconeogenesis cytoplasm 
40S ribosomal protein S16  GN=RPS16 146 protein translation cytoplasm, ribosome 
Apolipoprotein O-like  GN=APOOL  268 mitochondrial architecture mitochondria 
Mitochondrial glutamate carrier 1  GN=SLC25A22  323 glutamate carrier mitochondria 
Actin-related protein 3  GN=ACTR3  418 regulation of actin polymerization cytoskeleton 
Isocitrate dehydrogenase [NAD], mitochondrial  GN=IDH3A  331 oxidoreduction mitochondria 
26S protease regulatory subunit 7  GN=PSMC2  433 protein degradation cytoplasm 
Protein DEK  GN=DEK 375 chromatin organization nucleus 
Tyrosine--tRNA ligase, cytoplasmic  GN=YARS  528 gene expression cytoplasm 
Isoform 2 of Putative adenosylhomocysteinase 2  GN=AHCYL1  530 mRNA processing ER, cytoplasm 
Isoform 5 of Microtubule-associated protein 4  GN=MAP4  1152 microtubule assembly cytoskeleton 
Periodic tryptophan protein 2 homolog  GN=PWP2  919 RNA binding nucleus 
DNA mismatch repair protein Msh2  GN=MSH2  934 DNA repair nucleus 
DNA-directed RNA polymerase  GN=POLR2B  1099 transcription nucleus 
Cyclin-dependent kinase 9  GN=CDK9  372 transcription regulation nucleus 
Ribonucleases P/MRP protein subunit POP1  GN=POP1  1024 tRNA maturation nucleus 
WD repeat-containing protein 36  GN=WDR36  951 rRNA processing nucleus 
NF-X1-type zinc finger protein NFXL1  GN=NFXL1  911 RNA polymerase II dependent nucleus 
Disks large homolog 1  GN=DLG1  904 scaffolding protein PM 
Cullin-associated NEDD8-dissociated protein 1  GN=CAND1 1230 protein ubiquitination cytoplasm, nucleus 
Up-regulated during skeletal muscle growth protein 5  GN=USMG5  58 ATP synthesis mitochondria 
Brain acid soluble protein 1  GN=BASP1 227 gonad development PM 
Adenylate kinase 2, mitochondrial  GN=AK2 239 energy homeostasis mitochondria 
LIM and SH3 domain protein 1  GN=LASP1  261 cytoskeletal regulation cytoskeleton 
ATP synthase subunit O, mitochondrial  GN=ATP5O  213 respiration mitochondria 
Calponin-3  GN=CNN3  329 actomyosin structure cytoskeleton 
Eukaryotic translation initiation factor 3 subunit I  GN=EIF3I 325 protein synthesis cytoplasm 
Pachytene checkpoint protein 2 homolog  GN=TRIP13  432 chromosome recombination nucleus 
Quinone oxidoreductase  GN=CRYZ  329 catabolism of xenobiotics cytoplasm 
MKI67 FHA domain-interacting nucleolar phosphoproteinGN=MKI67IP  293 rRNA transcription nucleus 
DNAJC7 protein  GN=DNAJC7  494 HSP regulation cytoplasm, nucleus 
Lysophosphatidylcholine acyltransferase 2  GN=LPCAT2  544 phospholipid metabolism ER, Golgi 
SUMO-activating enzyme subunit 1  GN=SAE1  346 protein sumoylation nucleus 
Protein FAM49B  GN=FAM49B  324 - cilium, exosome 
UBX domain-containing protein 4  GN=UBXN4  508 unfolded protein response ER 
Glucose-6-phosphate isomerase  GN=GPI  558 glycolysis cytoplasm 
EH domain-containing protein 4  GN=EHD4  541 endosomal transport endosome 
Protein phosphatase 1G  GN=PPM1G  546 serine/threonine phosphatase cytoplasm 
Isoform 3 of Leukotriene A-4 hydrolase  GN=LTA4H  611 leukotriene B4 biosynthesis cytoplasm 
DNA mismatch repair protein Msh6  GN=MSH6  1360 DNA repair nucleus 
Pre-rRNA-processing protein TSR1 homolog  GN=TSR1 804 ribosome maturation nucleus 
Isoform 2 of Calpain-2 catalytic subunit  GN=CAPN2 700 non-lysosomal proteolysis cytoplasm 
Condensin complex subunit 1  GN=NCAPD2 1401 chromatin condensation nucleus, cytoplasm 
Myosin light polypeptide 6  GN=MYL6  151 muscle contraction cytoplasm 
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40S ribosomal protein S21  GN=RPS21 83 gene expression cytoplasm, ribosome 
Isoform 3 of Ethylmalonyl-CoA decarboxylase  GN=ECHDC1 307 metabolite proofreading cytoplasm 
60S ribosomal protein L18a  GN=RPL18A  154 gene expression ribosome 
Ubiquitin carboxyl-terminal hydrolase  GN=USP14  494 protein degradation cytoplasm 
Isoform 4 of Glutathione S-transferase kappa 1  GN=GSTK1 226 disulfide oxidoreduction peroxisome 
Copine-3  GN=CPNE3  537 membrane trafficking cytoplasm, PM 
Histidine--tRNA ligase, cytoplasmic  GN=HARS  509 translation cytoplasm 
Isoform 2 of U4/U6 small nuclear ribonucleoprotein Prp4  GN=PRPF4  522 pre-mRNA splicing nucleus 
Signal recognition particle 72 kDa protein  GN=SRP72  671 secretory protein targeting ER 
WD repeat-containing protein 74  GN=WDR74  385 blastocyst formation nucleus 
DnaJ homolog subfamily B member 11  GN=DNAJB11 358 unfolded protein response ER 
Isoform 2 of Cullin-4B  GN=CUL4B  913 protein degradation nucleus 
WD repeat-containing protein 1  GN=WDR1  606 actin disassembly cytoskeleton 
Isoform 3 of Apoptosis inhibitor 5  GN=API5 524 binds to ACIN1 nucleus 
MAGUK p55 subfamily member 6  GN=MPP6  160 rRNA maturation nucleus 
4-trimethylaminobutyraldehyde dehydrogenase  GN=ALDH9A1 494 carnitine biosynthesis cytoplasm 
Coatomer subunit delta  GN=ARCN1 511 intracellular transport Golgi, vesicle 
Dystrophin  GN=DMD 3685 actin binding PM, cytoskeleton 
ATP-binding cassette sub-family E member 1  GN=ABCE1 599 mRNA turnover cytoplasm, mito 
Isoform 5 of N-terminal kinase-like protein  GN=SCYL1 808 COPI-retrograde traffic Golgi, ER, vesicle 
CCAAT/enhancer-binding protein zeta  GN=CEBPZ  1054 transcription regulation nucleus 
Protein transport protein Sec24D  GN=SEC24D  1032 COPII coat ER, Golgi, cytoplasm 
Putative PIP5K1A and PSMD4-like protein  GN=PIPSL  862 protein degradation cytoplasm 
Fibronectin type III domain-containing protein 3B  GN=FNDC3B  1204 adipogenesis PM 
Golgi-specific guanine nucleotide exchange factor 1  GN=GBF1 1859 early secretory pathway trafficking ER, Golgi, cytoplasm 
40S ribosomal protein S23  GN=RPS23 143 translation cytoplasm, ribosome 
Isoform 2 of Proteasome subunit alpha type-3  GN=PSMA3 255 protein degradation cytoplasm 
Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitocho. GN=DUT  252 nucleotide metabolism nucleus 
26S proteasome non-ATPase regulatory subunit 4  GN=PSMD4  377 protein degradation cytoplasm 
PDZ and LIM domain protein 5  GN=PDLIM5 596 scaffolding protein cytoskeleton 
Isoform 2 of Transcription factor BTF3  GN=BTF3  206 transcription cytoplasm, nucleus 
Isoform 2 of Nuclear RNA export factor 1  GN=NXF1  619 RNA transport nucleus, cytoplasm 
Nitric oxide synthase-interacting protein  GN=NOSIP  301 inhibits NO production cytoplasm, nucleus 
40S ribosomal protein S13  GN=RPS13  151 gene expression cytoplasm, ribosome 
Serpin B5  GN=SERPINB5  375 tumor suppressor secreted 
Isoform 2 of 28S ribosomal protein S29, mitochondrial  GN=DAP3 398 apoptosis mitochondria 
26S protease regulatory subunit 10B  GN=PSMC6 389 protein degradation cytoplasm, nucleus 
Syntaxin-binding protein 1  GN=STXBP1  594 synaptic vesicle fusion cytoplasm, PM 
Fructose-bisphosphate aldolase  GN=ALDOC  364 carbohydrate degradation cytoplasm, exosome 
Serine/threonine-protein phosphatase GN=PPP4C  307 dephosphorylation cytoplasm, nucleus 
Retinoic acid receptor RXR-beta  GN=RXRB 533 gene expression regulation nucleus 
Isoform Short of Ancient ubiquitous protein 1  GN=AUP1 476 protein degradation ER, cytoplasm 
RNA-binding motif, single-stranded-interacting protein 1  GN=RBMS1 370 RNA binding 
COP9 signalosome complex subunit 4 (Fragment)  GN=COPS4  406 ubiquitin conjugation cytoplasm, nucleus 
mRNA cap guanine-N7 methyltransferase  GN=RNMT  476 gene expression nucleus 
Isoform 3 of Septin-10  GN=SEPT10 454 cytokinesis cytoskeleton 
Serine/threonine phosphatase 2A subunit B alpha, GN=PPP2R2A 447 dephosphorylation cytoplasm 
Copine-1  GN=CPNE1 537 membrane trafficking cytoplasm 
Tyrosine-protein phosphatase non-receptor type 11  GN=PTPN11  597 signal transduction cytoplasm 
phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3  GN=PLCD3  789 PIP2 hydrolysis PM, cytoplasm 
Complement decay-accelerating factor  GN=CD55 381 lipid binidng PM 
Isoform 2 of Protein unc-45 homolog A  GN=UNC45A 944 chaperone for HSP90 cytoplasm 
WD repeat-containing protein 5  GN=WDR5 334 histone modification nucleus 
Ribosomal RNA-processing protein 1 homolog A  GN=RRP1  461 rRNA generation nucleus 
Fanconi anemia group I protein  GN=FANCI  1090 DNA repair 
FAS-associated factor 1  GN=FAF1 650 apoptosis nucleus 
Calpain-1 catalytic subunit  GN=CAPN1 714 non-lysosomal proteolysis cytoplasm 
Peroxisomal biogenesis factor 3  GN=PEX3  373 membrane protein import peroxisome 
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Phosphoribosylformylglycinamidine synthase  GN=PFAS  1338 purine biosynthesis cytoplasm 
Isoform 2 of Reactive oxygen species modulator 1  GN=ROMO1 79 cell proliferation mitochondria 
Serine-threonine kinase receptor-associated protein  GN=STRAP  350 pre-mRNA splicing cytoplasm, nucleus 
Actin-related protein 2/3 complex subunit 4  GN=ARPC4  113 actin polymerization cytoskeleton 
Eukaryotic translation initiation factor 5A-1  GN=EIF5A  154 translation elongation cytoplasm, nucleus 
Dolichol-phosphate mannosyltransferase subunit 3  GN=DPM3  92 protein glycosylation ER 
Phosphoribosylaminoimidazole-succinocarboxamide synthase  GN=PAICS 425 IMP biosynthesis cytoplasm 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  GN=NDUFA4 81 respiration mitochondria 
Creatine kinase B-type  GN=CKB  381 energy transduction cytoplasm 
ATP synthase subunit d, mitochondrial  GN=ATP5H  161 energy homeostasis mitochondria 
Probable ribosome biogenesis protein RLP24  GN=RSL24D1  66 translation cytoplasm, ribosome 
Hypoxanthine-guanine phosphoribosyltransferase  GN=HPRT1 218 purine salvage cytoplasm 
28S ribosomal protein S18b, mitochondrial  GN=MRPS18B 258 translation mitochondria 
Ras-related protein Rap-2a  GN=RAP2A  183 cell migration recycling endosome 
CCR4-NOT transcription complex subunit 10  GN=CNOT10  744 mRNA degradation cytoplasm, nucleus 
Ubiquitin carboxyl-terminal hydrolase isozyme L5  GN=UCHL5  218 protein degradation cytoplasm 
NEDD8-conjugating enzyme Ubc12  GN=UBE2M 183 ubiquitin conjugation cytoplasm 
Peptidyl-prolyl cis-trans isomerase E  GN=PPIE  301 protein folding nucleus 
Isoform 2 of Proteasome assembly chaperone 1  GN=PSMG1  288 protein degradation ER, cytoplasm 
Glyoxylate reductase/hydroxypyruvate reductase  GN=GRHPR  328 oxidoreduction cytoplasm 
Phenylalanine--tRNA ligase beta subunit  GN=FARSB  589 translation cytoplasm 
Protein disulfide-isomerase A5  GN=PDIA5  519 oxidoreduction ER 
Exportin-7  GN=XPO7  1087 nuclear protein export cytoplasm, nucleus 
Endophilin-A2  GN=SH3GL1  368 endocytosis early endosome 
RNA-binding protein PNO1  GN=PNO1  252 
 
nucleus 
Protein kish-A  GN=TMEM167A  72 early secretory pathway Golgi 
Replication factor C subunit 5  GN=RFC5  340 DNA replication   nucleus 
Signal peptidase complex subunit 3  GN=SPCS3  180 translation ER, microsome 
Eukaryotic translation initiation factor 3 subunit G  GN=EIF3G 320 protein synthesis cytoplasm, nucleus 
Ribonucleoside-diphosphate reductase subunit M2  GN=RRM2  389 DNA replication cytoplasm 
F-box only protein 22  GN=FBXO22  403 ubiquitin conjugation cytoplasm 
Ribosomal RNA-processing protein 8  GN=RRP8  456 rDNA silencing nucleus 
Microtubule-associated protein RP/EB family member 1  GN=MAPRE1 268 microtubule elongation cytoskeleton 
Tumor necrosis factor receptor superfamily member 6  GN=FAS  335 cell death PM 
Mitochondrial inner membrane protease subunit 2  GN=IMMP2L 175 protein targeting mitochondria 
Mitochondrial import receptor subunit TOM34  GN=TOMM34 309 protein import mitochondria 
DnaJ homolog subfamily C member 9  GN=DNAJC9  260 chaperone   nucleus 
Translation initiation factor eIF-2B subunit alpha  GN=EIF2B1 305 translation cytoplasm, PM 
Phosphatidylinositol-binding clathrin assembly protein  GN=PICALM 652 endocytosis PM, vesicle 
Isoform 2 of ATP synthase subunit s-like protein  GN=ATP5SL 257 energy homeostasis mitochondria 
Nuclear protein localization protein 4 homolog  GN=NPLOC4  608 protein degradation ER, cytoplasm 
Sorbitol dehydrogenase  GN=SORD  357 oxidoreduction mitochondria 
Rho GTPase-activating protein 1  GN=ARHGAP1 439 cdc24 binding cytoplasm 
Elongator complex protein 2  GN=ELP2 826 chromatin organization cytoplasm, nucleus 
SUMO-activating enzyme subunit 2  GN=UBA2 640 protein sumoylation cytoplasm, nucleus 
Chromosome X open reading frame 56, isoform CRA_b  GN=CXorf56 222 
  Gelsolin  GN=GSN  782 actin capping cytoskeleton 
EH domain-containing protein 2  GN=EHD2 543 membrane reorganization PM, endosome 
Folate transporter 1  GN=SLC19A1  591 potocytosis PM 
Isoform Short of Ubiquitin carboxyl-terminal hydrolase 5  GN=USP5 858 protein deubiquitination lysosome 
Rho GTPase-activating protein 17  GN=ARHGAP17 881 cell polarity maintenance PM, cytoplasm 
Pseudouridine synthase  GN=PUS1 427 transcription mitochondria 
Pre-mRNA-processing factor 17 GN=CDC40 579 pre-mRNA splicing nucleus 
CKLF-like MARVEL transmembrane domain-containing protein 6  GN=CMTM6 183 chemotaxis PM, exosome 
Importin subunit alpha-3  GN=KPNA3  521 nuclear protein import cytoplasm, nucleus 
Negative elongation factor B  GN=COBRA1 580 transcription inhibition Nucleus 
Reticulon-4-interacting protein 1, mitochondrial  GN=RTN4IP1 396 oxidoreduction mitochondria 
Protein MAK16 homolog  GN=MAK16  300 RNA binding nucleus 
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Isoform 2 of 6-phosphofructokinase, muscle type  GN=PFKM  780 glycolysis cytoplasm 
Eukaryotic translation initiation factor 2D  GN=EIF2D  584 tRNA delivery to ribosome cytoplasm 
Cytoplasmic dynein 1 light intermediate chain 2  GN=DYNC1LI2  492 vesicle mobility cytoskeleton 
Cyclin-H  GN=CCNH 323 cell cycle control nucleus 
Coiled-coil domain-containing protein 50  GN=CCDC50 306 ubiquitin conjugation cytoplasm 
Coronin-1B  GN=CORO1B 489 cell motility cytoskeleton 
Ganglioside-induced differentiation-associated protein 1  GN=GDAP1 358 mitochondrial fission mitochondria 
MMS19 nucleotide excision repair protein homolog  GN=MMS19 1030 DNA repair nucleus 
Switch-associated protein 70  GN=SWAP70  585 membrane ruffling PM, cytoplasm 
5'-AMP-activated protein kinase catalytic subunit alpha-1  GN=PRKAA1  559 energy metabolism cytoplasm, nucleus 
Queuine tRNA-ribosyltransferase subunit QTRTD1  GN=QTRTD1  415 tRNA modification mitochondria 
Glioma pathogenesis-related protein 1  GN=GLIPR1  266 lipid metabolism PM 
Isoform 3 of Nucleoredoxin  GN=NXN 435 disulfide oxidoreduction cytoplasm, nucleus 
Signal transducer and activator of transcription 3  GN=STAT3  770 growth factor signaling cytoplasm, nucleus 
Exocyst complex component 2  GN=EXOC2  924 membrane fusion exocyst, PM 
EH domain-binding protein 1-like protein 1  GN=EHBP1L1  1523 
 
PM 
ATPase ASNA1  GN=ASNA1 348 protein targeting to ER ER, cytoplasm 
N-alpha-acetyltransferase 15, NatA auxiliary subunit  GN=NAA15 866 angiogenesis cytoplasm, nucleus 
Microtubule-associated protein 1B  GN=MAP1B  2468 microtubule polymerization cytoskeleton 
Tripartite motif-containing protein 16  GN=TRIM16  564 differentiation cytoplasm 
Elongator complex protein 1  GN=IKBKAP  1332 histone acyltransferase cytoplasm, nucleus 
Arf-GAP w/ coiled-coil, ANK repeat and PH domain-containing protein 2 GN=ACAP2  778 growth factor signaling endosome 
Dystonin  GN=DST  7570 cytoskeletal linker cytoskeleton 
EPS15L1 protein  GN=EPS15L1 864 endocytosis PM 
TFIIH basal transcription factor complex helicase XPB subunit GN=ERCC3  782 DNA repair nucleus 
Probable ATP-dependent RNA helicase DHX37  GN=DHX37 1157 RNA processing cytoplasm, nucleus 
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Appendix C – R code 
C.1. Source code for summarySE function (written by Frank Stein)
summarySE <- function(data=NULL, measurevar, groupvars=NULL, na.rm=FALSE, conf.interval=.95, .drop=TRUE) { 1 
  require(plyr) 2 
   3 
  # New version of length which can handle NA's: if na.rm==T, don't count them 4 
  length2 <- function (x, na.rm=FALSE) { 5 
    if (na.rm) sum(!is.na(x)) 6 
    else       length(x) 7 
  } 8 
   9 
  # This is does the summary; it's not easy to understand... 10 
  datac <- ddply(data, groupvars, .drop=.drop, 11 
                 .fun= function(xx, col, na.rm) { 12 
                   c( N    = length2(xx[,col], na.rm=na.rm), 13 
                      mean = mean   (xx[,col], na.rm=na.rm), 14 
                      sd   = sd     (xx[,col], na.rm=na.rm), 15 
                      IQR   = IQR     (xx[,col], na.rm=na.rm), 16 
                      quantile = quantile (xx[,col],na.rm=na.rm) 17 
                   ) 18 
                 }, 19 
                 measurevar, 20 
                 na.rm, 21 
                 .progress="text" 22 
  ) 23 
   24 
  # Rename the "mean" and quantile columns     25 
  #datac <- rename(datac, c("mean"=measurevar))  26 
  datac <- rename(datac, c("quantile.0%"="min")) 27 
  datac <- rename(datac, c("quantile.100%"="max")) 28 
  datac <- rename(datac, c("quantile.50%"="median")) 29 
  datac <- rename(datac, c("quantile.25%"="first.quartile")) 30 
  datac <- rename(datac, c("quantile.75%"="third.quartile")) 31 
   32 
  datac$se <- datac$sd / sqrt(datac$N)  # Calculate standard error of the mean 33 
   34 
 ciMult <- qt(conf.interval/2 + .5, datac$N-1) 35 
  datac$ci <- datac$se * ciMult 36 
   37 
  return(datac) 38 
} 39 
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C.2. Examplary script for analysis of calcium traces (used to generate Fig. 2.13) 
 
setwd("~/EMBL/Sph-Ca paper/NPC patient FB") 1 
library("ggplot2") 2 
library("reshape") 3 
 4 
npc1 <- read.delim("NPC_dataset.txt") 5 
npc2 <- read.delim("20141119_dataset.txt") 6 
npc <- rbind(npc1, npc2) 7 
rm(npc1) 8 
rm(npc2) 9 
 10 
npc["condition"] <- NA 11 
npc$condition[grep("WT", npc$Experiment.ID)]<- "WT" 12 
npc$condition[grep("NPC", npc$Experiment.ID)]<- "NPC" 13 
 14 
npc["lipid"] <- NA 15 
npc$lipid[grep("cgSph", npc$Experiment.ID)]<-"Sph" 16 
npc$lipid[grep("dhSph", npc$Experiment.ID)]<-"neg ctrl" 17 
 18 
npc["response"]<-F 19 
npc$response[which(npc$Max.change>=10)]<-T 20 
 21 
npc["duration"]<-TRUE 22 
npc$duration[which(npc$No.of.frames<60)]<-F 23 
 24 
npc$condition<-factor(npc$condition, ordered=T, levels=c("WT", "NPC")) 25 
 26 
npc_sum<-summarySE(npc, measurevar="Norm.Mean", groupvars=c("ROI.Class","condition", "lipid","time", "duration"), 27 
na.rm=TRUE) 28 
 29 
npc_plot<-ggplot(subset(npc_sum, time<=60&ROI.Class=="Uncaged_Cell"&lipid=="Sph"&duration=="TRUE"), 30 
aes(time,mean,colour=condition)) 31 
npc_plot<-npc_plot+geom_line(size=1.07)+geom_errorbar(aes(ymax=mean+se,ymin=mean-se),alpha=0.4, size=0.8) 32 
npc_plot<-npc_plot+theme_bw(base_size=16)+scale_y_continuous(limits=c(0.9,1.8))+scale_x_continuous(breaks=seq(0,60,10)) 33 
+theme(panel.grid.major=element_blank(),panel.grid.minor=element_blank())+theme(legend.justification=c(0,1), 34 
legend.position=c(0,1.05), legend.title=element_blank(), legend.text=element_text(size=14), 35 
legend.key=element_blank(), panel.border=element_blank(), axis.line=element_line(), 36 
axis.title.y=element_text(vjust=0.7), axis.title.x=element_text(vjust=0.7)) 37 
npc_plot+labs(title=" ",y="normalized intensity",x="time [s]")+scale_colour_manual(breaks=c("WT", "NPC"),  labels=c("WT", 38 
"NPC"), values=c("#1b9e77", "#d95f02")) 39 
 40 
ggsave(file="NPC_Uncaged_Cell.pdf", width=7,height=4.425) 41 
 42 
NPC_hist_plot<-ggplot(subset(npc,time==0&ROI.Class=="Uncaged_Cell"&(condition=="WT"|condition=="NPC")&lipid=="Sph"), 43 
aes(fill=condition, x=Max.change))+geom_histogram(binwidth=5, colour="black")+facet_grid(~condition) 44 
NPC_hist_plot<-NPC_hist_plot+theme_bw(base_size=16)+scale_x_continuous(breaks=seq(0,120,20)) 45 
+theme(legend.position="none")+theme(panel.grid.major=element_blank(),panel.grid.minor=element_blank(), 46 
axis.line=element_line(), axis.title.y=element_text(vjust=0.7), axis.title.x=element_text(vjust=0.7), 47 
panel.border = element_rect(fill=NA, colour = "black", size=0.7)) 48 
NPC_hist_plot<-NPC_hist_plot+theme(strip.background = element_rect(colour="black", fill="grey")) 49 
+scale_x_continuous(breaks=seq(0,120,20)) 50 
NPC_hist_plot+scale_fill_manual(values=c("#1b9e77", "#d95f02")) 51 
 52 
ggsave(file="NPC_histo.pdf", width=7, height=4.425) 53 
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